OA20447A - Benzisoxazole sulfonamide derivatives - Google Patents
Benzisoxazole sulfonamide derivatives Download PDFInfo
- Publication number
- OA20447A OA20447A OA1202100575 OA20447A OA 20447 A OA20447 A OA 20447A OA 1202100575 OA1202100575 OA 1202100575 OA 20447 A OA20447 A OA 20447A
- Authority
- OA
- OAPI
- Prior art keywords
- hydrogen
- compound
- methyl
- methoxy
- fluoro
- Prior art date
Links
- OIFAKIJHBGJKLD-UHFFFAOYSA-N 1,2-benzoxazole-3-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)=NOC2=C1 OIFAKIJHBGJKLD-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 361
- 239000000203 mixture Substances 0.000 claims abstract description 210
- 201000011510 cancer Diseases 0.000 claims abstract description 114
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- -1 -CHF2 Chemical group 0.000 claims description 369
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 315
- 229910052739 hydrogen Inorganic materials 0.000 claims description 240
- 239000001257 hydrogen Substances 0.000 claims description 239
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 132
- 150000002431 hydrogen Chemical group 0.000 claims description 100
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 98
- 125000001153 fluoro group Chemical group F* 0.000 claims description 72
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 64
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical group 0.000 claims description 42
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 37
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 206010006187 Breast cancer Diseases 0.000 claims description 27
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 125000001246 bromo group Chemical group Br* 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 11
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 11
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 10
- 239000012458 free base Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 19
- 230000002159 abnormal effect Effects 0.000 abstract description 17
- 230000010261 cell growth Effects 0.000 abstract description 16
- 150000003839 salts Chemical class 0.000 abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 255
- 235000019439 ethyl acetate Nutrition 0.000 description 122
- 239000000243 solution Substances 0.000 description 121
- 239000007787 solid Substances 0.000 description 113
- 238000005160 1H NMR spectroscopy Methods 0.000 description 110
- 230000015572 biosynthetic process Effects 0.000 description 106
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 238000003786 synthesis reaction Methods 0.000 description 84
- 230000002194 synthesizing Effects 0.000 description 83
- 238000006243 chemical reaction Methods 0.000 description 77
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- 230000002401 inhibitory effect Effects 0.000 description 62
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 61
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 51
- 229960001663 sulfanilamide Drugs 0.000 description 51
- 238000003818 flash chromatography Methods 0.000 description 50
- 239000003112 inhibitor Substances 0.000 description 47
- 210000004027 cells Anatomy 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 43
- 229910052938 sodium sulfate Inorganic materials 0.000 description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 37
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- 239000007832 Na2SO4 Substances 0.000 description 33
- 239000012267 brine Substances 0.000 description 32
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 description 31
- 229910052681 coesite Inorganic materials 0.000 description 31
- 229910052906 cristobalite Inorganic materials 0.000 description 31
- 229910052904 quartz Inorganic materials 0.000 description 31
- 229910052682 stishovite Inorganic materials 0.000 description 31
- 229910052905 tridymite Inorganic materials 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 235000011152 sodium sulphate Nutrition 0.000 description 30
- 102100002581 KAT5 Human genes 0.000 description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
- 238000000034 method Methods 0.000 description 29
- 101700057035 KAT5 Proteins 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000000725 suspension Substances 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 102100012453 KAT6A Human genes 0.000 description 23
- 101700002149 KAT6A Proteins 0.000 description 23
- 238000005755 formation reaction Methods 0.000 description 23
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 22
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 238000004166 bioassay Methods 0.000 description 22
- 230000002829 reduced Effects 0.000 description 22
- 102100012452 KAT7 Human genes 0.000 description 21
- 101700072448 KAT7 Proteins 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000003208 petroleum Substances 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 239000007858 starting material Substances 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- 201000009030 carcinoma Diseases 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000284 extract Substances 0.000 description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 235000011089 carbon dioxide Nutrition 0.000 description 16
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 108060000112 rimI Proteins 0.000 description 15
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 14
- 101700046984 CDK20 Proteins 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- KLVZDQNSNTUNGU-UHFFFAOYSA-N 2,6-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(OC)=C1S(Cl)(=O)=O KLVZDQNSNTUNGU-UHFFFAOYSA-N 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 102100012454 KAT6B Human genes 0.000 description 13
- 101700080507 KAT6B Proteins 0.000 description 13
- 102000004965 antibodies Human genes 0.000 description 13
- 108090001123 antibodies Proteins 0.000 description 13
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 12
- 238000000634 powder X-ray diffraction Methods 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrugs Drugs 0.000 description 12
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 102100008431 CCL26 Human genes 0.000 description 11
- 101700040437 CCL26 Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 10
- YDHCKXFPFBKZKF-UHFFFAOYSA-N COc1cc(CO)cc(F)c1C#N Chemical compound COc1cc(CO)cc(F)c1C#N YDHCKXFPFBKZKF-UHFFFAOYSA-N 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 9
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 8
- RCVMSHGRUGIUOD-UHFFFAOYSA-N 4-bromo-2-fluoro-6-methoxybenzonitrile Chemical compound COC1=CC(Br)=CC(F)=C1C#N RCVMSHGRUGIUOD-UHFFFAOYSA-N 0.000 description 8
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 101700059654 KAT8 Proteins 0.000 description 8
- 102100012455 KAT8 Human genes 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 230000000340 anti-metabolite Effects 0.000 description 8
- 239000002256 antimetabolite Substances 0.000 description 8
- 125000004429 atoms Chemical group 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000005712 crystallization Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000008079 hexane Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- IAYKYKBQMLBYAI-UHFFFAOYSA-N (2,3,5-trifluorophenyl)methanol Chemical compound OCC1=CC(F)=CC(F)=C1F IAYKYKBQMLBYAI-UHFFFAOYSA-N 0.000 description 7
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 7
- RRUDCFGSUDOHDG-UHFFFAOYSA-N Acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 7
- 210000000481 Breast Anatomy 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 206010061289 Metastatic neoplasm Diseases 0.000 description 7
- 206010046766 Uterine cancer Diseases 0.000 description 7
- 229960001171 acetohydroxamic acid Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 239000002168 alkylating agent Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 230000000903 blocking Effects 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 230000001394 metastastic Effects 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 6
- IJSKDLIEYWUZRK-UHFFFAOYSA-N 2,5-difluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC(F)=C(C#N)C=C1F IJSKDLIEYWUZRK-UHFFFAOYSA-N 0.000 description 6
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 6
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 6
- 229940088598 Enzyme Drugs 0.000 description 6
- 206010024324 Leukaemias Diseases 0.000 description 6
- 210000004072 Lung Anatomy 0.000 description 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 6
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 6
- 210000002307 Prostate Anatomy 0.000 description 6
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 6
- 108010076818 TEV protease Proteins 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 230000003388 anti-hormone Effects 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000000394 mitotic Effects 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 6
- 238000001742 protein purification Methods 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 5
- 210000003169 Central Nervous System Anatomy 0.000 description 5
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- KWYHDKDOAIKMQN-UHFFFAOYSA-N Tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 5
- 210000003932 Urinary Bladder Anatomy 0.000 description 5
- 230000001594 aberrant Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 230000002280 anti-androgenic Effects 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 230000001472 cytotoxic Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 5
- 239000000367 immunologic factor Substances 0.000 description 5
- 239000012444 intercalating antibiotic Substances 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- HUAHYBZBHGOZHJ-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzamide Chemical compound CC1=CC(Br)=C(F)C(C(N)=O)=C1 HUAHYBZBHGOZHJ-UHFFFAOYSA-N 0.000 description 4
- JFAQBRSYTNDGBL-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzoic acid Chemical compound CC1=CC(Br)=C(F)C(C(O)=O)=C1 JFAQBRSYTNDGBL-UHFFFAOYSA-N 0.000 description 4
- HHWSLVGBHIQKAW-UHFFFAOYSA-N 3-bromo-2-fluoro-5-methylbenzoyl chloride Chemical compound CC1=CC(Br)=C(F)C(C(Cl)=O)=C1 HHWSLVGBHIQKAW-UHFFFAOYSA-N 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- TZRYTXCWHNTTOG-UHFFFAOYSA-N C(#N)C1=CC(=C(C(=O)OC)C=C1F)C Chemical compound C(#N)C1=CC(=C(C(=O)OC)C=C1F)C TZRYTXCWHNTTOG-UHFFFAOYSA-N 0.000 description 4
- 101700064140 FOXP3 Proteins 0.000 description 4
- 102100011855 FOXP3 Human genes 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000003287 optical Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 125000004430 oxygen atoms Chemical group O* 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000012536 storage buffer Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- 230000002103 transcriptional Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JNORQCOCTKGJQQ-UHFFFAOYSA-N (4-cyano-2,5-difluorophenyl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC(F)=C(C#N)C=C1F JNORQCOCTKGJQQ-UHFFFAOYSA-N 0.000 description 3
- NCSXOMQDXHCTOY-UHFFFAOYSA-N 1,1,2,3-tetramethylguanidine Chemical compound CNC(=NC)N(C)C NCSXOMQDXHCTOY-UHFFFAOYSA-N 0.000 description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 3
- FGJGNZDVLPUDAJ-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonyl chloride Chemical compound COC1=CC(OC)=C(S(Cl)(=O)=O)C(OC)=C1 FGJGNZDVLPUDAJ-UHFFFAOYSA-N 0.000 description 3
- YGFKNUJLXOQZEK-UHFFFAOYSA-N 2,6-difluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC(F)=C(C#N)C(F)=C1 YGFKNUJLXOQZEK-UHFFFAOYSA-N 0.000 description 3
- GYOBZOBUOMDRRN-UHFFFAOYSA-N 2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC=C1S(Cl)(=O)=O GYOBZOBUOMDRRN-UHFFFAOYSA-N 0.000 description 3
- UUBJMNZSXXWTKU-UHFFFAOYSA-N 5-bromo-4-(bromomethyl)-2-fluorobenzonitrile Chemical compound FC1=CC(CBr)=C(Br)C=C1C#N UUBJMNZSXXWTKU-UHFFFAOYSA-N 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- 229940100228 Acetyl Coenzyme A Drugs 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 210000004100 Adrenal Glands Anatomy 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- KPGJEXZQSFSJNZ-UHFFFAOYSA-N BrC=1C(=C(C#N)C=C(C=1)C)F Chemical compound BrC=1C(=C(C#N)C=C(C=1)C)F KPGJEXZQSFSJNZ-UHFFFAOYSA-N 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- 206010006143 Brain stem glioma Diseases 0.000 description 3
- YEAFFGRKKDDFCH-UHFFFAOYSA-N COC(=O)c1cc(F)c(C#N)c(OC)c1 Chemical compound COC(=O)c1cc(F)c(C#N)c(OC)c1 YEAFFGRKKDDFCH-UHFFFAOYSA-N 0.000 description 3
- DAHBQEGFMSLLMH-UHFFFAOYSA-N Cc1cc(C#N)c(F)cc1CO Chemical compound Cc1cc(C#N)c(F)cc1CO DAHBQEGFMSLLMH-UHFFFAOYSA-N 0.000 description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
- 210000003679 Cervix Uteri Anatomy 0.000 description 3
- 206010008943 Chronic leukaemia Diseases 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102100016692 ESR1 Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000672609 Escherichia coli BL21 Species 0.000 description 3
- 210000003238 Esophagus Anatomy 0.000 description 3
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 229960002989 Glutamic Acid Drugs 0.000 description 3
- 101710021379 H2AZ1 Proteins 0.000 description 3
- 102100019004 H2AZ1 Human genes 0.000 description 3
- 101710017819 H2AZ2 Proteins 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 206010020243 Hodgkin's disease Diseases 0.000 description 3
- 206010061252 Intraocular melanoma Diseases 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 210000004940 Nucleus Anatomy 0.000 description 3
- 206010025310 Other lymphomas Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 210000003101 Oviducts Anatomy 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 210000002990 Parathyroid Glands Anatomy 0.000 description 3
- 210000004197 Pelvis Anatomy 0.000 description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 206010038038 Rectal cancer Diseases 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 210000001685 Thyroid Gland Anatomy 0.000 description 3
- 241000723792 Tobacco etch virus Species 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 210000000626 Ureter Anatomy 0.000 description 3
- 210000003708 Urethra Anatomy 0.000 description 3
- 210000001215 Vagina Anatomy 0.000 description 3
- 210000003905 Vulva Anatomy 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 201000002575 ocular melanoma Diseases 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 201000005746 pituitary adenoma Diseases 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 2
- AUDBREYGQOXIFT-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC(OC)=C1 AUDBREYGQOXIFT-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WLPACIZIAIUYDM-UHFFFAOYSA-N 1-methylsulfonylpyrazole Chemical compound CS(=O)(=O)N1C=CC=N1 WLPACIZIAIUYDM-UHFFFAOYSA-N 0.000 description 2
- RQUNVQGCKIBORD-UHFFFAOYSA-N 2,3,5-trifluorobenzaldehyde Chemical compound FC1=CC(F)=C(F)C(C=O)=C1 RQUNVQGCKIBORD-UHFFFAOYSA-N 0.000 description 2
- GGGHDYNGHFBELC-UHFFFAOYSA-N 2,3-dimethoxybenzenesulfonamide Chemical compound COC1=CC=CC(S(N)(=O)=O)=C1OC GGGHDYNGHFBELC-UHFFFAOYSA-N 0.000 description 2
- TUOLCSUKMUVDOE-UHFFFAOYSA-N 2,6-difluoro-4-formylbenzonitrile Chemical compound FC1=CC(C=O)=CC(F)=C1C#N TUOLCSUKMUVDOE-UHFFFAOYSA-N 0.000 description 2
- NNMFTPMBICNYPF-UHFFFAOYSA-N 2,6-dimethoxybenzenesulfonamide Chemical compound COC1=CC=CC(OC)=C1S(N)(=O)=O NNMFTPMBICNYPF-UHFFFAOYSA-N 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-Formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 2
- WLQHJQUGYACADR-UHFFFAOYSA-N 2-fluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=C(C#N)C(F)=C1 WLQHJQUGYACADR-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HWWYDZCSSYKIAD-UHFFFAOYSA-N 3,5-dimethylpyridine Chemical compound CC1=CN=CC(C)=C1 HWWYDZCSSYKIAD-UHFFFAOYSA-N 0.000 description 2
- TZHQWUAOIWRFSW-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C#N TZHQWUAOIWRFSW-UHFFFAOYSA-N 0.000 description 2
- AVBKISZUVMWQIA-UHFFFAOYSA-N 4-bromo-2-fluoro-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=C(F)C=C1Br AVBKISZUVMWQIA-UHFFFAOYSA-N 0.000 description 2
- GAMOILWTJHUYFX-UHFFFAOYSA-N 4-methyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2N(C)C=NS(=O)(=O)C2=C1 GAMOILWTJHUYFX-UHFFFAOYSA-N 0.000 description 2
- QTPIMXBTXKQSFZ-UHFFFAOYSA-N 5-bromo-2-fluoro-4-methylbenzonitrile Chemical compound CC1=CC(F)=C(C#N)C=C1Br QTPIMXBTXKQSFZ-UHFFFAOYSA-N 0.000 description 2
- SUFDFKRJYKNTFH-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCCC2=CC(OC)=CC=C21 SUFDFKRJYKNTFH-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZZSFXRQLSA-N Acetyl-CoA Natural products S(C(=O)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO[P@@](=O)(O[P@](=O)(OC[C@@H]1[C@@H](OP(=O)(O)O)[C@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C ZSLZBFCDCINBPY-ZZSFXRQLSA-N 0.000 description 2
- 241001251200 Agelas Species 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- AIRHNAJRBZQUEV-UHFFFAOYSA-N BrC1=CC(=CC=2C(=NOC=21)N)C Chemical compound BrC1=CC(=CC=2C(=NOC=21)N)C AIRHNAJRBZQUEV-UHFFFAOYSA-N 0.000 description 2
- 102100007290 CD274 Human genes 0.000 description 2
- 101710012053 CD274 Proteins 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N Deuterated acetone Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 102000027760 ERBB2 Human genes 0.000 description 2
- 108010066668 ErbB-2 Receptor Proteins 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 102100016347 H4-16 Human genes 0.000 description 2
- 101710017531 H4C15 Proteins 0.000 description 2
- 101710007269 H4C7 Proteins 0.000 description 2
- 101700032126 H4Y Proteins 0.000 description 2
- 101710007262 HHF2 Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M Lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 102100000541 MARK2 Human genes 0.000 description 2
- 101700064507 MARK2 Proteins 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 102100019764 PDCD1 Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 101700061430 SAT19 Proteins 0.000 description 2
- 210000002832 Shoulder Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 101700081234 TTR Proteins 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 230000001973 epigenetic Effects 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 2
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 239000002094 self assembled monolayer Substances 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 230000003319 supportive Effects 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- JOAWDCGAGJTSNY-UHFFFAOYSA-N tert-butyl-dimethyl-(1H-pyrazol-4-ylmethoxy)silane Chemical compound CC(C)(C)[Si](C)(C)OCC=1C=NNC=1 JOAWDCGAGJTSNY-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- GQHWSLKNULCZGI-UHFFFAOYSA-N trifluoromethoxybenzene Chemical compound FC(F)(F)OC1=CC=CC=C1 GQHWSLKNULCZGI-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- RNKOUSCCPHSCFE-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C(OC)=C1 RNKOUSCCPHSCFE-UHFFFAOYSA-N 0.000 description 1
- WQRNATFGDNQEOH-UHFFFAOYSA-N (4-cyano-3,5-difluorophenyl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC(F)=C(C#N)C(F)=C1 WQRNATFGDNQEOH-UHFFFAOYSA-N 0.000 description 1
- NLMVYUBGWZWUGB-UHFFFAOYSA-N 1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 1
- DPZNOMCNRMUKPS-UHFFFAOYSA-N 1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 1
- TYHOSUCCUICRLM-UHFFFAOYSA-N 1,3-oxazole-2-carbaldehyde Chemical compound O=CC1=NC=CO1 TYHOSUCCUICRLM-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-Phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- QDXQAOGNBCOEQX-UHFFFAOYSA-N 1-methylcyclohexa-1,4-diene Chemical compound CC1=CCC=CC1 QDXQAOGNBCOEQX-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- ILTSYYZDMQAOJZ-UHFFFAOYSA-N 1-quinolin-2-ylisoquinoline Chemical compound C1=CC=C2C(C3=NC4=CC=CC=C4C=C3)=NC=CC2=C1 ILTSYYZDMQAOJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- LTYQOIPPOYXYFJ-UHFFFAOYSA-N 1H-indazole;2H-isoindole Chemical compound C1=CC=C2C=NNC2=C1.C1=CC=CC2=CNC=C21 LTYQOIPPOYXYFJ-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- FJMQXAJQFNWGKL-UHFFFAOYSA-N 2,3-dihydro-1$l^{6}-benzothiepine 1,1-dioxide Chemical compound O=S1(=O)CCC=CC2=CC=CC=C12 FJMQXAJQFNWGKL-UHFFFAOYSA-N 0.000 description 1
- YJSQGDPNCJTELX-UHFFFAOYSA-N 2-(pyrazin-2-ylmethyl)benzonitrile Chemical compound N#CC1=CC=CC=C1CC1=CN=CC=N1 YJSQGDPNCJTELX-UHFFFAOYSA-N 0.000 description 1
- JLTBWYIUMFEOTN-UHFFFAOYSA-N 2-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=CC=C1S(Cl)(=O)=O JLTBWYIUMFEOTN-UHFFFAOYSA-N 0.000 description 1
- QLRKALMVPCQTMU-UHFFFAOYSA-N 2-bromo-1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C(Br)=C1 QLRKALMVPCQTMU-UHFFFAOYSA-N 0.000 description 1
- MYUPCEIJNBAAFL-UHFFFAOYSA-N 2-fluoro-4-formylbenzonitrile Chemical compound FC1=CC(C=O)=CC=C1C#N MYUPCEIJNBAAFL-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- QPIFPMUFEBZLHJ-UHFFFAOYSA-N 2-methoxy-5-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound COC1=CC=C(OC(F)(F)F)C=C1S(Cl)(=O)=O QPIFPMUFEBZLHJ-UHFFFAOYSA-N 0.000 description 1
- FSTPMFASNVISBU-UHFFFAOYSA-N 2-methoxybenzonitrile Chemical compound COC1=CC=CC=C1C#N FSTPMFASNVISBU-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- GBEXLVQIIMJOFQ-UHFFFAOYSA-N 2H-1,3-benzoxazol-3-amine Chemical compound C1=CC=C2N(N)COC2=C1 GBEXLVQIIMJOFQ-UHFFFAOYSA-N 0.000 description 1
- CPCFSCALAJVNSL-UHFFFAOYSA-N 2H-1,3-oxazol-3-amine Chemical compound NN1COC=C1 CPCFSCALAJVNSL-UHFFFAOYSA-N 0.000 description 1
- HLMABMJBEJCRQD-UHFFFAOYSA-N 2H-benzo[b][1,4]oxazine Chemical compound C1=C[C]2N=CCOC2=C=C1 HLMABMJBEJCRQD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- KBCNRKZRISOYSR-UHFFFAOYSA-N 3-methoxy-5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride Chemical compound C1CCCC2=C1C=C(OC)C(S(Cl)(=O)=O)=C2 KBCNRKZRISOYSR-UHFFFAOYSA-N 0.000 description 1
- GHLURQVACCNKAA-UHFFFAOYSA-N 3-methyl-1-methylsulfonylpyrazole Chemical compound CC=1C=CN(S(C)(=O)=O)N=1 GHLURQVACCNKAA-UHFFFAOYSA-N 0.000 description 1
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 4-(hydroxymethyl)benzene-1,2-diol Chemical compound OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 1
- VHCODCZMAYFSHT-UHFFFAOYSA-N 5-ethyl-2-methoxybenzenesulfonyl chloride Chemical compound CCC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 VHCODCZMAYFSHT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229940014175 Aloxi Drugs 0.000 description 1
- 229920002287 Amplicon Polymers 0.000 description 1
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N Anacardic acid Chemical compound CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 description 1
- ADFWQBGTDJIESE-UHFFFAOYSA-N Anacardic acid Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O ADFWQBGTDJIESE-UHFFFAOYSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- 102100003767 CREBBP Human genes 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229940097647 Casodex Drugs 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000017589 Chromo domain Human genes 0.000 description 1
- 108050005811 Chromo domain Proteins 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N DBDMH Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940108890 Emend Drugs 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N Ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- KIHWDBKCEXVRTL-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1F)CO Chemical compound FC1=C(C#N)C=CC(=C1F)CO KIHWDBKCEXVRTL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229940087051 Fragmin Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 101700001688 HAT Proteins 0.000 description 1
- 101710007992 HLA-DOA Proteins 0.000 description 1
- 102100005784 HLA-DOA Human genes 0.000 description 1
- 101710027872 HOXA9 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008750 Humoral Hypercalcemia Of Malignancy Diseases 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 101700058606 K2CO Proteins 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 101700081293 LMX1A Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010075710 Lysine Acetyltransferase 5 Proteins 0.000 description 1
- 101700002093 MEIS1 Proteins 0.000 description 1
- 102100010482 MEIS1 Human genes 0.000 description 1
- 101710023369 MT3532.1 Proteins 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N Methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 210000001853 Microsomes, Liver Anatomy 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine zwitterion Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- RQXGETUNXUENJX-UHFFFAOYSA-N N-[3-(trifluoromethyl)phenyl]propanamide Chemical compound CCC(=O)NC1=CC=CC(C(F)(F)F)=C1 RQXGETUNXUENJX-UHFFFAOYSA-N 0.000 description 1
- WNSXUAGCWVZDQC-UHFFFAOYSA-N N-ethylbenzenesulfonamide Chemical compound CCNS(=O)(=O)C1=CC=CC=C1 WNSXUAGCWVZDQC-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 229940085033 Nolvadex Drugs 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- WXIHDJIDMYXEPU-UHFFFAOYSA-N O(C)C1=C2C(NS(=O)(=O)C3=C(C=CC=C3OC)OC)=NOC2=CC(Br)=C1 Chemical compound O(C)C1=C2C(NS(=O)(=O)C3=C(C=CC=C3OC)OC)=NOC2=CC(Br)=C1 WXIHDJIDMYXEPU-UHFFFAOYSA-N 0.000 description 1
- 229910004730 OSO2 Inorganic materials 0.000 description 1
- 206010030032 Ocular disorder Diseases 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 101710027499 Os03g0268000 Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 101710018346 PDGFRB Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 229940088087 Plant Drugs 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
- 229940029359 Procrit Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 101710028884 SPAC1039.08 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229940034785 Sutent Drugs 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000036743 UNBOUND FRACTION Effects 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 229940072018 Zofran Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000397 acetylating Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000014398 anacardic acid Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N benzopyran Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 101700055260 colt Proteins 0.000 description 1
- 229940000425 combination drugs Drugs 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 201000000054 coronary restenosis Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000032671 dosage compensation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002172 effect on chromatin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 101700034354 metAA Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WRNVSUJHRFXTKQ-UHFFFAOYSA-N methyl 2,4,5-trifluoro-3-methoxybenzoate Chemical compound COC(=O)C1=CC(F)=C(F)C(OC)=C1F WRNVSUJHRFXTKQ-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001907 polarising light microscopy Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- CFMLURFHOSOXRC-UHFFFAOYSA-N potassium;cyclopropyl(trifluoro)boranuide Chemical compound [K+].F[B-](F)(F)C1CC1 CFMLURFHOSOXRC-UHFFFAOYSA-N 0.000 description 1
- GIIPADVFWNGSKY-UHFFFAOYSA-N potassium;ethyl(trifluoro)boranuide Chemical compound [K+].CC[B-](F)(F)F GIIPADVFWNGSKY-UHFFFAOYSA-N 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 238000000575 proteomic Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- DXBWJLDFSICTIH-UHFFFAOYSA-N pyrazine-2-carbaldehyde Chemical compound O=CC1=CN=CC=N1 DXBWJLDFSICTIH-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to compounds of formula (I)
Description
Benzisoxazole Sulfonamide Dérivatives
Field of the invention
The présent invention relates to novel benzisoxazoie sulfonamide dérivatives, which act as Lysine Acetyi Transferase (KAT) inhibitors of the MYST family and are useful in the treatment of abnormal cell growth, such as cancer, in patients. The présent invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment 10 of abnormal cell growth in patients.
Background of the Invention
The MYST family is the larges! family of KATs and is named after the founding 15 members in yeast and mammals: MOZ, Ybf2/ Sas3, Sas2 and TIP60 (Dekker 2014). MYST proteins médiate many biological functions including gene régulation, DNA repair, cell-cycle régulation and development (Avvakumov 2007; Voss 2009). The KAT proteins of the MYST family play key rôles in post-translational modification of histones and thus hâve a profound effect on chromatin structure in the eukaryotic nucléus (Avvakumov 2007). The family currently comprises five mammalian KATs: TIP60 (KAT5; HTATIP; MIM 601409), MOZ (KAT6A; MIM 601408; MYST3), MORF (KAT6b; QKF; MYST4), ΗΒΟ (KAT8; HBO1; MYST2) and MOF (KATS; MYST1) (Voss 2009). These five members of the MYST family are présent in humans and malfunction of MYST proteins is known to be associated with cancer (Avvakumov 2007). The most frequently used names for members of the MYST family are:
Common name | MYST name | Systematic name |
MOF | MYST1 | KAT8 |
HBO | MYST2 | KAT7 |
MOZ | MYST3 | KAT6A |
MORF | MYST4 | KAT6B |
TIP60 | KAT5 |
- 2 MYST functional domains
MYST proteins function in multisubunit protein complexes including adaptors such as ING proteins that médiate DNA binding (Avvakumov 2007). For instance, TIP60 is affiliated to the NuA4 multiprotein complex (which embraces more than 16 members) (Zhang 2017). However, there hâve also been some reports of a helix-turnhelix DNA-binding motif within the structure ofthe MOZ protein itself (Holbert2007), which suggests the capacity to bind directly to DNA.
The acetyltransferase activity of MYST proteins is effected by the MYST domain (the catalytic domain). The MYST domain contains an acetyl-coenzyme A binding motif, which is structuraliy conserved with other HATs, and an unusual CzHC-type zinc finger (Voss2009). The highiy conserved MYST domain, including the acetyl-CoA binding motif and zinc finger, is considered to be the defining feature of this family of enzymes (Avvakumov 2007).
Rôle of MYST proteins
Acétylation of histone residues is generally associated with transcriptional activation. However, in some instances, transcriptional repression has also been attributed to MYST proteins (Voss 2009). The individual members of the MYST family are known to participate in a broad range of important biochemical interactions:
HBO1 positively régulâtes initiation of DNA réplication (Avvakumov 2007; Aggarwal 2004; Doyon 2006; lizuka 2006) via acétylation of histone substrates, which presumably leads to a more accessible chromatin conformation (Avvakumov 2007, lizuka 2006). HBO1 is also known to play a rôle in the pathogenesis of breast cancer by promoting an enrichment of cancer stem-like cells (Duong 2013) and by destabilising the estrogen receptor a (ERa) through ubiquinitiation, which proceeds via the histoneacetylating activity of HBO1 (lizuka 2013). HBO1 has also been implicated in Acute myeloid leukemia (AML) (Shi2015).
TIP60 (KAT5) is the most studied member ofthe MYSTfamily. TIP60 plays an important rôle not oniy in the régulation of transcription but also in the process of DNA damage repair, particularly in DNA double-strand breaks (DSB) (GH2017). TIP60 can acetylate p53, ATM and c-Myc. TÎP60 and MOF specifically acetyiate lysine 120
-3(K120) of p53 upon DNA damage (Avvakumov 2007). TIP60 has also been implicated in being important for regulatory T-cell (Treg) biology. FOXP3 is the master regulator in the development and function of Tregs and it has been shown that acétylation of FOXP3 by TIP60 is essential for FOXP3 activity (Li 2007, Xiao 2014). Underscoring this, conditional TIP60 délétion in mice leads to a scurfy-like fatal autoimmune disease, mimicking a phenotype seen in FOXP3 knock out mice (Xiao 2014). In cancer, Treg cells can facilitate tumor progression by suppressing adaptive immunity against the tumor.
MOF (“males absent on the first”) was originally identified as one of the components of the dosage compensation in Drosophila, and was classified as a member of the MYST family based on functional studies and sequence analysis (Su 2016). The human ortholog exhibits significant similarity to drosophila MOF; containing an acetyl-CoA-binding site, a chromodomain (which binds histones) and a CzHC-type zinc finger (Su 2016). MOF is a key enzyme for acetylating histone H4K16, and MOFcontaining complexes are implicated in various essential cell functions with links to cancer (Su 2016). Besides the global réduction of histone acétylation, déplétion of MOF in mammalian cells can resuit in abnormal gene transcription, particularly causing abnormal expression of certain tumor suppressor genes or oncogenes, suggesting a critical rôle of MOF in tumorigenesis (Su 2016). For example, KAT activity of MOF has been shown to be required to sustain MLL-AF9 leukemia and may be important for multiple AML subtypes {Vaierio 2017).
KAT6B (Querkopf) was first identified in a mutation screen for genes regulating the balance between prolifération and différentiation during embryonic development (Thomas 2000). Mice homozygous for the KAT6B mutant allele hâve severe defects in cérébral cortex development resulting from a severe réduction in both prolifération and différentiation of specifically the cortical progenitor population during embryonic development. KAT6B is required for the maintenance of the adult neural stem cell population and is part of a System regulating différentiation of stem cells into neurons (Merson 2006). KAT6B is also mutated in rare forms of leukemia (Vizmanos 2003).
The MOZ locus ranks as the 12th most commonly amplified région across ail cancer types (Zack 2013). MOZ is within the 8p 11 -p12 amplicon, which is seen at frequencies around 10-15% in various cancers, especially breast and ovarian (TurnerIvey 2014). MOZ was first identified as a fusion partner of the CREB-binding protein
- 4 (CBP) during examination of a spécifie chromosomal translocation in acute myeloid leukemia (AML) (Avvakumov 2007; Borrow 1996). MOZ KAT activity is necessary for promoting the expression of MEIS1 and HOXa9, proteins that are typically seen overexpressed in some lymphomas and leukemias. Increased survivai of MOZ+/_ hétérozygote mice in the Εμ-Myc transgenic model of B-cell lymphoma is seen, where loss of a single MOZ allele leads to a biologically relevant réduction in Meisf and Hoxa9 levels in pre-B-cells (Sheikh 2015).
Inhibitors of some MYSTs are known. For example, the following Anacardic acid dérivative is reported (Ghizzoni 2012) as inhibiting TIP60 (ICso = 74μΜ) and MOF (IC50 10 = 47μΜ):
Other known inhibitors include (Zhang 2017):
NU9056
compound a
HN
SCoA
Ac-SGRGKGGKGLGKGGAKRHRK
H4K16CoA
SGRGKGGKGLGKGGAKRHRK, SEQ ID NO:1
Ο
Ac-ARTKQTARKSTGGKAPRKQL
H3K9me3K14CoA
ARTKQTARKSTGGKAPRKQL, SEQ iD NO:2
In light of the established rôle of KATs in general, and MYSTs in particular, in diseases such as cancer, a need exists for new inhibitors of these proteins.
Summary of the Invention
Each of the embodiments of the présent invention described below may be combined with one or more other embodiments of the présent invention described ίο herein which is not inconsistent with the embodiment(s) with which it is combined. In addition, each of the embodiments below describing the invention envisions within its scope the pharmaceutically acceptable salts of the compounds of the invention.
Accordingly, the phrase “or a pharmaceutically acceptable sait thereof is implicit in the description of ali compounds described herein.
-6This invention relates to a compound of formula (I)
or a pharmaceutically acceptable sait thereof, wherein
R1 is hydrogen or 5-6 membered heteroaryl optionally substituted by methyl;
R2 is hydrogen or -(CHRs)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH, provided that one of R1 and R2 is hydrogen, further provided that R1 and R2 are not both hydrogen;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or-OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or-Ocyclopropyl,
Ring A is Ce-Cw aryl or 9-10 membered heteroaryl;
R5 îs hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or-C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy;
R7 is hydrogen, bromo, chloro, fluoro, or methoxy;
R8 is hydrogen or -OH; and n is 0 or 1.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R1 is 5-6 membered heteroaryl
- 7 and R2 is hydrogen; R1 is 5 membered heteroaryl and R2 is hydrogen; or R1 is pyrazolyl and R2 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R1 is hydrogen and R2 is 5-6 membered heteroaryl; R1 is hydrogen and R2 is 5 membered heteroaryl; R1 is hydrogen and R2 is pyrazolyl; R1 is hydrogen, R2 is -(CHR8)-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH, and R8 is -OH; R1 is hydrogen and R2 is -(CH2)-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or-OH; R1 is hydrogen, R2 is-(CHR8)-(5-6 membered heteroaryl), and R3 is -OH; R1 is hydrogen and R2 is -(CH2)-(5-6 membered heteroaryl); R1 is hydrogen, R2 is -(CHR8)-(5 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH, and R8 is -OH; R1 is hydrogen and R2 is -(CH2)-(5 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or-OH; R1 is hydrogen, R2 is-(CHRa)-(5 membered heteroaryl), and R8 is -OH; R1 is hydrogen and R2 is -(CH2)-(5 membered heteroaryl); R1 is hydrogen and R2 is-(CH2)-triazolyl; R1 is hydrogen and R2 is-(CH2)-pyrazolyl optionally substituted by halogen or C1-C3 alkyl; R1 is hydrogen and R2 is-(CH2)-pyrazolyl optionally substituted by halogen; R1 is hydrogen and R2 is -(CH2)-pyrazolyl optionally substituted by C1-C3 alkyl; R1 is hydrogen and R2 is -(CH2)-pyrazolyl substituted by methyl; R1 is hydrogen and R2 is -(CH2)-pyrazolyl; R1 is hydrogen and R2 is -(CH2)-(6 membered heteroaryl); R1 is hydrogen and R2 is-(CHR8)-(6 membered heteroaryl), and R8 is -OH; R1 is hydrogen and R2 is -(CH2)-pyridine, -(CH2)-pyrazine, or -(CH2)pyrimidine; R1 is hydrogen and R2 is -(CH2)-(5-9 membered heteroaryl); or R1 is hydrogen and R2 is -(CH2)-indazolyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or -OCF3; and R4 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen and R4 is halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl; R3 is hydrogen, fluoro, bromo, or methyl; R3 is fluoro: R3 is methyl; R3 is
-8hydrogen; R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R4 is hydrogen; R4 is C1-C3 alkoxy; or R4 is methoxy, and any combination of R3 and R4 thereof.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein at least one of R3 and R4 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl and R4 is hydrogen; R3 is hydrogen, fluoro, bromo, or methyl and R4 is hydrogen; R3 is methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R3 is hydrogen and R4 is hydrogen; R3 is hydrogen and R4 is C1-C3 alkoxy; R3 is hydrogen and R4 is methoxy; or R3 is fluoro and R4 is methoxy.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, quinolinyl, benzoxazolyl, indanyl, ortetrahydronaphthyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R5 is methoxy.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, and R6 is methoxy.
-9One embodiment of the present invention relates to a compound of formula (I), or a pharmaceuticaily acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (1), 5 or a pharmaceuticaily acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (I), or a pharmaceuticaily acceptable sait thereof wherein Ring A is indanyl.
One embodiment of the present invention relates to a compound of formula (I), 10 or a pharmaceuticaily acceptable sait thereof, wherein Ring A is tetrahydronaphthyl.
One embodiment of the present invention relates to a compound of formula (I), or a pharmaceuticaily acceptable sait thereof, wherein Ring A is indanyl or tetrahydronaphthyl, R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (I), 15 or a pharmaceuticaily acceptable sait thereof, wherein Ring A is quinolinyl.
One embodiment of the present invention relates to a compound of formula (I), or a pharmaceuticaily acceptable sait thereof, wherein Ring A is benzoxazolyl.
One embodiment of the present invention relates to a compound of formula (I), or a pharmaceuticaily acceptable sait thereof, wherein Ring A is quinolinyl or benzoxazolyl, R5 is methyl or ethyl, R6 is hydrogen, and R7 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (I) can be combined with any other embodiment(s) above to the extent they are not incompatible.
-10This invention relates to a compound of formula (la)
or a pharmaceutically acceptable sait thereof, wherein
R1 is hydrogen or 5-6 membered heteroaryl optionally substituted by methyl;
R2 is hydrogen or -(CH2)n-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH, provided that one of R1 and R2 is hydrogen, further provided that R1 and R2 are not both hydrogen;
R3 is hydrogen, halogen, C1-C3 alkyl, -CF2H, -CF3, C1-C4 alkoxy, -OCHF2, or -OCFs;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -Ocyclopropyl, provided that at least one of R3 and R4 is hydrogen;
Ring A is Cs-Cw aryl or 9-10 membered heteroaryl;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or -C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy;
R7 is hydrogen, bromo, chloro, fluoro, or methoxy; and n is 0 or 1.
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein R1 is 5-6 membered heteroaryl and R2 is hydrogen.
- 11 One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein R1 is 5 membered heteroaryl and R2 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein R1 is pyrazolyl and R2 is hydrogen; R1 is hydrogen and R2 is 5-6 membered heteroaryl; R1 is hydrogen and R2 is 5 membered heteroaryl; R1 is hydrogen and R2 is pyrazolyl; R1 is hydrogen and R2 is(CH2)—(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, CH2OH, or -OH; R1 is hydrogen and R2 is -(CH2)-(5-6 membered heteroaryl); R1 is hydrogen and R2 is -(CH2)-(5 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH; R1 is hydrogen and R2 is -(CH2)-(5 membered heteroaryl); R1 is hydrogen and R2 is -(CH2)-triazolyl; R1 is hydrogen and R2 is -(CH2)pyrazolyl optionally substituted by halogen or C1-C3 alkyl; R1 is hydrogen and R2 is (CH2)-pyrazolyl optionally substituted by halogen; R1 is hydrogen and R2 is -(CH2)pyrazolyl optionally substituted by C1-C3 alkyl; R1 is hydrogen and R2 is -(CH2)pyrazolyl substituted by methyl; or R1 is hydrogen and R2 is -(CH2)-pyrazolyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is halogen, C1-C3 alkyl, CF2H, -CF3, C1-C4 alkoxy, -OCHF2, or-OCFa; and R4 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen and R4 is halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl.
One embodiment of the présent invention relates to a compound of formula (I), or a pharmaceutically acceptable sait thereof, wherein at least one of R3 and R4 is hydrogen,
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl and R4 is hydrogen; R3 is hydrogen, fluoro, bromo, or methyl and R4 is hydrogen; R3 is methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R3 is hydrogen and R4 is hydrogen; R3 is hydrogen and R4 is C1-C3 alkoxy; or R3 is hydrogen and R4 is methoxy.
- 12 One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, quinolinyl, benzoxazolyl, indanyl, or tetrahydronaphthyl.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl.
One embodiment ofthe present invention relates to a compound offormula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R5 is methoxy.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is methoxy.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is hydrogen.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, and R6 is methoxy.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, and R6 is hydrogen.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is indanyl.
One embodiment of the present invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is tetrahydronaphthyl.
- 13 One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is indanyl or tetrahydronaphthyl, R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is quinolinyl.
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is benzoxazolyl.
One embodiment of the présent invention relates to a compound of formula (la), or a pharmaceutically acceptable sait thereof, wherein Ring A is quinolinyl or benzoxazolyl, R5 is methyl or ethyl, R6 is hydrogen, and R7 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for Formula (la) can be combined with any other embodiment(s) above to the extent they are not incompatible.
This invention relates to a compound of formula (II) or a pharmaceutically acceptable sait thereof, wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, —OCHF2, or —OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -Ocyclopropyl;
Ring A is Cg-Cw aryl or 9-10 membered heteroaryl;
- 14 R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CHa-O-CHs, -C(O)OCH3, or -C(O)N(H)CHs;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein R2a is absent, fluoro, methyl, -CHaOH or -OH; R2a is absent, fluoro, or methyl; R2a is absent; R2a is fluoro; or R2a is methyl.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, C1-C3 alkyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or-OCFs.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl; R3 is hydrogen, fluoro, bromo, or methyl; R3 is fluoro; R3 is methyl; R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R4 is hydrogen: R4 is C1-C3 alkoxy; or R4 is methoxy, and any combination of R3 and R4 thereof.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein R3 is fluoro and R4 is methoxy.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein at least one of R3 and R4 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl and R4 is hydrogen; R3 is hydrogen, fluoro, bromo, or methyl and R4 is hydrogen; R3 is methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R3 is hydrogen and R4 is hydrogen; R3 is hydrogen and R4 is C1-C3 alkoxy; R3 is hydrogen and R4 is methoxy.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, quinolinyl, benzoxazolyl, indanyl, or tetrahydronaphthyl.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl.
- 15One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R5 is methoxy.
One embodiment of the présent invention relates to a compound of formula (II), 5 or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R6 is hydrogen.
îo One embodiment of the présent invention relates to a compound of formula (Ii), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl, R5 is methoxy, 15 and R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (II), 20 or a pharmaceutically acceptable sait thereof, wherein Ring A is phenyl R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is indanyl.
One embodiment of the présent invention relates to a compound of formula (II), 25 or a pharmaceutically acceptable sait thereof, wherein Ring A is tetrahydronaphthyl.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is indanyl or tetrahydronaphthyl, R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (II), 30 or a pharmaceutically acceptable sait thereof, wherein Ring A is quinolinyl.
One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceutically acceptable sait thereof, wherein Ring A is benzoxazolyl.
- 16 One embodiment of the présent invention relates to a compound of formula (II), or a pharmaceuticalIy acceptable sait thereof, wherein Ring A is quinolinyl, R5 is methyl or ethyl, R6 is hydrogen, and R7 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (11) can be combined with any other embodiment(s) above to the extent they are not incompatible.
This invention relates to a compound of formula (III)
or a pharmaceuticalIy acceptable sait thereof, wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or-OH;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or-OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1O4 alkoxy, or-Ocyclopropyl;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or -C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
One embodiment of the présent invention relates to a compound of formula (III), or a pharmaceuticalIy acceptable sait thereof, wherein R2a is absent, fluoro, methyl, -CH2OH or -OH; R2a is absent, fluoro, or methyl; R2a is absent; R2a is fluoro; or R2a is methyl.
- 17One embodiment of the présent invention relates to a compound of formula (III), or a pharmaceuticaily acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl; R3 is hydrogen, fluoro, bromo, or methyl; R3 is fluoro; R3 is methyl; R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R4 is hydrogen; R4 is C1-C3 alkoxy; R4 is methoxy; or R3 is fluoro and R4 is methoxy.
One embodiment of the présent invention relates to a compound of formula (III), or a pharmaceuticaily acceptable sait thereof, wherein at least one of R3 and R4 is hydrogen.
One embodiment of the present invention relates to a compound of formula (III), or a pharmaceuticaily acceptable sait thereof, wherein R3 is hydrogen, halogen, or C1-C3 alkyl and R4 is hydrogen; R3 is hydrogen, fluoro, bromo, or methyl and R4 is hydrogen; R3 is methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy; R3 is hydrogen and R4 is hydrogen; R3 is hydrogen and R4 is C1-C3 alkoxy; or R3 is hydrogen and R4 is methoxy.
One embodiment of the present invention relates to a compound of formula (III), or a pharmaceuticaily acceptable sait thereof, wherein R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
One embodiment of the present invention relates to a compound of formula (III), or a pharmaceuticaily acceptable sait thereof, wherein R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (lll) can be combined with any other embodiment(s) above to the extent they are not incompatible.
- 18This invention relates to a compound of formula (IV) or a pharmaceutically acceptable sait thereof, wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3) -O-cyclopropyl, -0ΗΞ-0-0Η3, -C(O)OCH3, or -C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
One embodiment of the présent invention relates to a compound of formula (IV), or a pharmaceutically acceptable sait thereof, wherein R2a is absent, fluoro, methyl, -CH2OH or -OH; R2a is absent, fluoro, or methyl; R2a is absent; R2a is fluoro; or R2a is methyl.
One embodiment of the présent invention relates to a compound of formula (IV), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (IV), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy, R6 is hydrogen, and R7 are hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (IV) can be combined with any other embodiment(s) above to the extent they are not incompatible.
- 19This invention relates to a compound of formula (V)
or a pharmaceutically acceptable sait thereof, wherein
X is N or -C(H)-;
Y is N or -C(H)-, provided that at least one of X and Y is -C(H)~;
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl;
R5 is hydrogen, methyl, -CF3, C1-C3 alkoxy, -CH2-OCH3, or -C(O)OCH3; and
R6 is hydrogen, fluoro, methyl, -OH, or methoxy.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein X is N and Y is -C(H)-.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein X is -C(H)- and Y is N.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein X is -C(H)- and Y is -C(H)-.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R2a is absent, fluoro, methyl, CH2OH or -OH; R2a is absent, fluoro, or methyl; R2a is absent; R2a is fluoro; or R2a is methyl.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R4 is hydrogen, fluoro, ethyl,
-20cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl; R4 is C1-C4 alkoxy; R4 is methoxy; or R4 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R6 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy and R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (V), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy and R6 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (V) can be combined with any other embodiment(s) above to the extent they are not incompatible.
This invention relates to a compound of formula (VI) or a pharmaceutically acceptable sait thereof, wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R3 is hydrogen, halogen, or C1-C3 alkyl;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl,
- 21 provided that at least one of R3 and R4 is hydrogen;
R5 is hydrogen, methyl, -CH2-OCH3, -CF3, C1-C3 alkoxy, or-C(O)OCH3; and
R6 is hydrogen, fluoro, methyl, -OH, or methoxy.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R2a is absent, fluoro, methyl, CH2OH or -OH; R2a is absent, fluoro, or methyl; R2a is absent; R2a is fluoro; or R2a is methyl.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R3 is hydrogen, fluoro, or methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen; R3 is methyl and R4 is hydrogen; R3 is hydrogen and R4 is hydrogen, fluoro, ethyi, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl; R3 is hydrogen and R4 is C1-C4 alkoxy; or R3 is hydrogen and R4 is methoxy.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R6 is hydrogen.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy and R6 is methoxy.
One embodiment of the présent invention relates to a compound of formula (VI), or a pharmaceutically acceptable sait thereof, wherein R5 is methoxy and R6 is hydrogen.
It is to be understood that any of the above-mentioned embodiment(s) for formula (VI) can be combined with any other embodiment(s) above to the extent they are not incompatible.
One embodiment of the présent invention provides a compound selected from the group consisting of the compounds exemplified in Examples 1 to 133, inclusive, or a pharmaceutically acceptable sait thereof.
This invention relates to a compound of any of the embodiments of the compounds of formula (I), formula (la), formula (11), formula (III), formula (IV), formula
- 22 (V), or formula (VI), or a pharmaceutically acceptable sait thereof, which is deuteriumlabeled.
This invention relates to a pharmaceutical composition comprising a compound of any of the embodiments of the compounds of formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or diluent.
This invention relates to a pharmaceutical composition comprising a compound of any ofthe embodiments of the compounds of formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or diluent, for treating cancer.
This invention relates to a method of treating cancer in a patient comprising administering to the patient an amount of a compound of any of the embodiments of the compounds of formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or formula (V), or a pharmaceutically acceptable sait thereof, that is effective in treating cancer.
This invention relates to a compound of any of the embodiments of the compounds of formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, for use in the treatment of cancer in a patient.
This invention relates to a use of a compound of any of the embodiments of the compounds of formula (1), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for the treatment of cancer.
This invention relates to a combination of a compound of any of the embodiments ofthe compounds of formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, with an anti-tumor agent or with radiation therapy, for the treatment of cancer.
This invention relates to a combination of a compound of any of the embodiments of the compounds formula (I), formula (la), formula (II), formula (III), formula (IV), formula (V), or formula (VI), or a pharmaceutically acceptable sait thereof, with an anti-tumor agent, for the treatment of cancer.
In one embodiment of the present invention the cancer is breast cancer.
-23In one embodiment of the présent invention the cancer is breast cancer, which breast cancer is ER positive breast cancer.
Brief Description of the Drawings
FIG. 1 shows the PXRD spectrum of 2-methoxy-Λ/-{4-methoxy-6-[(1H-pyrazol·'ίyl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide anhydrous (Form 1).
Detailed Description of the Invention
The présent invention may be understood more readily by reference to the following detailed description of the preferred embodiments of the invention and the Examples included herein. It is to be understood that the terminology used herein is for the purpose of describing spécifie embodiments only and is not intended to be limiting. It is further to be understood that unless specifically defined herein, the terminology used herein is to be given its traditional meaning as known in the relevant art.
As used herein, the singular form a, an, and the include plural references unless indicated otherwise. For example, a substituent includes one or more substituents.
The invention described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms comprising, consisting essentially of, and consisting of may be replaced with either of the other two terms.
For convenience, many Chemical moieties and compounds are represented using well known abbreviations, including but not limited to, Ac (acetyl), AcOH (acetic acid), AIBN (azobisisobutyronitrile), n-BuLi (n-butyllithium), CN (cyano), CPME (cyclopentyl methyl ether), DCM (dichloromethane or methylene chloride), acetone-de (deuterated acetone), CDCh (deuterated chloroform), DMSO-cfe (deuterated dimethylsulfoxide), methanol-^ (deuterated methanol), D2O (deuterated water), DIAD (diisopropyl azodicarboxylate), DMAP (A/,A/-dimethylpyridin-4-amine), DMF (N,Ndimethylformamide), DMSO (dimethylsulfoxide), dppf (1,1'bis(diphenyîphosphino)ferrocene), dppp (1,3-bis(diphenylphosphino)propane), Et (ethyl), ethyl acetate (EtOAc), EtOH (éthanol), LDA (lithium diisopropyl amide), Me (methyl), MeOH (methanol), MeCN (acetonitrile), MeOAc (methyl acetate), Ms
- 24 (methanesulfonyl), MsCI (methanesulfonyl chloride), MTBE (methyl tert-butyl ether), NADPH (nicotinamide adenine dinucleotide phosphate), N/D (not determined); NaOMe (sodium methoxide), NaOtPn (sodium tert-pentoxide), Pd(0Ac)2 (palladium(ll) acetate), PdCbfdppf) or Pd(dppf)Cl2 (1 ,T-bis(diphenylphosphino)ferrocene dichloropalladium (II)), Pd(PPha)4 (tetrakis(triphenylphosphine)palladium(O)), Pet. Ether (petroleum ether),
Ph (phenyl), 2-PrOH (isopropanol, 2-propanyi), t-Bu (tert-butyl), TBAF(tetra-nbutylammonium fluoride), TBS (tert-butyldimethylsilyl), TMG (tetramethylguanidine), TBSCI (tert-butyldimethylsilyl chloride), TEA (triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TM EDA (tetramethylethylenediamine), and X-Phos (210 dicyclohexylphosphino-2,,4',6,-triisopropylbiphenyl).
In addition, TLC refers to thin layer chromatography, HPLC refers to highperformance liquid chromatography, LCMS refers to liquid chromatography-mass spectrometry, and S FC (supercritical fluid chromatography).
Other abbreviations: rt or Rt (rétention time), min (minute or minutes), h (hour or 15 hours), RT (room température), aq. (aqueous), said. (saturated), eq or eq.
(equivalent(s)).
The term “halogen”, as used herein, refers to a fluorine, chlorine, bromine, or iodine atom or fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
The term “alkyl”, as used herein, refers to saturated monovalent hydrocarbon 20 radicals containing, in certain embodiments, from one to six, or from one to three carbon atoms, having straight or branched moieties. The term “C1-C4 alkyl” refers to an alkyl radical containing from one to four carbon atoms, having straight or branched moieties. The term “C1-C4 alkyl” includes within its définition the term “C1-C3 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 25 butyl, isobutyl, sec-butyl, and tert-butyl.
The term alkoxy”, as used herein, refers to an alkyl radical that is single bonded to an oxygen atom. The attachaient point of an alkoxy radical to a molécule is through the oxygen atom. An alkoxy radical may be depicted as alkyl-O-. The terms “C1-C4 alkoxy” and “C1-C3 alkoxy”, refer to an alkoxy radical containing from one to four carbon 30 atoms and from one to three carbon atoms, respectively, having straight or branched moieties. Alkoxy groups, include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like.
-25The term ‘aryl , as used herein, refers to a cyclic group derived from an aromatic hydrocarbon. The term “Ce-Cio aryl” contains from six to ten carbon atoms. Examples of such groups include, but are not limited to, phenyl and naphthyl. The term “aryl” also includes fused polycyclic aromatic ring Systems in which an aromatic ring is fused to one or more rings. Examples include, but are not limited to, 1 -naphthyl, 2-naphthyl, 1 anthracyl and 2-anthracyl. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl (2,3-dihydro-1/7-indene) or tetrahydronaphthyl (also known as 1,2, 3, 4-tetrahydronaphthyl), where the radical or point of attachment is on the aromatic ring.
The term “heterocycle” as used herein, refers to a group derived from an aryl group, in which at least one of the ring carbon atoms has been replaced with a heteroatom selected from oxygen, nitrogen and sulfur.
The term “heteroaryl, as used herein, refers to a group derived from an aromatic monocyclic or bicyclic heterocycle, and in particular with respect to the bicyclic heterocycle, to a benzo-fused heterocyclic group, in which an aromatic or non-aromatic heterocycle is fused to a phenyl group. As used herein, the term “5 membered heteroaryl” has a total of 5 atoms in its ring system, the term “5-6 membered heteroaryl”, has a total of 5 or 6 atoms in its ring system, and the term “5-9 membered heteroaryl” has a total of 5, 6, 7, 8 or 9 atoms in its ring system. Additionally, each of the 5 membered heteroaryl”, “5-6 membered heteroaryl” and “5-9 membered heteroaryl” groups hâve one, two or three heteroatoms independently selected from nitrogen and oxygen, with the proviso that the ring system does not contain two adjacent oxygen atoms. Examples include, but are not limited to, pyrazolyl and triazolyl. As used herein, the term “9-10 membered heteroaryl”, has a total of 9 or 10 atoms in its ring system, and one or two heteroatoms each independently selected from nitrogen and oxygen, with the proviso that the ring system does not contain two adjacent oxygen atoms.
-26Examples of a “9-10 membered heteroaryl, according to the présent invention, include, but are not limited to,
2H-isoindole 1 H-indazole
3/7-indole (3H-indolyl)
1H-indole (1 H-indolyl) (2H-isoindolyl) (1H-indazolyl)
benzimidazole (benzimidazolyl) benzofuran (benzofuranyl) iso benzofuran (isobenzofuranyl)
benzo[d]isozazole, 1,2-benzisoxazole (benzo[d]isozazolyl, 1,2-benzisoxazolyl) benzo[c]isozazole, 2,1-benzisoxazole (benzo[dcisozazolyl, 2,1-benzisoxazolyl) benzo[d]oxazole, benzoxazole (benzo[d]oxazolyl, benzoxazolyl)
quinoiine (quinolinyl) isoquinoline quinoxîlîne quinazoline (isoquinoiinyl) (quinoxilinyl) (qumazoltnyl)
2H-chromene 1H-isochromene 2H-benzo[b][1,4]oxazine 2/7-benzo[e][1,3]oxazine (2H-chromenyl) (IH-isochromenyl) (2H-benzo[b][1,4]oxazinyl) (2H-benzo[e][1,3]oxazinyl)
ch romane isoch romane (chromanyl) (îsochromanyl)
The term treating, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disease, disorder or 5 condition to which such term applies, or one or more symptoms of such disease, disorder or condition. The term “treatment”, as used herein, unless otherwise indicated, refers to the act of treating as “treating” is defined immediately above.
The term “combination”, as used herein, unless otherwise indicated, means a fixed-dose combination or a combination of agents that is administered intermittently, ίο concurrently or sequentially, according to the same or different route of administration.
As used herein, an “effective” amount refers to an amount of a substance, agent, compound, or composition that is of suffïcient quantity to resuit in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prévention of impaimnent or disability due to the disease affliction - either 15 as a single dose or according to a multiple dose regimen, alone or in combination with other agents or substances. One of ordinary skill in the art would be able to détermine such amounts based on such factors as the patient’s size, the severity of the patient’s symptoms, and the particular combination, composition or route of administration selected. The patient or subject may be a human or non-human mammal in need of 20 treatment. In one embodiment, the patient is human.
Unless indicated otherwise, ail references herein to the inventive compounds include references to salts, solvatés, hydrates and complexes thereof, and to solvatés, hydrates and complexes of salts thereof, including polymorphs, stereoisomers, and isotopically labelled versions thereof.
Embodiments disclosed herein include isotopically-labeled compounds, which are identical to those recited in formulas (I), (la) (II), (III), (IV), (V) or (VI) but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes that can be incorporated into compounds of the embodiments
-28disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chiorine, such as, but not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36CI, respectively. In one embodiment, the isotope incorporated into compounds of formulas (I), (la) (II), (III), (IV), (V) or (VI) is 2H. Compounds described herein and pharmaceutically acceptable salts of said compounds which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the présent embodiments. Certain isotopically-labeled compounds of the embodiments disclosed herein, for example, those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-labeled compounds of embodiments disclosed herein can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically-labeled reagent for a non-isotopically-labeled reagent. In one embodiment, the compounds of formulas (I), (la) (II), (III), (IV), (V) or (VI) are deuterium-labeled.
Some embodiments relate to the pharmaceutically acceptable salts of the compounds described herein. The compounds described herein that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to préparé pharmaceutically acceptable acid addition salts of such basic compounds described herein are those that form non-toxic acid addition salts, e.g., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,Tmethylene-bis-(2-hydroxy-3-naphthoate)] salts. The compounds described herein that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
-29Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds described herein are known to one of skill in the art.
The term “solvaté” is used herein to describe a molecular complex comprising a compound described herein and one or more pharmaceutically acceptable solvent molécules, for example, éthanol.
The compounds described herein may also exist in unsolvated and solvated forms. Accordingly, some embodiments relate to the hydrates and solvatés of the compounds described herein. When the solvent or water is tightly bound, the complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm. The term ‘solvaté’ is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molécules, for example, éthanol. The term ‘hydrate’ is employed when the solvent is water. Pharmaceutically acceptable solvatés in accordance with the invention include hydrates and solvatés wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, de-DMSO.
Also included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvatés, the drug and host are présent in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975), the disclosure of which is incorporated herein by reference in its entirety.
The invention also relates to prodrugs of the compounds of the formulae provided herein. Thus, certain dérivatives of compounds of the invention which may hâve little or no pharmacological activity themselves can, when administered to a patient, be converted into the inventive compounds, for example, by hydrolytic cleavage. Such
-30dérivatives are referred to as 'prodrugs. Further information on the use of prodrugs may be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T Higuchi and WStella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are 5 incorporated herein by reference in their entireties.
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the inventive compounds with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H Bundgaard (Elsevier, 1985), the disclosure of which is 10 incorporated herein by reference in its entirety.
Some non-limiting examples of prodrugs in accordance with the invention include:
(i) where the compound contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement of the hydrogen with (Ci-Cg)alkyl;
(ii) where the compound contains an alcohol functionality (-OH), an ether thereof, is for example, replacement of the hydrogen with (Ci-C6)alkanoyloxymethyl, or with a phosphate ether group; and (iii) where the compound contains a primary or secondary amino functionality (-NH2 or -N H R where R # H), an amide thereof, for example, replacement of one or both hydrogens with a suitably metabolically labile group, such as an amide, carbamate, urea, 20 phosphonate, sulfonate, etc.
Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references. Finally, certain inventive compounds may themselves act as prodrugs of other of the inventive compounds.
Also included within the scope of the invention are métabolites of compounds of the formulae described herein, i.e., compounds formed in vivo upon administration of the drug.
Compounds described herein containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound described herein contains 30 an alkenyl or alkenylene group, géométrie cis/trans (or Z/E) isomers are possible.
Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism (‘tautomerism’) can occur. This can take the form of proton tautomerism in compounds described herein containing, for example, an imino, keto, or oxime group,
- 31 or so-called valence tautomerîsm in compounds which contain an aromatic moiety. A single compound may exhibit more than one type of isomerism.
The compounds of the embodiments described herein include ail stereoisomers (e.g., cis and trans isomers) and ail optical isomers of compounds described herein (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers. While ail stereoisomers are encompassed within the scope of our claims, one ski lied in the art will recognize that particular stereoisomers may be preferred.
In some embodiments, the compounds described herein can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form ίο and géométrie isomers and mixtures thereof. Ail such tautomeric forms are included within the scope of the présent embodiments. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, the présent embodiments include ail tautomers of the présent compounds.
The présent embodiments also include atropisomers of the compounds described herein. Atropisomers refer to compounds that can be separated into rotationally restricted isomers.
Included within the scope of the présent embodiments are ail stereoisomers, géométrie isomers and tautomeric forms of the compounds described herein, including 20 compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof.
Cis/trans isomers may be separated by conventional techniques well known to those skiiled in the art, for example, chromatography and fractional crystallisation.
Conventional techniques for the preparation/isolation of individual enantiomers 25 include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high performance liquid chromatography (HPLC) or S FC.
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where a 30 compound described herein contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartane acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the
-32diastereo isomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
“Abnormal cell growth” or “cancer” as used herein, unless otherwise indicated, refers to cell growth that is îndependent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1 ) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliférative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant serine/threonine kinase activation; (5) benign and malignant cells of other proliférative diseases in which aberrant serine/threonine kinase activation occurs; (6) any tumors that proliferate by aberrant signaling, metabolic, epigenetic and transcriptional mechanism; and (7) benign and malignant cells of other proliférative diseases in which aberrant signaling, metabolic, epigenetic and transcriptional mechanism.
For convenience, certain well-known abbreviations, may be used herein, including: estrogen receptor positive (ER+), human epidermal growth factor receptor 2 négative (HER2-), non-small cell lung cancer (NSCLC) and castration résistant prostate cancer (CRPC).
Further embodiments relate to methods of treating abnormal cell growth in a patient. Additional embodiments relate to a method of treating abnormal cell growth in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating abnormal cell growth.
In other embodiments, the abnormal cell growth is cancer.
In some embodiments, the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal région, stomach cancer, hepatic carcinoma, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the pénis, prostate cancer, hematology malignancy, chronic or acute leukemia, lymphocytic
- 33 lymphomas, cancer ofthe bladder, cancer ofthe kidney or ureter, rénal cell carcinoma, carcinoma of the rénal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, glioblastoma, brain stem glioma, pituitary adenoma, or a combination of two or more of the foregoing cancers.
Additional embodiments relate to methods of treating solid tumors in a patient, Some embodiments relate to the treatment of solid tumors in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating the solid tumor.
In one embodiment, the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, or bladder.
In one embodiment, the solid tumor is breast, lung, prostate, pancreatic, or ovarian.
In one embodiment, the cancer is breast cancer.
In one embodiment, the breast cancer is ER+ breast cancer.
In one embodiment, the breast cancer is ER+ HER2- breast cancer.
In one embodiment, the breast cancer is Iocally advanced or metastatic ER+ HER2- breast cancer.
In one embodiment, the lung cancer is non-small cell lung cancer.
In one embodiment, the lung cancer is Iocally advanced or metastatic non-small cell lung cancer.
In one embodiment, the prostate cancer is castration résistant prostate cancer.
In one embodiment, the prostate cancer is Iocally advanced or metastatic castration résistant prostate cancer.
Additional embodiments relate to methods of treating hématologie tumors in a patient. Some embodiments relate to the treatment of hématologie tumors in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating the hématologie tumor.
In one embodiment, the hématologie tumor is leukemia, lymphoma or multiple myeloma.
In one embodiment, the hématologie tumor is leukemia or lymphoma.
Additional embodiments relate to methods of treating cancer in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating cancer.
- 34 In one embodiment, the cancer is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, bladder, or hématologie.
In one embodiment, the cancer is breast, lung, prostate, pancreatic, ovarian, or hématologie.
In one embodiment, the cancer is breast, lung, prostate, pancreatic, or ovarian.
In one embodiment, the cancer is breast cancer.
In one embodiment, the breast cancer is ER+ breast cancer.
In one embodiment, the breast cancer is ER+ HER2- breast cancer.
In one embodiment, the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.
In one embodiment, the lung cancer is non-small cell lung cancer.
In one embodiment, the lung cancer is locally advanced or metastatic non-small cell lung cancer.
In one embodiment, the prostate cancer is castration résistant prostate cancer.
In one embodiment, the prostate cancer is locally advanced or metastatic castration résistant prostate cancer.
In one embodiment, the cancer is hématologie.
In one embodiment, the hématologie tumor is leukemia or lymphoma.
Further embodiments relate to methods of treating cancer in a patient which comprises administering to the patient an amount of a compound described herein that is effective in treating cancer in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, antihormones, and anti-androgens.
More embodiments relate to pharmaceutical compositions for treating cancer in a patient comprising an amount of a compound described herein that is effective in treating cancer, and a pharmaceutically acceptable carrier.
Additional embodiments relate to a method of treating cancer in a patient, and in particular a human, comprising administering to the patient an amount of a compound described herein, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof, that is effective in treating cancer. In one embodiment of this method, the cancer, includes, but is not limited to, lung cancer, bone cancer, pancreatic cancer, skin
- 35 cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal région, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine System, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the pénis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, rénal cell carcinoma, carcinoma of the rénal pelvis, neoplasms of the central nervous System (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In one embodiment the method comprises comprising administering to a patient an amount of a compound described herein that is effective in treating said cancer solid tumor. In one preferred embodiment the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder cancer.
In another embodiment of said method, said cancer is a benign proliférative disease, inciuding, but not limited to, psoriasis, benign prostatic hypertrophy or reste nosis.
Some embodiments relate to a method of treating cancer in a patient which comprises administering to said patient an amount of a compound described herein, or a pharmaceutically acceptable sait, solvaté, hydrate or prodru g thereof, that is effective in treating cancer in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalaîing antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
Additional embodiments relate to a pharmaceutical composition for treating cancer in a patient, and in particuiar a human, comprising an amount of a compound described herein, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof, that is effective in treating cancer, and a pharmaceutically acceptable carrier. In one embodiment of said composition, the cancer, inciudes, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck,
-36cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal région, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma ofthe vagina, carcinoma ofthe vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer ofthe pénis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, rénal cell carcinoma, carcinoma of the rénal pelvis, neoplasms of the central îo nervous System (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said pharmaceutical composition, said abnormal cell growth is a benign proliférative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.
Further embodiments relate to a method of treating cancer in a patient which comprises administering to said patient an amount of a compound described herein, or a pharmaceutically acceptable sait, solvaté, or hydrate thereof, that is effective in treating cancer in combination with another anti-tumor agent seiected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens. Some embodiments contemplate a pharmaceutical composition for treating abnormal cell growth wherein the composition includes a compound described herein, or a pharmaceutically acceptable sait, solvaté, or hydrate thereof, that is effective in treating abnormal cell growth, and another anti-tumor agent seiected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, antihormones, and anti-androgens.
Yet more embodiments relate to a method of treating a disorder associated with angiogenesis in a patient, including a human, comprising administering to said patient an amount of a compound described herein, as defined above, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof, that is effective in treating said
- 37 disorder m combination with one or more anti-tumor agents listed above. Such disorders include cancerous tumors such as melanoma; ocular disorders such as agerelated macular degeneration, presumed ocular histoplasmosis syndrome, and retinal neovascularization from proliférative diabetic retinopathy; rheumatoid arthritis; bone loss disorders such as osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and osteoporosis induced by glucocorticoid treatment; coronary restenosis; and certain microbial infections including those associated with microbial pathogens selected from adenovirus, hantaviruses, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and group A Streptococcus.
Some embodiments relate to a method of (and to a pharmaceutical composition for) treating cancer in a patient which comprise an amount of a compound described herein, or a pharmaceutically acceptable sait, solvaté, or hydrate thereof, in combination with an amount of one or more substances selected from antiangiogenesis agents, signal transduction inhibitors (e.g., inhibiting the means by which regulatory molécules that govern the fondamental processes of cell growth, différentiation, and survival communicated within the cell), and antiproliférative agents, which amounts are together effective in treating said abnormal cell growth.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound described herein in the methods and pharmaceutical compositions described herein.
Tyrosine kinase inhibitors can also be combined with a compound described herein.
VEGF inhibitors, for example, sutent and axitinib, can also be combined with a compound described herein.
ErbB2 receptor inhibitors may be administered in combination with a compound described herein. Various other compounds, such as styrene dérivatives, hâve also been shown to possess tyrosine kinase inhibitory properties, and some of tyrosine kinase inhibitors hâve been identified as erbB2 receptor inhibitors.
Epidermal growth factor receptor (EGFR) inhibitors may be administered in combination with a compound ofthe present invention.
- 38 PI3K inhibitors, such as PI3K alpha or PI3K beta inhibitors, may be administered in combination with a compound of the présent invention.
Mammalian target of rapamycin (mTOR) inhibitors may be administered in combination with a compound ofthe présent invention.
c-Met inhibitors may be administered in combination with a compound of the présent invention.
CDK inhibitors may be administered in combination with a compound of the présent invention.
MEK inhibitors may be administered in combination with a compound ofthe présent invention.
PARP inhibitors may be administered in combination with a compound of the présent invention.
JAK inhibitors may be administered in combination with a compound of the présent invention.
An antagonist of a Programmed Death 1 protein (PD-1) may be administered in combination with a compound ofthe présent invention.
An antagonist of Programmed Death-Ligand 1 (PD-L1) may be administered in combination with a compound of the présent invention.
Other antiproliférative agents that may be used with the compounds described herein include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr.
A compound described herein may also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocyte antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliférative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase.
A compound described herein may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic inhibitors, alkylating agents, anti-metabolites, growth factor inhibitors, cell cycle inhibitors, intercalating antibiotics, enzymes, and anti-hormones.
The compounds described herein may be used alone or in combination with one or more of a variety of anti-cancer agents or supportive care agents. For example, the
- 39 compounds described herein may be used with cytotoxic agents. Some embodiments also contemplate the use of the compounds described herein together with hormonal therapy. Further, some embodiments provide a compound described herein alone or in combination with one or more supportive care products, e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
The compounds described herein may be used with antitumor agents, alkylating agents, antimetabolites, antibiotics, plant-derived antitumor agents, camptothecin dérivatives, tyrosine kinase inhibitors, antibodies, interférons, and/or biological response modifiers. In this regard, the following is a non-limiting list of examples of secondary agents that may be used with the compounds described herein.
Some embodiments also relate to a pharmaceutical composition comprising a compound of formulas (I), (la) (II), (111), (IV), (V) or (VI), or a pharmaceutically acceptable sait or solvaté thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
Further embodiments relate to a pharmaceutical composition which comprises mixing a compound of formulas (I), (la) (II), (111), (IV), (V) or (VI), or a pharmaceutically acceptable sait or solvaté thereof, as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound formulas (I), (la) (II), (111), (IV), (V) or (VI), or pharmaceutically acceptable sait thereof, may be in the range from 1 mg to 1 gram; from 1 mg to 250 mg; from 1 mg to 100 mg; from 1 mg to 50 mg; from 1 mg to 25 mg; and from 1 mg to 10 mg.
The présent embodiments also encompass sustained release compositions. Administration of the compounds described herein (hereinafter the “active compound(s)”) can be affected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parentéral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
- 40 The active compound may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic inhibitors, for example Vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No. 239362 such as N-(5-[A/-(3,4dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as Nolvadex® (tamoxifen) or, for example anti-androgens such as Casodex® (4'-cyano-3-(4-ΐluorophenylsulphonyl)-2-hydroxy-2-methyl·3'(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parentéral injection as a stérile solution, suspension or émulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of précisé dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound described herein as an active ingrédient. In addition, it may include other médicinal or pharmaceutical agents, carriers, adjuvants, etc.
Exempiary parentéral administration forms include solutions or suspensions of active compounds in stérile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingrédients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnésium stéarate, sodium lauryl sulfate and
- 41 talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or élixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, éthanol, propylene glycol, glycerin, or combinations thereof.
The examples and préparations provided below further illustrate and exemplify the compounds described herein and methods of preparing such compounds. The scope of the embodiments described herein is not limited in any way by the following examples and préparations. In the following examples, molécules with a single chiral center, unless otherwise noted, exist as a racemlc mixture. Those molécules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiemers/diastereomers may be obtained by methods known to those skilled in the art.
In the examples shown, sait forms were occasionally isolated as a conséquence of the mobile phase additives during HPLC based chromatographie purification. In these cases, salts such as formate, trifluoroacetate and acetate were isolated and tested without further processing. It will be recognized that one of ordinary skill in the art will be able to realize the free base form by standard methodology (such as using ion exchange columns, or performing simple basic extractions using a miid aqueous base).
In general, the compounds described herein may be prepared by processes known in the Chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds described herein are provided as further features of the embodiments and are illustrated in the réaction schemes provided below and in the experimental section.
EXAMPLES
The following examples are provided solely to illustrate the présent invention and are not intended to limit the scope of the invention, as described herein.
-42General Experimental Details
Unless otherwise stated the following generalizations apply. 1H NMR spectra were recorded on a Broker Ultrashield Plus (400 MHz) or a Bruker AVANCE III (400 MHz). The multiplicity of a signal is designated by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; sept, septet; dd, doublet of doublets; dt, doublet of triplets; tt, triplet of triplets; br, broad; m, multiplet. Ail observed coupling constants, J, are reported in Hertz (Hz). Exchangeable protons are not always observed. LCMS data was generated using either an Agilent 6100 Sériés Single Quad, an Agilent 1260 Infinity Sériés UPLC/MS, an Agilent 1200 (LCMS-A), a Waters 2695 alliance, an Agilent 6120 Single Quad or mass-directed HPLC-MS. Chlorine isotopes are reported as 35CI, Bromine isotopes are reported as either 79Br or81 Br or both 79Br/81Br.
Représentative LCMS methodoloqy is Drovided below:
Instrument: Agilent 6100 Sériés Single Quad LC/MS, Agilent 1200 Sériés HPLC, Pump: 1200 Sériés G1311A Quaternary pump, Autosampler: 1200 Sériés G1329A Thermostatted Autosampler, Detector: 1200 Sériés G1314B Variable Wavelength Detector
LC conditions: Reverse Phase HPLC analysis, Column: Luna C8 (2) 5 pm 50 χ 4.6 mm 100 Â, Column température: 30 °C, Injection Volume: 5 pL, Solvent A: Water 0.1 % Formic Acid, Solvent B: MeCN 0.1 % Formic Acid, Gradient: 5-100 % Solvent B over 10 min, Détection: 254 nm or 214 nm
MS conditions: Ion Source: Quadrupole, Ion Mode: Multimode-ES, Drying gastemp: 300 °C, Vaporizer température: 200 °C, Capillary voltage (V): 2000 (positive), Capillary voltage (V): 4000 (négative), Scan Range: 100-1000, Step size; 0.1 sec, Acquisition time: 10 min
LCMS method A (LCMS-A): LC model: Agilent 1200, Pump type: Binary Pump, Detector type: DAD, MS model: Agilent G6110A Quadrupole, LC conditions: Column; Xbridge-C18, 2.5 pm, 2.1x30 mm, Column température: 30 °C, Acquisition of
-43wavelength: 214 nm, 254 nm, Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH; MS conditions: MS: Ion source: ES+ (or ES-) MS range: 50 - 900 m/z, Fragmenter: 60, Drying gasflow: 10 L/min, Nebulizer pressure: 35 psi Drying gas température: 350 °C, Vcap: 3.5 kV Gradient Table :
Flow (mL/min) | T (min) | A (%) | B (%) |
0.5 | 0.0 | 70 | 30 |
0.5 | 0.2 | 70 | 30 |
0.5 | 1.8 | 5 | 95 |
0.5 | 2.4 | 5 | 95 |
0.5 | 2.6 | 70 | 30 |
0.5 | 3.5 | 70 | 30 |
Sample préparation:
The sample was dissolved in methanol, the concentration about 0.11 - 1 mg/mL, then filtered through syringe filter with 0.22 pm. (Injection volume: 1 - 10pL)
General Methods:
Unless stated otherwise, the variables in Schemes l-Vl hâve the same meanings as defined herein.
H3CO2S^X base
Ν-γΖ 11 X = N,-C(H)-
Y = N, -C(H)-
X = N, -C(H)Y = N, -C(H)-
X = N, -C(H)Y = N, -C(H)As exemplified in Scheme I, a compound of Type I can be treated with a compound of Type II in the presence of an effective base (such as CS2CO3) in an appropriate solvent (such as MeCN) to provide a compound of Type 111. A compound of Type III can be converted into a compound of Type IV by treatment with N-hydroxyacetamide in the presence of an effective base (such as K2CO3 or 1,1,3,3’tetramethylguanidine) in an appropriate solvent mixture (such as DMF/H2O). A compound of Type IV can be treated with a compound of Type V in the presence of an effective base (such as pyridine, NaH, or NaOtPn), neat, or in an appropriate solvent (such as THF or DMF) to provide a compound of Formula (A). In some cases, compounds of Type II, III, and IV, or Formula (A) may contain protecting groups, which can be appended or removed by additional steps in the synthetic sequence using conditions known in the art (Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981 or Protecting Groups, 10 Georg Thieme Verlag, 1994).Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R2a, R3, R4, R5, R6, R7, and R8 are as defined in the embodiments, schemes, examples, and claims herein.
- 45 Scheme ΙΕ:
As exemplified in Scheme II, a compound of Type VI can be deuterated by treatment with an effective base (such as CS2CO3) in an appropriate solvent (such as CD3OD) to 5 provide a compound of Type VII. A compound of Type VII can be converted into a compound of Type VIII by treatment with A/-hydroxyacetamide in the presence of an effective base (such as 1,1,3,3-tetramethylguanidine) in an appropriate solvent mixture (such as MeCN/DaO). A compound of Type VIII can be treated with a compound of Type V in the presence of an effective base (such as pyridine), neat, to provide a compound of Formula (B). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R3, R4, R5, R6, and R7 are as defined in the embodiments, schemes, examples, and daims herein.
As exemplified in Scheme III, a compound of Type IX can be converted to a compound 5 of Type X by treatment with 1 -(methanesulfonyl)-l /-Apyrazole in the presence of an effective base (such as CS2CO3) in an appropriate solvent (such as MeCN). A compound of Type X can be treated with a compound of Type V in the presence of an effective base (such as pyridine), neat, to provide a compound of Formula (C). Compounds at every step may be purified by standard techniques, such as column 10 chromatography, crystallization, or reverse phase SFC or H P LC. Variables R3, R4, R5, R6, and R7are as defined in the embodiments, schemes, examples, and claims herein.
- 47 Scheme IV:
Z = -Br, -OSO2CH3
As exemplified in Scheme IV, a compound of Type XI, with an appropriate leaving group (such as -Br or -SO2CH3) may be converted into a compound of Type VI by treatment with 1H-pyrazole in the presence of an effective base (such as CS2CO3) in an appropriate solvent (such as MeCN). A compound of Type VI may be converted into a compound of Type X by treatment with M-hydroxyacetamide in the presence of an effective base (such 1,1,3,3-tetramethylguanidine) in an appropriate solvent mixture (such as DMF/H2O). A compound of Type X can be treated with a compound of Type V in the presence of an appropriate base (such as pyridine), neat, to provide a compound of Formula (C). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R3, R4, R5, R6, and R7 are as defined in the embodiments, schemes, examples, and claims herein.
Scheme V
As exemplified in Scheme V, a compound of Type XII may be converted into a compound 5 of Type XIII by treatment with an appropriately optionally substituted 1H-pyrazole in the presence of an effective base (such as CS2CO3) in an appropriate solvent (such as MeCN). A compound of Type XIII may be converted into a compound of Type XIV under Suzuki cross-coupling conditions in the presence of an effective catalyst (such as methanesulfonato(tri-t-butylphosphino)(2amino-1,1-biphenyl-2-yl) palladium (II)) in an 10 appropriate solvent mixture (such as PhMe/HsO). A compound of Type XIV may be converted to a compound of Type XV by treatment with /V-hydroxyacetamide in the presence of an effective base (such 1,1,3,3-tetramethylguanidine) in an appropriate solvent mixture (such as DMF/H2O). A compound of Type XV can be treated with a compound of Type V in the presence of an appropriate base (such as pyridine), neat, to
- 49 provide a compound of Formula (D). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R2a, R4, R5, Rs, and R7 are as defined in the embodiments, schemes, examples, and daims herein.
Scheme VI:
deprotection
As exemplified in Scheme VI, a compound of Type XVI may be converted into a compound of Type XVII by treatment with (3,5-dimethoxyphenyl)methanol under
Mitsunobu conditions (PPha, DIAD) in an appropriate solvent (such as 2-Me-THF). A compound of Type XVII may be converted into a compound of Type XVIII under Suzuki cross-coupling conditions in the presence of an effective catalyst/ligand combination (such as Pd(OAc)2/X-Phos) in an appropriate solvent (such as CPME/H2O). A compound of Type XVII may be converted to a compound of Formula (C) by treatment with an effective acid (such as TFA) in an appropriate solvent (such as DCM). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R3, R4, R5, R6, and R7 are as defined in the embodiments, schemes, examples, and daims herein.
-50Synthesis of Intermediates:
Préparation of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01 ) according to Scheme 1.
Scheme 1:
NaOMe
MeOH, THF 52% yield
Pd(OAc)2 dppp, TEA
MeOH, 80 ’C
70% yield
LiBH4
THF, 70 ’C
96% yield
step 1 step 2 step 3
Step 1 : Synthesis of 4-bromo-2-fluoro-6-methoxybenzonitrile (1 b).
To a solution of 4-bromo-2,6-difluorobenzonitrile (1a) (40.0 g, 183.5 mmol) in THF (210.0 mL) and MeOH (30.0 mL) was added NaOMe (11.9 g, 220 mmol) portion-wise at 0 °C. The mixture was stirred at room température for 16 h. TLC analysis (1:4 EtOAc/petroleum ether) showed consumption of the starting material. The mixture was transferred to a separatory funnel and washed with H2O (150 mL). The aqueous layer was extracted with EtOAc (300 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography (330 g S1O2, 10% EtOAc/petroleum ether) to provide 4-bromo-2-fluoro6-methoxybenzonitrile (1b) (15.7 g, 52% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 7.49 (dd, J=1.5, 8.8 Hz, 1H), 7.41 (s, 1H), 3.98 (s, 3H).
Step 2: Synthesis of methyl 4Cyano-3-fluoro-5-methoxybenzoate (1c).
A solution of 4-bromo-2-fluoro-6-methoxybenzonitrile (1b) (15.7 g, 68.2 mmol), TEA (20.7 g, 205 mmol), dppp (2.8 g, 6.8 mmol), and Pd(0Ac)2 (766 mg, 3.4 mmol) in MeOH (150 mL) was stirred at 80 °C under an atmosphère of CO for 16 h. TLC analysis (1:4 EtOAc/petroleum ether) showed consumption of the starting material. The réaction was concentrated to dryness. The residue was purified by flash chromatography (120 g SiO2, 1:4 EtOAc/petroleum ether) to provide methyl 4-cyano-3-fluoro-5
- 51 methoxybenzoate (1c) (10.0 g, 70% yield) as a yellow solid. Ή NMR (400 MHz, DMSOd6) δ 7.53 - 7.47 (m, 2H), 4.03 (s, 3H), 3.91 (s, 3H).
Step 3: Synthesis of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01).
To a solution of methyl 4-cyano-3-fluoro-5-methoxybenzoate (1c) (9.5 g, 45.4 mmol) in THF (50 mL) was added L1BH4 (2.0 g, 90.8 mmol) portion-wise at 0 °C. The mixture was stirred at 70 °C for 2 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was quenched by slow addition of H2O (100 mL). The mixture was transferred to a separatory funnel and extracted with EtOAc (2x150 mL). The combined organic extracts were washed with brine and saturated aqueous NaHCOs, dried over Na2SO4, filtered, and concentrated to provide 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01) (7.9 g, 96% yield) as a brown oil. 1H NMR (400 MHz, DMSO-cfe) δ 7.05 (s, 1H), 6.98 (d, J=10.0 Hz, 1 H), 4.58 (d, J=5.7 Hz, 2H), 3.95 (s, 3H).
The intermediates in the table below were prepared according to the methods used for the synthesis of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01 ). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize.
Table 1:
Compound Number | Structure/IUPAC Name | Analytïcal Data |
lnt-02 | çh3 N . F 2-fluoro-4-(hydroxymethyl)-6[(propan-2-yl)oxy]benzonitrile | 1H NMR (400 MHz, DMSO-cfe) δ 7.04 (s, 1H), 6.93 (d, J=10.0 Hz, 1H), 5.58 (t, J=5.8 Hz, 1H), 4.80 (sept, J=6.1 Hz, 1 H), 4.56 (d, J=6.0 Hz, 2H), 1.32 (d, J=6.0 Hz, 6H). |
lnt-03 | F | 1H NMR (400 MHz, DMSO-cfe) δ 7.32 (S, 1 H), 7.00 (d, J=9.8 Hz, 1 H), 5.64 (t, J=5.8 Hz, 1H), 4.59 (d, |
2-(cyclopropyloxy)-6-fluoro-4(hydroxymethyl)benzonitrile | J=5.8 Hz, 2H), 4.13-4.01 (m, 1H), 0.91 -0.73 (m,4H). | |
lnt-04 | ch3 % î ,όη F 2-ethoxy-6-fluoro-4- (hydroxymethyl)benzonitrile | ^H NMR (400 MHz, DMSO-d6) δ 7.02 (S, 1H), 6.95 (dd, J=0.6, 10.0 Hz, 1H), 5.57 (t, J=&.7 Hz, 1H), 4.56 (d, J=5.9 Hz, 2H), 4.21 (q, J=7.0 Hz, 2H), 1.42 - 1.34 (m, 3H). |
Alternative préparation of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (Int01) according to Scheme 2.
Step 1: Synthesis of 2,6-difluoro-4-(hydroxymethyl)benzonitrile (2b).
A solution of 2,6-difluoro-4-formylbenzonitrile (2a) (21.5 g, 129 mmol) in absolute EtOH (400 mL) was cooled in an ice-water bath to ~3 °C (internai). Solid NaBH4 (5x1 g pellets, 5.0 g, 130 mmol) was added, causing slight gas évolution. The mixture was stirred with ice-water bath cooling for 2 h and then quenched at the same température by drop-wise addition of deionized H2O (100 mL over 5 min). Aqueous HCl (2.0 N, 50 mL over 30 min) was added slowly, maintaîning the température <10 °C (internai). The solution was concentrated under vacuum to remove the EtOH. The aqueous residue was transferred to a separatory tunnel, leaving behind a gummy white solid. The aqueous phase was extracted with EtOAc (2x). The combined organic extracts were washed with b ri ne (2x), dried over MgS04, filtered, and concentrated. The cru de material was triturated with heptane, filtered, and dried under vacuum to provide 2,6
- 53 difluoro-4-(hydroxymethyl)benzonitrile (2b) (21.3 g, 98%) as a free-flowing white solid. 1H NMR (400 MHz, DMSO-cte) δ 7.34 (d, J=9.3 Hz, 2H), 5.69 (br. s, 1H), 4.60 (br. s, 2H).
Step 2: Synthesis of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01 ).
A solution of 2,6'difluoro-4-(hydroxymethyl)benzonitrile (2b) (21.3 g, 126 mmol) in anhydrous MeOH (400 mL) was cooled to -40 °C (internai) with a dry ice/acetonitrile bath. A solution of NaOMe (5.0 M in MeOH, 100 mL, 500 mmol) was added over a period of 10 min via dropping tunnel addition. After the addition was complété the cooling bath was removed. The mixture was allowed to warm naturally to room température and stirred for a further 8 h. The reaction mixture was cooled to 0 °C (internai) and HCl (2.0 N, 200 mL) was added dropwise to provide a solution with pH -5-6. The mixture was concentrated under vacuum to remove the MeOH. The aqueous solution was extracted with EtOAc (3x). The combined organic extracts were washed with brine (2x), dried over MgSO4, and filtered. The mixture was concentrated to -150 mL on the rotovap (bath température -35 °C) and the resulting slurry was allowed to cool to room température. The solids were collected by filtration. The filter cake was washed with heptane (2x). The filtrate and heptane washes were further concentrated to afford a second crop of solids, which were collected by filtration. The combined solids were dried under vacuum to provide 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01) (18.6 g, 82%) as a pale yellow solid. 1H NMR (400 MHz, CDCb) δ 6.82 (s, 1H), 6.79 (d, J=9.2 Hz, 1H), 4.76 (S, 2H), 3.97 (S, 3H).
The intermediate in the table below was prepared according to the methods used for the synthesis of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01). The following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize.
Table 2:
Compound Number | Structure/IUPAC Name | Analytical Data |
lnt-05 | 0XK.0H dTd D 2-fluoro-4-(hydroxymethyl)-6- [(2H3)methyloxy]benzonitrile | 1H NMR (400 MHz, CDCh) 5 6.776.84 (m, 2H), 4.76 (d, J=4.65 Hz, 2H), 1.89 (br. t, J=5.69 Hz, 1H). |
Préparation of 2-fluoro-4-(hydroxymethyl)benzonitrile (lnt-06) according to Scheme 3.
Scheme 3:
F
3a 82% yield lnt-06
A solution of (5.0 g, 33.5 mmol) 2-fluoro-4-formylbenzonitrile (3a) in EtOH (100 mL) was cooled to 0 °C. NaBH4 (1.3 g, 33 mmol) was added and the réaction was stirred at 0 °C for 2 h. The mixture was quenched by dropwise addition of H2O (25 mL over 5 min). Dilute HCl (2 N, 13 mL) was added, maintaining the internai température <10 °C. The solution was concentrated under vacuum to remove the EtOH. The aqueous mixture was extracted with EtOAc (2x). The combined organics were washed with brine, dried over Na2SÜ4, filtered, and concentrated. The residue was triturated with heptane and dried to provide 2-fluoro-4-(hydroxymethyl)benzonitrile (lnt-06) (4.2 g, 82% yield) as a yellow solid. Ή NMR (400 MHz, DMSO-cf6) δ 7.87 (dd, J=7.9, 6.8 Hz, 1 H), 7.42 (dd, J=10.6, 1.3 Hz, 1 H), 7.35 (dd, J=8.0, 1.3 Hz, 1 H), 5.55 (t, J=5.7 Hz, 1 H), 4.60 (d, J=5.7 Hz, 2H).
Préparation of 5-bromo-4-(bromomethyl)-2-fluorobenzonitrile (lnt-07) according to Scheme 4.
Scheme 4:
MeCN, 80 °C
84% yield
lnt-07
To a solution of 5-bromo-2-fluoro-4-methylbenzonitrile (4a) (1.01 g, 4.72 mmol) in
MeCN (10.0 mL) was added 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (701 mg, 2.45 mmol) and AIBN (101 mg, 0.613 mmol). The mixture was stirred at 80 °C overnight and then concentrated to dryness. The residue was purified by flash chromatography (80 g S1O2, 0-30% EtOAc/heptane) to provide (lnt-07) (847 mg, 84% yield) as awhite solid. 1H NMR (400 MHz, CDCI3) δ 7.84 (d, 7=6.0 Hz, 1 H), 7.38 (d, 7=8.9 Hz, 1 H), 4.54 (s, 2H).
The intermediate in the table below was prepared according to the methods used for the synthesis of 5-bromo-4-(bromomethyl)-2-fluorobenzonitrile (lnt-07). The following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize.
Table 3:
Compound number | Structure/IUPAC name | Analytical data |
lnt-08 | 2-bromo-4-(bromomethyl)-6fluorobenzonitrile | 1H NMR (400 MHz, CDCI3) δ 7.53 (S, 1H), 7.18-7.22 (m, 1H), 4.40 (S, 2H). |
-56Préparation of (4-cyano-2,5~difluorophenyl)methyl methanesulfonate (lnt-09) according to Scheme 5.
Scheme 5:
NaBH4
EtOH, 0°C
80% yield
Step 1
5b 86% yield lnt-°9
Step 2
Step 1: Synthesis of 2,5-difluoro-4-(hydroxymethyl)benzonitrile (5b)
A solution of 2,5-difluoro-4-formylbenzonitnle (5a) (250 mg, 1.5 mmol) in EtOH (5.0 mL) was cooled to 0 °C with an ice bath and then NaBH4 (60 mg, 1.6 mmol) was added. The mixture was stirred for 30 min at 0 °C. The reaction was quenched at the same température by addition of H2O (0.5 mL) and HCl (6.0 N, 0.32 mL). The mixture was extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCOs and brine, dried over Na2SO4, filtered, and concentrated to provide 2,5-difluoro-4(hydroxymethyl)benzonitrile (5b) (202 mg, 80% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.44 (dd, J=5.62, 8.80 Hz, 1H), 7.30 (dd, J=4.89, 8.56 Hz, 1H), 4.85 (s, 2H).
Step 2: Synthesis of (4-cyano-2,5-difluorophenyl)methyl methanesulfonate (Int09)
A solution of 2,5-difluoro-4-(hydroxymethyl)benzonitrile (5b) (915 mg, 5.41 mmol) in DCM (25.0 mL) was cooled to 0 °C and then TEA (871 mg, 5.84 mmol) and MsCI (649 g, 5.66 mmol) were added. After 2 h, the reaction was loaded directly onto SIO2 and purified by flash chromatography (40 g S1O2, 0-75% EtOAc/heptane) to provide (4cyano-2,5-difluorophenyl)methyl methanesulfonate (lnt-09) (1.15 g, 86% yield) as a clear oil, which solidified upon standing. 1H NMR (400 MHz, CDCIa) δ 7.44 - 7.39 (m, 2H), 5.34-5.32 (m, 2H), 3.14 (s, 3H).
The intermediate in the table below was prepared according to the methods used for the synthesis of (4-cyano-2,5-difluorophenyl)methyl methanesulfonate (lnt-09). The
-57following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Table 4:
Compound number | Structure/IUPAC name | Analytical data |
lnt-10 | N. î o CH> (4-cyano-3,5difluorophenyl) methyl methanesulfonate | Ή NMR (400 MHz, CDCIa) δ 7.12 (d, J=7.5 Hz, 2H), 5.25 (s, 2H), 3.12 (S, 3H). |
Préparation of 2-fluoro-4-(hydroxymethyl)-5-methylbenzonitrile (lnt-11) according to Scheme 6.
Scheme 6:
PdCI2(dppf) TEA, CO bar, MeOH, 55 °C
79% yield step 1
LiBH4
THF 82% yield step 2
lnt-11
Step 1 : Synthesis of methyl 4-cyano-5-fluoro-2-methylbenzoate (6b)
To a solution of 4-bromo-2-fluoro-5-methylbenzonitrile (6a) (1.0 g, 4.67 mmol) and TEA (1.7 g, 17 mmol) in MeOH (30.0 mL) in a 100 mL stainless Steel vessel was added PdChfdppf) (247 mg, 0.327 mmol). The vessel was pressurized with CO to 4 bar and stirred at 55 °C for 20 h. The réaction was filtered and concentrated. The residue was purified by flash chromatography (40 g Si02, 0-55% EtOAc/heptane) to provide methyl 4-cyano-5-fluoro-2-meîhylbenzoate (6b) (716 mg, 79% yield) as a white solid. 1H NMR (400 MHz, CDCh) δ 7.74 (d, J=9A Hz, 1H), 7.52 (d, J=6.1 Hz, 1H), 3.95 (s, 3H), 2.59 (S, 3H).
- 58 Step 2: Synthesis of 2-fluoro-4-(hydroxymethyl)-5-methylbenzonitrile (lnt-11) To a solution of methyl 4-cyano-5-fluoro-2-methylbenzoate (6b) (710 mg, 3.68 mmoi) in THF (18.4 mL) was added LiBH4 (120 mg, 5.51 mmol) and the mixture was stirred at room température overnight. The reaction was quenched with H2O (3 mL). The mixture was stirred for 30 min and then cooled with an ice bath. The mixture was carefully quenched with HCl (6.0 N, 0.60 mL). The THF was removed under vacuum and the residue was partitioned between EtOAc and 1:1 HaO/saturated aqueous NaHCOs. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (24 g SiOs, 0-80% EtOAc/heptane) to provide 2-fluoro-4-(hydroxymethyl)-5-methylbenzonitrile (lnt-11) (495 mg, 82% yield) as a white solid. 1H NMR (400 MHz, CDCi3) δ 7.44-7.35 (m, 2H), 4.74 (d, J=5.5 Hz, 2H), 2.26 (s, 3H), 1.84 (t, J=5.5 Hz, 1H); 19F NMR (376 MHz, CDCI3) δ -110.29 (dd, J=5.7, 10.3 Hz).
Préparation of (3-amino-5-fluoro-4-methoxy-1,2-benzoxazol-6-yl)methanol (lnt-12) according to Scheme 7.
Scheme 7
F
F 7a
CHO
NaBH4
THF, 0 °C
41% yield step 1
87% yield
7b
LDA; TsCN THF, -70 °C step 2 step 3
24% yield (2 steps) lnt-12
7e
46% yield
MaOMe
THF, 0 °C
NC
OTBS
7d step 5 step 4
- 59 Step 1: Synthesis of (2,3,5-trifluorophenyl)methanol (7b)
To a solution of 2,3,5-trifluorobenzaldehyde (7a) (1.8 g, 11 mmol) in THF (30 mL) was added NaBH4 (468 mg, 12.4 mmol) portion-wise at 0 “C. The mixture was stirred at 0 °C for 2 h. LCMS analysis showed consumption of the starting material. The réaction was quenched by slow addition of H2O (10 mL) and concentrated to dryness. The residue was purified by flash chromatography (40 g S1O2, 0-50% EtOAc/heptane) to provide (2,3,5-trifluorophenyl)methanol (7b) (740 mg, 41% yield) as a colorless oil. 1H NMR (400 MHz, CDCh) ô 7.10 - 6.96 (m, 1 H), 6.94 - 6.78 (m, 1 H), 4.81 (d, J=5.9 Hz, 2H), 1.91 (t, J=6.1 Hz, 1H).
Step 2: Synthesis of tert-butyl(dimethyl)[(2,3,5-trifluorophenyl)methoxy]silane (7c) To a solution of (2,3,5-trifluorophenyl)methanol (7b) (740 mg, 4.56 mmol) in DCM (20 mL) was added DMAP (27.9 mg, 0.228 mmol), TEA (639 mg, 6.85 mmol), and a solution of TBSCI (894 mg, 5.93 mmol) in DCM (5 mL). The mixture was stirred at ambient température for 18 h. LCMS showed consumption ofthe starting material. The mixture was concentrated to dryness and the residue was purified by flash chromatography (40 g S1O2, 0-10% EtOAc/petroleum ether) to provide tertbutyl(dimethyl)[(2,3,5-trifluorophenyl)methoxy]silane (7c) (1.1 g, 87% yield) as a colorless oil. NMR (400 MHz, CDCh) δ 7.06 - 6.95 (m, 1 H), 6.87 - 6.70 (m, 1 H), 4.79 (S, 2H), 0.95 (s, 9H), 0.13 (s, 6H).
Step 3: Synthesis of 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,3J6trifluorobenzonitrile (7d)
A solution of LDA (0.07 M in THF, 20.0 mL, 1.41 mmol ) in THF (20 mL) at was cooled to -70 °C and then treated dropwise with a solution of tert-butyl(dimethyl)[(2,3,5tri1luorophenyl)methoxy]silane (7c) (300 mg, 1.09) in THF (5 mL) over 5 min. The mixture was stirred for 2 h at -70 °C and then treated dropwise with a solution of ptolylsulfonyl cyanide (216 mg, 1.19 mmol) in THF (5 mL) over 10 min. The mixture was stirred at -70 °C for 1 h. The mixture was quenched by addition of saturated aqueous NH4CI and portioned between EtOAc (60 mL) and H2O (60 mL). The organic layer was washed with brine, dried over NazSCX filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 3:1 - 10:1 EtOAc/petroleum ether). The
-60combined product-containing fractions were repurified by préparative HPLC with an Agela DuraShell C18 column (150x25 mm, 5 pm particle size), which was eluted with 70-100% MeCN/H2O (+0.04% NhkOH, +10 mM NH4HCO3) with a flow rate 25 mL/min to provide 4-({[fert-butyl(dimethyl)silyl]oxy}methyl)-2,3,6-trifluorobenzonitrile (7d) (150 mg, 46% yieid) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.10-7.02 (m, 1H), 4.69 (s, 2H), 0.81 (s, 9H), 0.00 (S, 6H).
Step 4: Synthesis of 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3,6-difluoro-2methoxybenzonitrile (7e)
To a solution of 4-({[tert-buty!(dimethyl)silyl]oxy}methyl)-2,3,6-trifluorobenzonitrile (7d) (150 mg, 0.498 mmol) in THF (20 mL) was added NaOMe (71.7 mg, 0.398 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h. The mixture was quenched with H2O and partitioned between EtOAc and H2O. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to provide crude 4-({[tertbutyl(dimethyl)silyl]oxy}meÎhyl)-3,6-difluoro-2-methoxybenzonitrile (7e) (150 mg, 96% yieid) as a yellow oil, which was taken on without further purification.
Step 5: Synthesis of (3-amino-5-fluoro-4-methoxy-1>2-benzoxazol·6-yl)methanol (lnt-12)
To a solution of crude 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3,6-difluoro-2methoxybenzonitrile (7e) (150 mg,0.479 mmol) and M-hydroxyacetamide (108 mg, 1.33 mmol) in DMF (10 mL) and H2O (2 mL) was added K2CO3 (397 mg, 2.87 mmol). The mixture was stirred at 60 °C for 16 h. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by préparative HPLC with an Agela DuraShell C18 column (150x25 mm, 5 pm particle size), which was eluted with 5-35% MeCN/H2O H2O (+0.04% NH4OH, +10 mM NH4HCO3) with a flow rate 25 mL/min to provide (3-amino-5-fluoro-4-methoxy-1,2-benzoxazol-6-yl)methanol (lnt-12) (25 mg, 24% yieid over two steps) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 7.12 (d, J=4.3 Hz, 1H), 6.03 (s, 2H), 5.47 (t, J=5.8 Hz, 1H), 4.62 (d, J=5.6 Hz, 2H), 4.05 (s, 3H); m/z (ESI+) 213.1 (M+H)+.
Préparation of 1-(methanesulfonyl)-1H-pyrazole (lnt-13) according to Scheme 8.
-61 Scheme 8:
h3c^ n O
MsCI, TEA
DCM 90% yield
lnt-13
To a solution of 1H-pyrazole (8a) (33.0 g, 485 mmol) and TEA (73.6 mg, 727 mmol) in DCM was added MsCI (73.9 g, 645 mmol) slowly at 0 °C. The mixture was stirred at 0 °C for 10 min and then room température for 1 h. TLC analysis (1:1 EtOAc/petroleum ether) showed consumption of the starting material. The réaction was diluted with saturated aqueous NH4CI (200 mL) and the mixture was separated. The aqueous layer was extracted with DCM (200 mL). The combined organic layers were washed with brine (300 mL) and saturated aqueous Na2CO3 (300 mL), dried over anhydrous Na2S04, filtered, and concentrated to provide 1-(methanesulfonyl)-1/7-pyrazole (lnt-13) (64 g, 90% yield) as a pale-yellow oil. 1H NMR (400 MHz, CDCI3) δ 8.04 (d, J=2.6 Hz, 1 H), 7.86 - 7.79 (m, 1 H), 6.46 (dd, J=1.6, 2.7 Hz, 1 H), 3.33 (s, 3H).
The intermediates in the table below were prepared according to the methods used for the synthesis of 1-(methanesulfonyl)-1H-pyrazole (lnt-13). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize. If indicated, regioisomeric mixtures were isolated without further séparation.
Table 5:
Compound Number | Structure/IUPAC Name | Analytical Data |
lnt-14 | h3c. P S- N^/ 4-fluoro-1-(methanesuîfonyl)-1/-/pyrazole | 1H NMR (400 MHz, CDCI3) δ 7.91 (d,J=5.0 Hz, 1 H), 7.74 (d, Hz, 1 H), 3.32 (s, 3H) |
lnt-15 | H=%'° υ । j^ch3 h3c yy (~1 : 1 mixture) 1 -(methanesulfonyl)-5-methyl-1 Hpyrazole and 1-(methanesulfonyl)-3methyl-1 H-pyrazole | 1H NMR (400 MHz, CDCI3) δ 7.89 (d, J=2.8 Hz, 1H), 7.61 (s, 1 H), 6.23 (d, J=2.8 Hz, 1 H), 6.13 (S, 1 H), 3.29 (s, 3H), 3.26 (S, 3H), 2.58 - 2.37 (m, 3H), 2.37 2.28 (m, 3H) |
lnt-16 | HA/ H3C. zp 6' ΎΑ * ά 'n'\ (-5.5 : 1 mixture) 1 -(methanesulfonyl)-l H-1,2,3triazole and 2-(methanesulfonyl)-2H1,2,3-triazole | 1H NMR (400 MHz, CDCI3) ô 8.18 (d, J=1.3 Hz, 1H), 7.97 (s, 0.37H)*, 7.81 (d, J-1.3 Hz, 1 H), 3.56 (s, 3H), 3.44 (s, 0.6H)*; (*denotes peaks belonging only to minor regioisomer, multiple overlapping peaks). |
Préparation of 4-({[tert-butyl(dimethyl)silylloxy}methyl)-1-(methanesulfonyl)-1Hpyrazole (lnt-17) according to Scheme 9.
h3
o
Si CH h3c ch3
Scheme 9:
TBSCI, TEA
DCM 92% yield
MsCI, TEA
DCM OTBS
9b 80% yield
step 1 step 2
Step 1: Synthesis of 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrazole (9b).
To a solution of (1/-/-pyrazoi-4-yl)methanol (9a) (500 mg, 5.1 mmol) in DCM (10.0 mL) was added TBSCI (845 mg, 5.6 mmol), TEA (774 mg, 7.7 mmol), and DMAP (31.1 mg, 10 0.26 mmol). The solution was stirred at room température for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was diluted with DCM (20 mL) and washed successively with H2O (20 mL), saturated aqueous NaHCOa (20 mL), and brine (20 mL). The organic phase • '63' was dried over NasSCH, filtered, and concentrated to provide 4-({[iertbutyl(dimethyl)silyl]oxy}methyl)-1H-pyrazole (9b) (1.0 g, 92% yield), which wastaken on without further purification, m/z (ESI+) 212.8 (M+H)+,
Step 2: Synthesis of 4-({[tert-butyl(dîmethyl)silyl]oxy}methyl)-1(methanesulfonyl)-IH-pyrazole (lnt-17).
To a solution of 4-({[ie/7-butyl(dimethyl)silyl]oxy}methyl)-1 H-pyrazole (9b) (1.0 g, 4.7 mmol) in DCM (15.0 mL) was added TEA (619 mg, 6.1 mmol). The mixture was cooled to 0 °C with an ice-water bath. MsCI (3.8 g, 33.0 mmol) was added dropwise. The mixture was stirred for 2 h at 0 °C and room température for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was diluted with DCM (100 mL) and washed with successively with H2O (50 mL), saturated aqueous NaHCOa (50 mL), and brine (50 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to provide 4-({[tert15 butyl(dimethyl)silyl]oxy}methyl)-1-(methanesulfonyl)-1H-pyrazole (lnt-17) (1.1 g, 80% yield), which was taken on without further purification, m/z (ESI+) 291.1 (M+H)+.
The intermediate in the table below was prepared according to the methods used for the synthesis of 4-({[ieft-butyl(dimethyl)silyl]oxy}meÎhyl)-1-(methanesulfonyl)-1H20 pyrazole (lnt-17). The following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize. If indicated, regioisonnerie mixtures were isolated without further séparation.
Table 6:
Compound Number | Structure/IUPAC Name | Analytical Data |
lnt-18 | H3O ZO s h3c ch3 H C ?H3 T A * ° 'si CH3 3 A æA/ H3C-S-n Y 0 YcH, H3C^Si CH3 h3c ch3 (unseparated mixture) 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1- (methanesulfonyl)-IH-pyrazole and 3-({[terL | m/z (ESI+) 291.1 (M+H)+ |
butyl(dimethyl)silyl]oxy}methyl)-1- | ||
(methanesulfonyl)-l H-pyrazole |
Préparation of 2,4,6-trîmethoxybenzene-1-sulfonyl chloride (lnt-19) according to Scheme 10.
Scheme 10:
ciso3h neat, -10 eC
60% yield
H3CO
lnt-19
Chlorosulfuric acid (15.0 mL) was cooled to -10 °C and 1,3,5-trimethoxybenzene (10a) (1.4 g, 8.4 mmol) was added in one portion. The mixture was stirred at -10 °C for 15 min. TLC analysis (1:1 EtOAc/petroleum ether) indicated consumption of the sterling material. The reaction was quenched by carefully pou ring over ice-water. The mixture was extracted with DCM (3x100 mL). The combined organic extracts were washed with saturated aqueous NaHCOa (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (20 g SiO2, 0-50% EtOAc/petroleum ether) to provide 2,4,6-trimethoxybenzene-1-sulfonyl chloride (lnt-19) (1.8 g, 60% yield) as a solid, which was taken on without further purification. NMR (400 MHz, CDCI3) δ 6.12 (s, 2H), 3.96 (S, 6H), 3.89 (S, 3H).
The intermediate in the table below was prepared according to the methods used for the synthesis of 2,4,6-trimethoxybenzene-l-sulfonyl chloride (lnt-19). The following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that one skiMed in the art would be able to realize.
Table 7:
Compound Number | Structure/IUPAC Name | Analytical Data |
lnt-20 | H3C.„ 9 O ri J O γ kCH3 5-ethyl-2,4-dimethoxybenzene-1 sulfonyl chloride | Ή NMR (400 MHz, CDCh) δ 7.71 (s, 1 H), 6.63 - 6.42 (m, 1 H), 4.05 (S, 3H), 3,94 (S, 3H), 2.60 (q, J=7.5 Hz, 2H), 1.20 (t, J=7.5 Hz, 3H). |
Préparation of 2-methoxy-5-(trifluoromethoxy)benzene-1-sulfonyl chloride (lnt-21) according to Scheme 11.
Scheme 11 :
och3
ocf3
11a
CISOjH neat, 0 °C - rt
86% yield
OCF3 lnt-21
Chlorosulfuric acid (26.0 mL) was cooled to 0 °C and 1 -methoxy-4îo (trifluoromethoxy)benzene (11a) (2.0 g, 10.4 mmol) was added in one portion, The mixture was stirred at room température for 18 h. The reaction was quenched by carefully pouring over ice-water. The mixture was extracted with EtOAc (2x60 mL). The combined organic extracts were washed with saturaîed aqueous NaaCOs (50 mL), dried over Na2SO4, fîltered, and concentrated to provide 2-methoxy-515 (trifluoromethoxy)benzene-l -sulfonyl chloride (lnt-21) (2.6 g, 86% yield) as a yellow oil, which was taken on without further purification. ‘'H NMR (400 MHz, CDCh) δ 7.85 (d, J=2.8 Hz, 1H), 7.56 (dd, J=2.4, 9,1 Hz, 1H), 7.16 (d, J=9.2 Hz, 1 H), 4.08 (s, 3H).
Préparation 2-methoxy-5,6,7,8-tetrahydronaphthalene-1-sulfonyl chloride and 3methoxy-5,6,7,8-tetrahydronaphthalene-2-suifonyl chloride (lnt-22) according to Scheme 12.
A mixture of CHCIg (10.0 mL) and chlorosulfuric acid (1.0 mL) was cooled to -10 °C and 6-methoxy-1,2,3,4-tetrahydronaphthalene (12a) (1.0 g, 6.1 mmol) was added. The mixture was stirred at -10 °C for 15 min. TLC analysis (1:1 EtOAc/petroleum ether) indicated consumption of the starting material. The reaction was quenched by carefully pouring over ice-water. The mixture was extracted with DCM (3x50 mL). The combined organic extracts were washed with saturated aqueous NaHCOs (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (40 g S1O2, 0-50% EtOAc/petroleum ether) to provide 2-methoxy-5,6,7,8- tetrahydronaphthalene-1-sulfonyl chloride and 3-methoxy-5,6,7,8tetrahydronaphthalene-2-suifonyl chloride (lnt-22) (-1:1 mixture, 600 mg, 37% yield) as apaleyellowgum.1H NMR (400 MHz, CDCI3) 5 7.65 (s, 1H), 7.35 (d, J=8.5 Hz, 1H), 6.92 (d, J=8.5 Hz, 1 H), 6.79 (s, 1 H), 4.01 (s, 6H), 3.23 (t, J=6.0 Hz, 2H), 2.91 - 2.63 (m, 6H), 1.88 - 1.69 (m, 8H).
The intermediate in the table below was prepared according to the methods used for the synthesis of 2-methoxy-5,6,7,8-tetrahydronaphthalene-1-sulfonyl chloride and 3methoxy-5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride (lnt-22). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Table 8:
Compound number | Structure/IUPAC name | Analytical data |
lnt-23 | %-cl OCX ch3 6-methoxy-2,3-dihydro-1/7-indene- 5-sulfonyl chloride | Ή NMR (400 MHz, CDCI3) δ 7.77 (S, 1H), 6.99 (s, 1H), 4.03 (S, 3H), 3.00 (t, J=7.5 Hz, 2H), 2.92 (t, J=7.5 Hz, 2H), 2.16 (p, J=7.5 Hz, 2H). |
Préparation of 4-cyclopropyl-2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-24) according to Scheme 13.
Scheme 13:
1. n-BuLi, TMEDA
13a lnt-24
55% yield
A solution of (13a) (1.0 g, 5.61 mmol) (J. Org. Chem. 2008, 7481-7485) and TMEDA (717 mg, 6.17 mmol) in petroleum ether (15.0 mL) was cooled in an ice-water bath and then treated dropwise with n-BuLi (2.5 M in hexanes, 2.5 mL, 6.17 mmol) via addition tunnel, maintaining the température <5 °C (internai). The mixture was stirred at 0 °C for is 20 min and then cooled to -70 °C with a dry-ice/acetone bath. A pre-cooled solution (-65 °C) of SO2 (5.4 g, 84.2 mmol) in Et?O (100 mL) was added slowly, maintaining the température < -60 °C (internai). The pale-yellow reaction mixture was slowly warmed to
-6810 °C. The résultant solids were collected by filtration and washed with dry Et20. The filter cake was suspended in hexane (30 mL) and the mixture was cooled to 0 °C. To the cold suspension was added a solution of SOCI2 (757 mg, 5.61 mmol) in hexane (20 mL) slowly, maintaining the température <3 °C (internai). The resulting mixture was stirred at 0 °C for 18 h. The solution was filtered and the filter cake was washed with cold hexane (20 mL). The solids were taken up in EtOAc (50 mL) and washed with H2O (50 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to provide 4-cyclopropyl-2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-24) (856 mg, 55% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 6.32 (s, 2H), 3.97 (s, 6H), 1.93 (tt, J=5.0, 8.3 Hz, 1H), 1.18-1.11 (m, 2H), 0.86-0.80 (m, 2H).
Préparation of 4-methoxy-6-((4-methyl-1 H-pyrazol-1 -yl)methyl)benzo[d]isoxazol-3amine (lnt-25) according to Scheme 14.
Scheme 14:
step 3
CH3
Step 1 : Synthesis of 4-(bromomethyl)-2-fluoro-6-methoxybenzonitrile (14b).
To a solution of 24luoro-4-(hydroxymethyl)-6-methoxybenzonÎtrile (lnt-01 ) (8.0 g, 44.2 mmol) and PPh3 (18.7 g, 71.2 mmol) in acetonitrile (400 mL) was added Br2 (11.8 g, 73.8 mmol) and the mixture was heated at 55 °C for 2 h. Water and excess Na2SOs
-69were added and the mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Pet.
Ether/EtOAc = 10/1) to give the title compound (9.7 g, 91 %) as a white solid, which was 5 used directly in the next step.
Step 2: Synthesis of 2-fluoro-6-methoxy-4-((4-methyl-1H-pyrazol-1yl)methyl)benzonitrile (14c).
A mixture of 4-(bromomethyl)-2-fluoro-6-methoxybenzonitrile (14b) (100 mg, 0.41 10 mmol), 4-methyl-1/-/-pyrazole (40 mg, 0.49 mmol) and K2COs(113 mg, 0.82 mmol) in
DM F (5 mL) was heated at 60 °C overnight. The mixture was diluted with water, extracted with EtOAc and the organic extract was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The reaction was scaled up accordingly using 4-(bromomethyl)-2-fluoro-6-methoxybenzonitrile (14b) (500 mg, 2.05 15 mmol) and the two batches were combined and purified by column chromatography (DCM/MeOH = 10/1) to give the title compound (380 mg, 63%) as a yellow solid. m/z 246.0 [M+H]4.
Step 3: Synthesis of 4-methoxy-6-((4-methyl-1H-pyrazol-120 yl)methyl)benzo[c/]isoxazol-3-amine (lnt-25)
To a solution of N-hydroxyacetamide (238 mg, 3.18 mmol) in anhydrous DMF (13 mL) at 0 °C was added t-BuOK (357 mg, 3.18 mmol) and the mixture was stirred for 30 min. 2-Fluoro-6-methoxy-4-((4-methyl-1H-pyrazol-1-yl)methyl)benzonitrile (14c) (260 mg, 1.06 mmol) was then added and the mixture was allowed to warm to RT and stirred 25 overnight. Water was added and the mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 50/1 ) to give the title compound (150 mg, 55%) as a yellow solid. m/z 259.1 [M+H]+. 1H NMR (400 MHz, CDCIs) δ 7.37 (s, 1H), 7.20 (s, 1H), 6.76 (s, 1H), 6.43 (s, 1H), 5.31 (s, 2H), 30 3.90 (S, 3H), 2.07 (s, 3H).
Préparation of 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) according to Scheme 15.
-70h3Cs
ch3
Scheme 15:
15a lnt-26
To a solution of 1,3-dimethoxybenzene (5.0 g, 36 mmol) and TMEDA (4.6 g, 39.8 mmol) 5 in n-hexane (100 mL) at 0 °C under N2 was added n-BuLi (2.5 M solution in hexanes, 16.0 mL, 39.8 mmol) dropwise while keeping the internai réaction température below 5 “C. The mixture was stirred at 0 °C for 20 min then cooled to -78 °C and bubbled with SO2 gas for 20 min. The mixture was then allowed to warm slowly to 10 °C and the resulting precipitate was collected by filtration and washed with dry diethyl ether. The solid was suspended in n-hexane (100 mL), cooled to 0 °C and a solution of SO2CI2 (4.9 g, 36 mmol) in n-hexane (20 mL) was added dropwise while keeping the internai température below 3 °C. The mixture was then stirred at 0 °C for 1 h and the solids were collected by filtration and washed with cold n-hexane. The solids were then partîtioned between diethyl ether and water, the layers were separated and the aqueous layer was further extracted with diethyl ether. The combined organic extracts were dried over anhydrous Na2SÛ4, filtered and concentrated under reduced pressure to give the title compound (4.0 g, 47%) as a whîte solid. 4H NMR (400 MHz, CDCh) δ 7.54 (t, J=8A Hz, 1 H), 6.66 (d, J=8.4 Hz, 2H), 3.97 (s, 6H).
Préparation of N-(6-bromo-4-methoxybenzo[d]isoxazol-3-yl)-2,6dimethoxybenzenesulfonamide (lnt-27) according to Method AA.
- 71 Method AA:
LiHMDS R2_ P
RiNH2 + r2so2ci —----—--0 H
To a solution ofthe amine (0,5 mmol, 1,0 eq.) in anhydrous THF (10 mL) at -78 °C under N2 was added LiHMDS (1 M solution in THF, 3 eq.) dropwise and the mixture was stirred s at -78 °C for 30 min. A solution of the sulfonyl chloride (1.5 eq.) in anhydrous THF (2.0 mL) was then added dropwise and the mixture was allowed to warm to RT and stirred overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column ίο chromatography or prep. TLC to give the tille compound. Variations to above conditions hâve been noted in the table immediately below.
Table 9:
Name and Structure | Analytical | Intermediates | Notes |
H3C. ? O „O N-o IîVnÂÂ U- H FL ^0 0XABr CH, N-(6-bromo-4m ethoxy benzo [tf] isoxazo 1 3-yl)-2,6dimethoxybenzenesulfona mide, lnt-27 | m/z 442.9 [M+H]+; 1H NMR (400 MHz, DMSO-cfe) δ 9.80 (S, 1H), 7.547.48 (m, 2H), 7.05 (s, 1 H), 6.78 (d, J=8.4 Hz, ΞΗ), 3.92 (s, 3H), 3.76 (S, 6H). | 2,6-dimethoxy benzenesulfonyl chloride (lnt-26) 6-bromo-4methoxybenzo[c/]îs oxazol-3-amine (14b) | 4 eq. LiHMDS used. Prep. TLC (DCM/MeOH= 100/1) |
Préparation of 7-bromo-5-methylbenzo[d]isoxazol-3-amîne (lnt-28) according to Scheme 16.
Scheme 16:
step 2
step 3
16c 1601 step 5
Step 1 : Synthesis of 3-bromo-2-fluoro-5-methylbenzoic acid (16a)
To a solution of 2-bromo-1 -fluoro-4-methylbenzene (10.0 g, 53 mmol) and diisopropylamine (5.9 g, 58 mmol) in anhydrous THF (200 mL) at -78 °C under N2 was added n-BuLi (2.5 M solution in hexanes, 25.6 mL, 64.0 mmol) dropwise and the mixture stirred at -78 °C for 1 h. Excess solid CO2 (dry ice) was added and stirring was 10 continued at -78 DC for 3 h. The mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (12.3 g, 100%) as a brown solid, which was used in the next step without further purification. m/z 232.8 [M+H]+.
Step 2: Synthesis of 3-bromo-2-fluoro-5-methylbenzoyl chloride (16b)
To a solution of 3-bromo-2-fluoro-5-methylbenzoic acid (16a) (12.3 g, 53 mmol) and DMF (4 drops) in DCM (100 mL) at RT under N2 was added oxalyl chloride (13.0 g, 106 mmol) dropwise and the mixture was stirred for 2 h. The mixture was concentrated 20 under reduced pressure to give the title compound (14.0 g, 100%) as a brown solid, which was used in the next step without further purification.
-73Step 3: Synthesis of 3-bromo-2-fluoro-5-methylbenzamide (16c)
A solution of 3-bromo-2-fluoro-5-methylbenzoyl chloride (16b) (14.0 g, 53 mmol) in DCM (100 mL) was added dropwise to a 30% aqueous ammonium hydroxide solution (100 mL) and the mixture was stirred for 2 h. The mixture was diluted with EtOAc (200 mL), washed with water (200 mL x 3), brine and the organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (12.0 g, 97%) as a brown solid, which was used in the next step without further purification, m/z 231.9 [M+H]+,
Step 4: Synthesis of 3-bromo-2-fluoro-5-methylbenzonitrile (16d)
A solution of 3-bromo-2-fluoro-5-methylbenzamide (16c) (10.0 g, 43.0 mmol) and thionyl chloride (15.4 g, 129 mmol) in DMF (100 mL) was heated at 100 °C for 3 h. The mixture was diluted with EtOAc (200 mL) and washed with water (400 mL x 5), brine and the organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (5.0 g, 54%) as a brown solid, which was used in the next step without further purification, m/z 213.9 [M+H]+.
Step 5: Synthesis of 7-bromo-5-methylbenzo[d]isoxazol-3-amine (lnt-28)
A suspension of AZ-hydroxyacetamide (5.27 g, 70.2 mmol) and t-BuOK (7.88 g, 70.2 mmol) in anhydrous DMF (200 mL) was stirred at 0 °C for 1 h. 3-Bromo-2-fluoro-5methylbenzonitrile (I6d) (5.0 g, 23.4 mmol) was then added and the mixture was allowed to warm to RT and stirred overnight. The mixture was diluted with EtOAc (300 mL), washed with water (600 mL x 4), brine and the organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Pet. ether/EtOAc = 10/1) to give the title compound (2.8 g, 52%) as a yellow solid. m/z 226.9 [M+H]+.
Préparation of W-(7-bromo-5-methylbenzo[djisoxazol-3-y 1)-2,6dimethoxybenzenesulfonamide (lnt-29) according to Method AB.
r2so2ci r P
------------ S. .Ri pyridine A' N
Method AB:
R-jNHs
To a solution of the amine (0.2 mmol, 1.0 eq.) in pyridine (2 mL) was added the sulfonyl 5 chloride (1.5 eq.) and the mixture was heated at 120 °C under microwave irradiation for
h. The mixture was partitioned between water and EtOAc, the layers were separated and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep. TLC to give the title compound. Variations to above conditions hâve been noted in the table îo immediately below.
Table 10:
Name and structure | Analytical | Intermediates | Notes |
H3C-^ 9 O^O N-0 s N -JBr LÀ H TT — o N-(7-bromo-5- methylbenzo[d]isoxazol-3- yl)-2,6- dimethoxybenzenesulfonam ide, lnt-29 | m/z 427.0, 429.0 [M+H]+; 1H NMR (400 MHz, DMSOcfe) δ 11.5 (s, 1H), 7.85 (s, 1H), 7.73 (s, 1H), 7.48 (t, J=8.4 Hz, 1H), 6.75 (d, J=8.4 Hz, 2H), 3.74 | 2,6-dimethoxy benzenesulfon yl chloride (Int26) 7-bromo-5m ethyl benzofd] isoxazol-3- amine (lnt-28) | 0.2 eq. DMAP used. Organic layer washed with 0.1 M aq. HCl in workup. Prep. TLC (DCM/MeOH, 20/1) |
(s, 6H), 2.40 (s, 3H). |
Sulfonamide Formation Methods:
X = N, C-R1a lv Y = N, C-R3a
Method A:
To a solution of compound of Type IV (1.0 eq) in pyridine (c = 0.1 M) was added compound of Type V (1.2 eq). The mixture was stirred at heated at a température between 80 and 120 °C for -3-16 h. The reaction was cooled to room température, concentrated to dryness, and purified by standard methods known to those in the art to provide compound of Formula (A).
Method B:
To a suspension of NaH (60% dispersion in minerai oil, 3.0 eq) in THF (c = 0.15 M) at 0 °C was added a solution of compound of Type IV (1.0 eq) in 1:1 THF/DMF (c = 0.15 M) or THF (c = 0.15 M) drop-wise. A solution of compound of Type V (1.3 eq) in 2:1 THF/DMF (c = 0.15 M) or THF (c = 0.15 M) was added atthe same température. The réaction mixture was stirred at 60 °C for 16 h. The reaction was cooled to room température, concentrated to dryness, and purified by standard methods known to those in the art to provide compound of Formula (A).
Method C:
To a solution of compound of Type IV (1.0 eq) in THF (c = 0.3 M) was added NaOfPn (40% in PhMe, 1.0 eq) and a solution of compound of Type V (1.0 eq) in THF (c = 0.3 M). The mixture was stirred at 60 °C for 16 h. The reaction was cooled to room température, concentrated to dryness, and purified by standard methods known to those in the art to provide compound of Formula (A).
-76Method D:
To a solution of compound of Type IV (1.0 eq) and compound of Type V (1.2 eq) in ACN (c = 0.2 M) was added a 0.05 M solution of DMSO in ACN (1.0 mL/mmol compound of Type IV, 0.05 eq DMSO), followed by 3,5-lutidine (3.0 eq). The mixture was stirred at room température for 16 hours, concentrated to dryness, and purified by standard methods known to those in the art to provide compound of Formula (A).
Préparation of Examples
Example 01 : Préparation of 5-ethyl-2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme A.
Scheme A:
H3CO2Sx
CS2CO3 lnt-13
MeCN, 70 °C
78% yield
Step 1
pyridine, 80 °C
63% yield
Step 3
Step 2
KZCO3
DMF, H2O, 60°C
88% yield
- 77 Step 1: Synthesis of 2-fluoro-6-methoxy-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (A-1).
To a solution of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01 ) (7.0 g, 38,6 mmol) and 1-(methanesulfonyl)-1/-/-pyrazole (lnt-13) (6.2 g, 42.5 mmol) in MeCN (150 5 mL) was added CS2CO3 (18.9 g, 58 mmol). The mixture was stirred at 70 °C for 2 h.
LCMS analysis showed consumption of the starting material. The reaction was filtered and the filtrate was concentrated to dryness. The crude residue was purified by flash chromatography (40 g S1O2, 1:1 EtOAc/petroleum ether) to provide 2-fluoro-6-methoxy4-[(1/7-pyrazol-1 -yl)methyl]benzonitrile (A-1) (7.0 g, 78% yield) as a yellow solid. m/z 10 (ESI+) 231.8 (M+H)+.
Step 2: Synthesis of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3amine (A-2).
To a solution of 2-fluoro-6-methoxy-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (A-1) (7.0 g, is 30.3 mmol) and N-hydroxyacetamide (6.8 g, 90.8 mmol) in DM F (200 mL) and H2O (30 mL) was added K2CO3 (25.1 g, 182 mmol). The mixture was stirred at 60 °C for 16 h. TLC analysis (EtOAc) showed consumption of the starting material. The reaction mixture was concentrated to remove the majority of the DM F and then diluted with H2O (100 mL). The résultant precipitate was collected by filtration. The filter cake was washed with H2O (3x20 mL) and dried in vacuum to provide 4-methoxy-6-[(1 H-pyrazol1 -yl)methyl]-1,2-benzoxazol-3-amine (A-2) (6.0 g). The above filtrate was extracted with EtOAc (2x30 mL). The combined organic layers were dried over Na2SÛ4, filtered, and concentrated. The residue was purified by flash chromatography (S1O2, EtOAc) to provide an additional batch of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-325 amine (A-2) (0.5 g). The two batches of product were combined and dried under vacuum to provide 4-methoxy-6-[(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-amine (A2) (6.5 g, 88% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-de) δ 7.88 (d, J=2.0 Hz, 1 H), 7.51 (d, J=1.3 Hz, 1 H), 6.70 (s, 1 H), 6.63 (s, 1 H), 6.31 (t, J=2.0 Hz, 1 H), 6.08 5.78 (m, 2H), 5.52 - 5.31 (m, 2H), 3.93 - 3.73 (m, 3H). m/z (ESI+) 244.8 (M+H)+.
Step 3: Synthesis of 5-ethyl-2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 01) according to Sulfonamide Formation Method A.
- 78 To a solution of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol·3-amine (A-2) (1.23 g, 5.032 mmol) in pyridine (2.5 mL) was added 5-ethyl-2-methoxybenzene-1 sulfonyl chloride (1.54 g, 6.54 mmol). The reaction was stirred at 80 °C for 3.5 h. LCMS analysis showed consumption of the starting material with formation ofthe desired product mass. The reaction solidified upon cooling. The solid was dissolved in DCM and AcOH (1.4 mL) with a minimal amount of MeOH. The mixture was purified by flash chromatography (40 g SiO2, 10-70% MeOAc/heptane). The pure fractions containing the title compound were collected. The impure fractions were repurified by flash chromatography (40 g S1O2, 10-70% MeOAc/heptane). The pure fractions were combined with the previously isolated pure fractions and concentrated to provide a white solid. The solid was suspended in MeOAc, refluxed for 1 h, and allowed to cool to room température. The résultant solid was collected by filtration and dried under vacuum to provide 5-ethyl-2-methoxy-/V-{4-methoxy-6-[(1H-pyrazol-1-y I) methyl]-1,2benzoxazol-3-yl}benzene-1 -sulfonamide (Example 01) (1.4 g, 63% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.62 (d, J=2.3 Hz, 1H), 7.49 (d, J=1.5 Hz, 1 H), 7.46 (dd, J=2.0, 8.5 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 6.83 (S, 1H), 6.74 (s, 1H), 6.30 (t, J=2.0 Hz, 1H), 5.43 (s, 2H), 3.81 (s, 3H), 3.74 (s, 3H), 2.59 (q, J=7.5 Hz, 2H), 1.13 (t, J=7.5 Hz, 3H); m/z (ESI+) 443.1 (M+H)\
Example 02: Préparation of 2,6-dimethoxy-N-{4-methoxy-6-[(3-methyl-1H-pyrazol1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide according to Scheme B.
Example 03: Préparation of 2,6-dimethoxy-N-{4-methoxy-6-[(5-methyl-1H-pyrazol1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme B.
-79Scheme B:
,SO2CH3 ,SO2CH3
N-N N-N lr,t'15 // \ + // \ (-1:1 mixture)
W^CH3
Cs2CO3
MeCN, 70 °C 84% yield (-1:1 mixture)
B-1: R2b = CH3, R2c = H
B-2: R2b = H, R2c = CH3 step 1
K2CO3
DMF, H2O, 60 °C
O 2
HO. Jkp 75% yield u 3 (-1:1 mixture) step 2
Exampie 02: R2b = CH3, R2c = H (2% yield)
Exampie 03: R2b = H, R2c = CH3 (4% yield)
pyridine, 120 °C step 3
B-3: R2b = CH3, R2c = H
B-4: R2b = H, R2c = CH3
Step 1 : Synthesis of 2-fluoro-6-methoxy-4-[(3-nΊethyl·1H-pyrazol-1yl)methyl]benzonitrile (B-1) and 2-fluoro-6-methoxy-4-[(5-methyl-1H-pyrazol-1yl)methyl]benzonitrîle (B-2).
To a mixture (~1:1) of 1 -(methanesulfonyl)-3-methyl-1/7-pyrazole and 1 10 (methanesulfonyl)-5-methyl-1/-/-pyrazole (lnt-15) in MeCN (25 mL) was added 2-fluoro4-(hydroxymethyl)-6-methoxybenzonitrile (lnt-01) (1.0 g, 5.5 mmol) and CS2CO3 (2.3 g,
7.2 mmol). The mixture was stirred at 70 °C for 1 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was cooled to room température and concentrated to dryness. The residue was purified by flash chromatography (20 g SiO2, 100% EtOAc) to provide a mixture (-1:1) of 2-fluoro-6-methoxy-4-[(3-methyl-1H-pyrazol-1-yl)methyl]benzonitrile (B-1) and 2-fluoro-6-methoxy-4-[(5-methyl-1H-pyrazol-1-yl)methyl]benzonitrile (B-2) (1.13 g, 84% yield) as a yellow gum. m/z (ESI+) 245.8 (M+H)\
Step 2: Synthesis of 4-methoxy-6-[(3-methyl-1H-pyrazol-1-yl)methyl]-1,210 benzoxazol-3-amine (B-3) and 4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-amine (B-4).
To a mixture (-1:1) of 2-fluoro-6-methoxy-4-[(3-methyl-1H-pyrazol-1 yl)methyl]benzonitrile (B-1) and 2-fluoro-6-methoxy-4-[(5-methyl-1H-pyrazol-1yl)methyl]benzonitrile (B-2) (1.13 g, 4.73 mmol) in DMF (20 mL) and H?O (3 mL) was 15 added /V-hydroxyacetamide (1.07 g, 14.2 mmol) and K2CO3 (3.9 g, 28.4 mmol). The mixture was stirred at 60 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was concentrated to dryness. The residue was taken up in EtOAc (30 mL) and washed with H2O (30 mL). The organic layer was dried over Na2SÛ4, filtered, and concentrated. The 20 residue was purified by flash chromatography (20 g S1O2, 100% EtOAc) to provide a mixture (-1:1) of 4-methoxy-6-[(3-methyl-1H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3amine (B-3) and 4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3amine (B-4) (916 mg, 75% yield) as a solid. m/z (ΕΘΙ+) 258,8 (M+H)+.
Step 3: Synthesis of 2,6-dimethoxy-N-{4-methoxy-6-[(3-methyl-1H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 02) and 2,6dimethoxy-N-{4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3yl}benzene-1-sulfonamide (Example 03) according to Sulfonamide Formation Method A.
To a mixture (—1:1) of 4-methoxy-6-[(3-methyl-1H-pyrazol-1-yl)methyl]-1,2-benzoxazol3-amine (B-3) and 4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]-1,2-benzoxazoî-3amine (B-4) (800 mg, 3.1 mmol) in pyridine (10.0 mL) was added 2,6dimethoxybenzene-1-sulfonyl chloride (lnt-26) (1.1 g, 4.65 mmol). The mixture was
- 81 stirred at 120 °C for 2 h. The reaction was cooled to room température and concentrated to dryness. The residue was purified by flash chromatography (20 g S1O2, 1:4 MeOH/EtOAc). The material was re-purified by préparative HPLC with a YMC Tri art column (20x150 mm, 7 μηη particle size), which was eluted with 23-63% MeCN/H2O (+0.225% formic acid) with a flow rate of 25 mL/min. The material was re-purified by préparative SPC with a Diacel CHIRALCEL OD-H column (30x250 mm, 5 pm particle size), which was eluted with 45% EtOH/CO2 (+0.1% NH4OH) with a flow rate of 60 mUmin to provide 2,6-dimethoxy-M-{4-methoxy-6-[(3-methyl-1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 02) (63 mg, 4% yield) as the first eluting peak as a white solid. 1H NMR (400 MHz, DMSO-de) δ 9.62 (br. s, 1 H), 7.74 (d, J=2.1 Hz, 1H), 7.49 (t, J=8.4 Hz, 1H), 6.81 (s, 1H), 6.77 (d, J=8.3 Hz, 3H), 6.07 (d, J=2.1 Hz, 1H), 5.33 (s, 2H), 3.93-3.84 (m, 3H), 3.77 (s, 6H), 2.15 (s, 3H); m/z (ESI+) 458.8 (M+H)+. 2,6-Dimethoxy-/V-{4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}benzene-1 -sulfonamide (Example 03) (33 mg, 2% yield) was obtained as the second eluting peak as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.64 (br. s, 1 H), 7.49 (t, J=8.6 Hz, 1 H), 7.40 (d, J=1.7 Hz, 1 H), 6.78 (s, 1 H), 6.76 (s, 1 H), 6.66 (s, 1H), 6.61 (s, 1H), 6.11 (dd, J=1.8, 0.9 Hz, 1H), 5.41 (s, 2H), 3.86 (s, 3H), 3.76 (s, 6H), 2.21 (s, 3H); m/z (ESI+) 458.8 (M+H)+.
The examples in the table below were synthesized according to the methods used for the synthesis of 5-ethyl-2-methoxy-W-{4-methoxy-6-[(1 H-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1-sulfonamide (Example 01), 2,6-dimethoxy-/V-{4-methoxy-6[(3-methyl-1 H-pyrazol-1 -yi)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 02), and 2,6-dimethoxy-A/-{4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 03) and the general sulfonamide formation methods A-D. The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. If necessary, séparation of regioisomeric mixtures was carried out under standard methods known in the art, such as SFC or HPLC, and was conducted at any suitable step in the synthetic sequence.
-82 Table 11:
Example Number | Structure/IUPAC Name | Analytical Data | Sulfonamide Formation Method |
04 | 0 /r^ O-S-NH J J CH3 O W-{4-methoxy-6-[(1 /7-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzenesulfonamide | NMR (400 MHz, DMSO-c/e) δ 10.95 (br. s, 1H), 8.03-7.95 (m, 2H), 7.87 (d, J=2.3 Hz, 1H), 7.71 -7.65 (m, 1H), 7.64-7.58 (m, 2H), 7.49 (d, J=1.8 Hz, 1 H), 6.83 (S, 1H), 6.74 (S, 1H), 6.30 (t, J=2.0 Hz, 1H), 5.44 (S, 2H), 3.85 (s, 3H); m/z (ESI+) 244.7 (M+H)+. | A |
05 | JL J O O f | O=S'NH 0. H3C-°k/ ch3 Cj p h3c 2,4 -d im eth oxy-/V-{4 -m eth oxy-6[(1H-pyrazol-1-yî)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-tfe) δ 9.88 (br. S, 1H), 7.87 (d, J=2.2 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.49 (d, J=1.9 Hz, 1H), 6.81 (S, 1H), 6.74 (s, 1H), 6.69 — 6.57 (m, 2H), 6.30 (t, J=2.1 Hz, 1H), 5.43 (S, 2H), 3.86 (s, 3H), 3.82 (S, 3H), 3.77 (s, 3H); m/z (ESI+) 445.0 (M+H)+. | B |
06 | va J w o J O=S'NH Η3Ο°χ/ CH3 Cr 2-fluorO'6-methoxy-A/'{4methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | Ή NMR (400 MHz, DMSO-d6) δ 10.67 (br. S, 1H), 7.89 (d, J=2.3 Hz, 1H), 7.62 (td, J=8.5, 6.0 Hz, 1H), 7.50 (d, J=1.8 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 6.95 (dd, J=10.9, 8.4 Hz, 1H), 6.85 (s, 1H), 6.76 (s, 1 H), 6.31 (t, J=2.1 Hz, 1 H), 5.45 (S, 2H), 3.81 (s, 3H), 3.80 (s,3H); m/z (ESI+) 432.9 (M+HJ. | B |
07 | vl J Q O / f λ O=S'NH eu F H3C-°x/ CH3 />-V VY ch3 N-{6-[(4*fluoro-1 H-pyrazol-1 yl) methyl]-4-methoxy-1,2benzoxazol-3-yl}-2,6dimethoxybenzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 8,85 (br. s, 1H), 8.02 (d, J=4.6 Hz, 1H), 7.53 (d, J=4.2 Hz, 1H), 7.46 (t, J=8.5 Hz, 1 H), 6.86 (S, 1H), 6.76-6.71 (m, 3H), 5.33 (S, 2H), 3.87 (s, 3H), 3.74 (s, 6H); m/z (ESI+) 463.0 (M+H)+. | A |
08 | 'WA MU W θ / θΑΝΗ 0. HgCVx/ ch3 VJ/ CH3 Br 4-bromo-2,6-dimethoxy-N-{4- methoxy-6-[(1 H-pyrazol-1 - | 1H NMR (400 MHz, DMSO-de) δ 7.84 (d, J=2.3 Hz, 1H), 7.48 (d, J=1.9 Hz, 1H), 6.76 (s, 2H), 6.54 (S, 1H), 6.49 (S, 1H), 6.29 (t, J=2.1 Hz, 1H), 5.37 (S, 2H), 4.09 (br. s, 1H), 3.83 (s, 3H), 3.59 (s, 6H); | C |
yl)methyl]-l ,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 522.9, 524.9 (Μ+Η)+. | ||
09 | va J O ο /Vr (VNH O^.D / Va q W ch3 2,6-dim ethoxy -N-{4[(2H3)methyloxy]-6-[(1/-/-pyrazol1 -yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 9.56 (s, 1H), 7.87 (d, J=1.96 Hz, 1H), 7.43-7.55 (m, 2H), 6.83 (s, 1H), 6.77 (d, J=8.80 Hz, 3H), 6.30 (t, J=2.08 Hz, 1H), 5.44 (S, 2H), 3.76 (s, 6H); m/z (ESI+) 448.1 (M+H)+. | A |
10 | vJO V/ ο / 0=S'NH cloh3 h3c'°\V V W-A ch3 W ch3 2,6-dimethoxy-A/-{4-[(propan-2y l)oxy]-6-[(1 H-pyrazol-l yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 9.09 (s, 1H), 7.89 (d, J=2.3 Hz, 1H), 7.60-7.34 (m, 2H), 6.81 (d, J=13.0 Hz, 2H), 6.76 (d, J=9.6 Hz, 2H), 6.31 (t, J=2.1 Hz, 1H), 5.45 (S, 2H), 4.75 (sept, J=6.1 Hz, 1H), 3.75 (S, 6H), 1.34 (d,J=6.0 Hz, 6H); m/z (ESI+) 473.1 (M+H)+. | A |
11 | vXXû 0 Γ Ύ n O^S'NH i H3C'Ox/ Γ>-Α v/ ch3 /V-{4-(cyclopropyloxy)-6-[(1Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-2,6dimethoxybenzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-cfe) Ô 9.56 (s, 1H), 7.89 (dd, J=2.3, 0.7 Hz, 1H), 7.56 — 7.37 (m, 2H), 6.97 (s, 1H), 6.87 (s, 1H), 6.77 (S, 1H), 6.75 (S, 1H), 6.32 (t, J=2A Hz, 1H), 5.48 (S, 2H), 3.993.88 (m, 1H), 3.73 (s, 6H), 0.87-0.77 (m, 2H), 0.75-0.68 (m, 2H); m/z (ESI+) 471.1 (M+H)\ | B |
Ji J w o Yy o=s-nh O. H3c'°yZ CH3 ζχ | 1H NMR (400 MHz, DMSO-cfe) δ 10.16 (br. S, 1H), 7.86 (d, J=2.0 Hz, 1H), 7.75 (d, J=1.6 Hz, 1H), 7.48 (S, 2H), 7.12 (br. d,J=8.5 Hz, | ||
12 | H3C'° 2-methoxy-5-(methoxymethyl)/V-{4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | 1H), 6.77 (br. s, 1H), 6.68 (br. s, 1H), 6.29 (S, 1H), 5.42 (s, 2H), 4.37 (s, 2H), 3.81 (S, 3H), 3.75 (S, 3H), 3.25 (s, 3H); m/z (ESI+) 459.1 (M+H)+. | B |
13 | CŒ'û ο Çj 2-fluoro-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl )m ethyl]-1,2benzoxazol-3-yl}-6- methylbenzene-1 -sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 11.26 (br. S, 1H), 7.88 (d, J=2.2 Hz, 1H), 7.62-7.43 (m, 1H), 7.27-7.15 (m, 2H), 6.82 (br. s, 1H), 6.72 (br. s, 1H), 6.31 (t, J=2,1 Hz, 1H), 5.44 (S, 2H), 3.79 (s, 4H), 2.60 (s, 3H); m/z (ESI+) 417.0 (M+H)+. | B |
14 | w ο / γ^ O=S'NH H3C'°CL/ CH3 y°, ch3 H3C'° 2)4,6-trimethoxy-A/-{4-methoxy6-((1 /-/-pyrazol-1 -yl) methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | Ή NMR (400 MHz, DMSO-de) δ 9.21 (br. s, 1H), 7.88 (d, J=2.0 Hz, 1H), 7.49 (d, J=1.3 Hz, 1H), 6.81 (S, 1H), 6.75 (S, 1H), 6.30 (t, J=2.Q Hz, 1 H), 6.26 (s, 2H), 5.44 (S, 2H), 3.91 (s, 3H), 3.80 (s, 3H), 3.75 (s, 6H); m/z (ESI+) 475.1 (M+H)+. | A |
15 | vXJ w ο / γ^ O-g-NH H3C°\7 CH3 Q / V-CH3 h3c-° 5-ethyl-2,4-dimethoxy-A/-{4methoxy-6-[(1 /-/-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | Ή NMR (400 MHz, CD3OD) δ 7.78 (d, J=2.4 Hz, 1H), 7.70 (S, 1H), 7.57 (d, J=1.9 Hz, 1H), 6.79 (s, 1H),6.68 (S, 1H), 6.61 (s, 1H), 6.38 (t, J=2.2 Hz, 1H), 5.47 (S, 2H), 4.00 (s, 3H), 3.89 (S, 3H), 3.87 (S, 3H), 2.59 (q, J=7.5 Hz, 2H), 1.17 (t, J=7.5 | B |
Hz, 3H); m/z (ESI+) 473.1 (M+H)+. | |||
16 | PYVVt \Ji J w O / O^S-NH O. H3C'°X -J CH3 Q F °AF 2-methoxy-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-5(trifluoromethoxy)benzene-l sulfonamide | 1H NMR (400 MHz, DMSO-de) ô 7.87 (d, J=2.2 Hz, 1H), 7.72 (d, J=3.0 Hz, 1H), 7.62 — 7.56 (m, 1H), 7.50 (d, J=1.8 Hz, 1H), 7.29 — 7.21 (m, 1H), 7.146.97 (m, 1H), 6.80 — 6.75 (m, 1H), 6.726.64 (m, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.42 (s, 2H), 3.79 (s, 3H), 3.77 (s, 3H); m/z (ESI+) 499.0 (M+H)+. | B |
17 | vlJ 0 r o=s-NH eu H3C'°\/ CH3 ^ch3 2-methoxy-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-5- m ethyl benzene-1 -sulfonamide | Ή NMR (400 MHz, DMSO-cfe) δ 9.96 (s, 1 H), 7.87 (d, J=2.3 Hz, 1H), 7.61 (d, J=2.3 Hz, 1H), 7.50 (d, J=1.8 Hz, 1H), 7.36 (d, J=5.1 Hz, 1 H), 7.04 (d, J=8.4 Hz, 1H), 6.78 (br. s, 1H), 6.70 (br. s, 1H), 6.30 (t, J=2.2 Hz, 1H), 5.43 (s, 2H), 3.83 (S, 3H), 3.73 (s, 3H),2.28 (s, 3H); m/z (ESI+) 429.0 (M+H)+. | B |
18 | V-O w ο O=S'NH H3C-°v/ ch3 Q ^y-cH3 h3c 2-methoxy W-{4-methoxy-6~[(1 H- pyrazol-1 -yl)methyl]-1,2- benzoxazol-3-yl}-5-(propan-2yl)benzene-1 -sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 10.04 (s, 1H), 7.87 (d, 7=2.3 Hz, 1 H), 7.65 (d, 7=2.3 Hz, 1H), 7,50 (S, 1H), 7.48 -7.43 (m, 1H), 7.09 (d, 7=8.6 Hz, 1H), 6.81 (br. s, 1H), 6.71 (br. s, 1 H), 6.30 (s, 1H), 5.43 (S, 2H),3.81 (S, 3H), 3.73 (S, 3H), 2.90 (hept, 7=6.7 Hz, 1H), 1.17 (d, 7=6.9 Hz, 6H); m/z (ESI+) 457.2 (M+H)+. | A |
19 | ο f o=^nh Η^'θΑΖ CH 3 Q ^O'CH3 2,5 -d im ethoxy-/V-{4-m eth oxy-6[(1 /7-pyrazol-1 -yl)methyl]-1,2benzoxazol·3-yl}benzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 10.16 (s, 1 H), 7.87 (d, 7=2.3 Hz, 1 H), 7.50 (d, 7=1.8 Hz, 1 H), 7.33 (d, 7=3.0 Hz, 1H), 7.18-7.00 (m, 2H),6.78 (br. s, 1H), 6.69 (br. s, 1 H), 6.30 (t, 7=2.1 Hz, 1H), 5.43 (s, 2H), 3.83 (S, 3H), 3.73 (s, 3H), 3.71 (s, 3H); m/z (ESI+) 445.0 (M+H)+. | B |
1H NMR (400 MHz, | 1---' | ||
VA J w | DMSO-de) δ 9.84 (s, 1 H), 7.88 (d, J-2.3 Hz, | ||
0 / 'l O=S-NH / vch3 | 1 H), 7.50 (d, J=1.9 Hz, 1H), 7.49 (s, 1H), 6.86 | ||
r\=J CH3 | (s, 1H), 6.84 (s, 1H), | ||
20 | 3-methoxy-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2- benzoxazol-3-yl}-5,6,7,8- tetrahydronaphthalene-2sulfonamide | 6.75 (S, 1H), 6.31 (t, J=2.1 Hz, 1H), 5.44 (s, 2H), 3.87 (S, 3H), 3.73 (S, 3H), 2.80 — 2.71 (m, 2H), 2.69-2.63 (m, 2H), 1.77-1.61 (m, 4H); m/z (ESI+) 468.8 (M+H)+. | A |
NMR (400 MHz, DMSO-de) δ 9.56 (s, | |||
ΝνΉ-·1,, N. Il J w | 1H), 7.88 (d, J=2.0 Hz, 1 H), 7.50 (d, J=1.2 Hz, | ||
o / o=s-NH 0. /-XJ CH3 CH3 | 1 H), 7.29 (d, J=8.6 Hz, 1H), 6.99 (d, J=8.6 Hz, 1 H), 6.83 (S, 1 H), 6.76 | ||
21 | 2-methoxy-/V-{4-methoxy-6-[(1 Hpyrazol-1 -yl)m ethyl]-1,2benzoxazol-3-yl}-5,6,7,8tetrahydronaphthalene-1 sulfonamide | (S, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.44 (s, 2H), 3.88 (s, 3H), 3.78 (s, 3H), 3.12 (t, J=5.7 Hz, 2H), 2.72 (t, J=6.0 Hz, 2H), 1.73-1.59 (m, 4H); m/z (ESI+) 468.8 (M+H)+. | A |
22 | N χ J T U./N o O=S-NH H3C'°\/ ch3 ΓΗ V CH3 2,6-d im ethoxy-N-{4 -m eth oxy-6 - [(1H-1,2,3-triazol-1 -yl)methyl]- 1,2-benzoxazol-3-yl}benzene-1 sulfonamide | Ή NMR (400 MHz, DMSO-cfe) δ 10.34 (br. s, 1H), 9.78 (br. s, 1H), 8.26 (S, 1H), 7.78 (s, 1H), 7.46 (t, J=8.4 Hz, 1H), 6.98 (s, 1H), 6.82 (S, 1 H), 6.76 (S, 1H), 6.74 (s, 1H), 5.72 (s, 2H), 3.89 (S, 3H), 3.74 (s, 6H); m/z (ESI+) 446.1 (M+H)+. | A |
23 | N, ' / 0 O^-NH H3C 0\V θΗ3 ch3 2,6-d i m eth oxy-A/-{4 -m eth oxy-6- [(2/-/-1,2,3-triazol-2-yl)methyl]- 1,2-benzoxazol-3-yl}benzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-cfe) δ 9.66 (br. S, 1H), 7.87 (s, 2H), 7.50 (t, J=8.5 Hz, 1H), 6.92 (S, 1H), 6.796.77 (m, 2H), 6.76 (s, 1H), 5.79 (s, 2H), 3.88 (S, 3H), 3.77 (s, 6H); m/z (ESI+) 446.1 (M+H)+. | A |
24 | ο Γ^χ n O-S-NH i H3C'°x/ ch3 A-P VJ ch3 4-cyclopropyl-2,6-dimethoxy-/V{4-methoxy-6-[(1/7-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | 1H NMR (400 MHz, DMSO-cfe) δ 8.58 (br. S, 1H), 7.87 (d, J=2.3 Hz, 1 H), 7.50 (d, J=1.9 Hz, 1 H), 6.78 (S, 1H), 6.72 (S, 1H), 6.39 (s, 2H), 6.30 (t, J=2.1 Hz, 1 H), 5.43 (S, 2H), 3.89 (S, 3H), 3.72 (S, 6H), 2.00-1.83 (m, 1H), 1.03-0.90 (m, 2H), 0.87-0.68 (m, 2H); | A |
m/z (ESI+) 485.1 (M+H)+. | |||
25 | 0 N^/ O-S'NH À H3C-O\7 Λ >Τ ch3 V θΗβ M-{4-ethoxy-6-[(1 H-pyrazol-1 yl)methyl]-l,2-benzoxazol-3-yl}2,6-dimethoxybenzene-1 sulfonamide | Ή NMR (400 MHz, DMSO-cfe) δ 9.34 (br. S, 1H), 7,89 (d, J=2.0 Hz, 1H), 7,53-7.48 (m, 2H), 6.83 (s, 1H), 6,78 (d, J=8.5 Hz, 2H), 6.75 (S, 1H), 6.31 (t, J=2A Hz, 1 H), 5.45 (S, 2H), 4.20 (q, J=7.0 Hz, 2H), 3.75 (S, 6H), 1.38 (t, J=7.0 Hz, 3H); m/z (ESI+) 459.1 (M+H)+. | A |
26 | VO w ο / γ Q-g—NH H3C \I-4 X7 /¥^7 v T# ch3 H3C'0 W-{4-(cyclopropyloxy)-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-2,4,6trimethoxybenzene-1 sulfonamide | 1H NMR (400 MHz, CDCI3) δ 7.99 (s, 1H), 7.59 (S, 1H), 7.48 (br. S, 1 H), 6.77 (s, 2H), 6.34 (S, 1H), 6.08 (s, 2H), 5.42 (S, 2H), 3.90 -3.83 (m, 7H), 3.81 (s, 3H), 0.92-0.86 (m, 4H); m/z (APCI+) 501.2 (M+H)+. | A |
27 | nMI 1 Q 0 λ ch3 O=S'NH H3C-O/ XV0. A# ch3 2,6-dimethoxy-/V-{5-methyl-6- [(1 H-pyrazol-1 -yl)methyl]-1,2- | 1H NMR (400 MHz, DMSO-cfe) δ 11.30 (s, 1H), 7.83 (S, 1H), 7.79 (d, J=2.2 Hz, 1H), 7.51 (d, J=1.2 Hz, 1H), 7.46 (t, J=8.5 Hz, 1H), 6.86 (S, 1H), 6.73 (d, J=8A | A |
benzoxazol-3-yl}benzene-1 sulfonamide | Hz, 2H), 6.32 (t, J=2.0 Hz, 1H), 5.47 (s, 2H), 3.74 (s, 6H), 2.35 (s, 3H); m/z (ESI+) 429.1 (M+H)+. | ||
28 | o / O^S'NH h3c-°k/ /Or0 v/ ch3 2J6-dimethoxy-W-{6-[(1Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | Ή NMR (400 MHz, DMSO-Gfe) δ 11.41 (s, 1H), 8.01 (d, J=8.3 Hz, 1H), 7.87 (d, J=2.3 Hz, 1H), 7.49 (S, 1H), 7.46 (t, J=8.5 Hz, 1H), 7.33 (S, 1H), 7.18 (d, J=8.3 Hz, 1H), 6.72 (d, J=8.5 Hz, 2H), 6.29 (t, J=2.1 Hz, 1H), 5.49 (s, 2H), 3.72 (s, 6H); m/z (ESI+) 415.1 (M + H)+. | A |
29 | vj ο / -> 0=SNH 0, H3C'°\_J CH3 o 6-methoxy-A/-{4-methoxy-6-[(1 H- pyrazol-1 -yl)methyl]-1,2- benzoxazol-3-yl}-2,3-dihydro-1H- indene-5-sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 9.74 (s, 1 H), 7.86 (d, J=1.8 Hz, 1H), 7.63 (S, 1H), 7.49 (d, J=1.3 Hz, 1H), 7.07 (S, 1H), 6.82 (S, 1H), 6.74 (S, 1H), 6.29 (t, J=2.1 Hz, 1 H), 5.43 (s, 2H), 3.86 (s, 3H), 3.76 (S, 3H), 2.89 (t, J=7.5 Hz, 2H), 2.83 (t, J=7.3 Hz, 2H), 2.07-1.96 (m, 2H); m/z (ESI+) 454.9 (M+H)+. | A |
30 | h3c. A°s° N-o ί η A. ü H J| η Ν^\ ?H oWA ^^3 I \ / ch3 w /V-(6-((1H-indazol-1-yl)methyl)-4methoxybenzo[tf|isoxazol-3-yl)2,6- dimethoxybenzenesulfonamide | jH NMR (400MHz, DMSO-d6) δ 9.60 (br S, 1H), 8.16 (S, 1H), 7.80 (d, J=8.1 Hz, 1 H), 7.72 (d, A8.4 Hz, 1H), 7.50 - 7.36 (m, 2H), 7.16 (t, J=7.5 Hz, 1H), 6.81 (S, 2H), 6.75 (d, A8.4 Hz, 1 H), 6.776.70 (m, 1H), 5.77 (s, 2H), 3.85 (S, 3H), 3.74 (s, 6H); m/z 495.0 (M+H)+. | A |
31 | h3c NO S ' / O ° H V h3c [> A/-[5-cyclopropyl-6-(1 /7-pyrazol1 -ylmethyl)-1,2-benzoxazol-3-yl]2,6- d i m eth oxybe nzenesu If ο n am ide | Ή NMR (400 MHz, DMSO-de) δ 11.29 (s, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.80 (S, 1H), 7.52 (d, J=1.3 Hz, 1H), 7.46 (t, J=8.5 Hz, 1H), 6.79 (S, 1 H), 6.73 (d, J=8.4 Hz, 2H), 6.33 (t, J=2.1 Hz, 1H), 5.65 (S, 2H), 3.73 (S, 6H), 2.10 2.00 (m, 1H), 1.01 0.95 (m, 2H), 0.63 0.57 (m, 2H); m/z 455.2 (M+H)+. | A |
32 | h3c b -ο P/zzp CH3 f 5-ethyl-N-[5-fluoro-6-(1Hpyrazol-1-ylmethyl)-1,2b enzoxazo l-3-y I] -2methoxybenzenesulfonamide | Ή NMR (400 MHz, DMSO-cfe) δ 11.68 (s, 1H), 7.84 (d, J=2.2 Hz, 1 H), 7.81 (d,J=9.3 Hz, 1H), 7.69 (d, J=2.2 Hz, 1H), 7.48 (d, J=1.3 Hz, 1 H), 7.45 (dd, J=2.1, 8.6 Hz, 1H), 7.28 (d, J=5.3 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H), 6.29 (1, J=2.1 Hz, 1 H), 5.50 (s, 2H), 3.70 (s, 3H), 2.60 (q, J=7.5 Hz, 2H), 1.14 (t, J=7.6 Hz, 3H); m/z 431.1 (M+H)+. | A |
33 | h3c b o PI h3c M-[4-chloro-6-(1 H-pyrazol-1 ylmethyl)-1,2-benzoxazol-3-yl]2,6- dimethoxybenzenesulfonamide | Ή NMR (400MHz, DMSO-cfe) δ 10.20 (br. S, 1 H), 7.92 (S, 1H), 7.57-7.50 (ΠΊ, 2H), 7.47 (s, 1H), 7.27 (S, 1H), 6.79 (d, J=8.4 Hz, 2H), 6.32 (S, 1H), 5.51 (S, 2H), 3.75 (S, 6H); m/z 449.0 (M+H)+, | A |
34 | h,c /Z> N'°x NO \\ Z 11 y—J \__/ O H 2-methoxy-A/-[6-(1 H-pyrazol-1 ylmethyl)-1,2-benzoxazol-3yi]benzenesulfonamide | 1H NMR (400 MHz, DMSO-cfe) δ 11.69 (br. S, 1H), 7.88 - 7.80 (m, 3H), 7.51 (br. s, 1H), 7.47 (d, J=1.3 Hz, 1H), 7.30 - 7.19 (m, 1H), 7.09 (br. t, J=7A Hz, 2H), 7.05 - 6.96 (m, | C |
1H), 6.28 (t, J=2.0 Hz, 1H), 5.45 (S, 2H), 3.72 (s, 3H); m/z 385.1 (M+H)+. | |||
35 | h3c O V>=\ NJ \\ yL H il__/ \__/ TAs - N O H 2,4-dimethoxy-/V-[6-(1 /-/-pyrazol1 -ylmethyl)-1,2-benzoxazol-3yl]benzenesulfonamide | Ή NMR (400 MHz, DMSO-cfe) δ 7.82 (d, J=2.2 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.56 (br. s, 1H), 7.46 (d, J=^7 Hz, 1H), 7.04 (br. s, 1 H), 6.96 (br. s, 1 H), 6.46 (br. S, 2H), 6.28 - 6.25 (m, 1H), 5.41 (s, 2H), 3.75 (S, 3H), 3.66 (s, 3H); m/z 415.1 (M+H)+. | C |
36 | h3c „o nA ζχ o t >=. nJ ci Cl OH 5-chloro-2-methoxy-/V-[6-(1 Hpyrazol-1 -ylmethyl)-1,2benzoxazol-3- yl]benzenesulfonamide | 1H NMR (400 MHz, DMSO-cfe) δ 11.95 (br. S, 1H), 7.89 - 7.74 (m, 3H), 7.56 (br. d, J=8.9 Hz, 1H), 7.49 - 7.45 (m, 1H), 7.32 - 7.19 (m, 1H), 7.12 (br. t, J=7.3 Hz, 2H), 6.27 (t, J=2.1 Hz, 1 H), 5.45 (S, 2H), 3.72 (s, 3H); m/z 419.1 (M+H)+. | C |
37 | h3ç ζ-^ζθ *rO. o y=\ n-^ W zV. f—J \__/ ' N^Y Y \ OH O H3C 2-methoxy-5-(methoxymethyl)- N-[6-(1 H-pyrazol-1-ylmethyl)- 1,2-benzoxazol-3yl]benzenesulfonamide | Ή NMR (400 MHz, DMSO-de) δ 11.70 (s, 1H), 7.91 -8.05 (m, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.81 (d, J=2.2 Hz, 1H), 7.49-7.56 (m, 1 H), 7.48 (d, J=1.7 Hz, 2H), 7.28-7.36 (m, 1H), 7.08-7.20 (m, 2H), 6.29 (t, J=2.0 Hz, 1H), 5.47 (s, 2H), 4.38 (S, 2H), 3.74 (s, 3H), 3.25 (S, 3H); m/z 429.2 (M+H)+. | C |
38 | h3c _ z° .o H3CY^< Ο ΐ >=\ 'NJ/ \\ zU. y—J \__/ 0 H 2-methoxy-4-methyl-A/-[6-(1 Hpyrazol-1-ylmethy[)-1,2benzoxazol-3yl]benzenesulfonamide | 1H NMR (400 MHz, DMSO-Gfe) δ 7.81 (d, J=1.7 Hz, 1 H), 7.63 (d, J=7.8 Hz, 1H), 7.56 (d, J=7.9 Hz, 1H), 7.46 (d, J=1.1 Hz, 1H), 7.03 (S, 1 H), 6.95 (d,J=8.1 Hz, 1H), 6.75 (S, 1 H), 6.67 (d, J=8.1 Hz, 1H), 6.26 (t, J=2.0 Hz, 1H), 5.40 (S, 2H), 3.64 (s, 3H), 2.27 (s, 3H); m/z 399.2 (M+H)+. | C |
39 | h3c P 0 H’c 2,6-dimethoxy-A/-[5-meÎhoxy-6(1 H-pyrazol-1 -yimethyl)-1,2benzoxazol-3- yl]benzenesulfonamide | 1H NMR (400MHz, DMSO-de) δ 11.29 (br. S, 1H), 7.81 (d, J=2.0 Hz, 1H), 7.62 (s, 1H), 7.52 - 7.41 (m, 2H), 6.79 (S, 1H), 6.73 (d, J=8.6 Hz, 2H), 6.30 (t, J=2.0 Hz, 1H), 5.39 (s, 2H), 3.85 (S, 3H), 3.73 (s, 6H); m/z 445.0 (M+H)+. | A |
40 | h3c 0 o O H3C h3c N-[5-ethoxy-6-(1/-/-pyrazol-1 ylmethyl)-1,2-benzoxazol-3-yl]2,6dimethoxybenzenesulfonamide | 1H NMR (400MHz, CDCh) δ 8.12 (br. s, 1H), 7.49 (d, J=1.4 Hz, 1H), 7.45 (S, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.32 (t, J=8.5 Hz, 1H), 6.79 (S, 1 H), 6.53 (d,J=8.6 Hz, 2H), 6.23 (t, J=1.9 Hz, 1H), 5.35 (S, 2H), 4.16-4.01 (m, 2H), 3.89-3.75 (m, 6H), 1.41 (t, J=6.9 Hz, 3H); m/z 459.1 (M+H)+. | A |
41 | h3c .o NZ /) /> 0 H H3C u \ A/-[5-(difluoromethoxy)-6-(1 Hpyrazol-1 -ylmethyl)-1,2benzoxazol-3-yl]-2,6dimethoxybenzenesulfonamide | 1H NMR (400MHz, DMSO-de) δ 11.55 (s, 1H), 8.00 (S, 1H), 7.85 (d, J=2.0 Hz, 1 H), 7.51 (d, J=1.3 Hz, 1H), 7.48 (t, J=8.4 Hz, 1H), 7.38 - 6.94 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 6.32 (t, Hz, 1H), 5.48 (s, | B |
2H), 3.73 (s, 6H); m/z 481.1 (M+H)+. | |||
42 | h3c /¾^° N°\ N,Y CX° a?=v^n o 0 H Λ7 h3c 7-methoxy-A/-[4-methoxy-6-(1 H- pyrazol-1-ylmethyl)-1,2- benzoxazol-3-yl]-3,4-dihydro-2Hchromene-6-sulfonamide | 1H NMR (400MHz, CDCh) 5 7.99 (br. s, 1H), 7.80 (S, 1H), 7.56 (S, 1H), 7.43 (d, J=1.8 Hz, 1 H), 6.77 (s, 1H), 6.43 (s, 1H), 6.31 (br. d, J=7.5 Hz, 2H), 5.37 (S, 2H), 4.25-4.13 (m, 2H), 3.95 (S, 3H), 3.80 (S, 3H), 2.75 (br. t, J=6.3 Hz, 2H), 2.02 1.92 (m, 2H); m/z 471.1 (M+H)+. | B |
43 | h3c N'°\ A Av k ÀAs - N fl / OH ox ch3 7-methoxy-A/-[4-methoxy-6’(1H- pyrazol-1 -ylmcthyl)-1,2- benzoxazol-3-yl]-3,4-dihydro-1H- isochromene-6-sulfonamtde | 1H NMR (400MHz, DMSO-de) 5 10.02 (br. S, 1 H), 7.88 (d, J=2.0 Hz, 1 H), 7.58 (s, 1H), 7.50 (d, J=1.3 Hz, 1H), 7.23-7.08 (m, 1H), 6.94-6.63 (m, 2H), 6.30 (t, J=2.0 Hz,1H), 5.43 (s, 2H), 4.68 (S, 2H), 3.89 - 3.85 (m, 2H), 3.85 (S, 3H), 3.72 (S, 3H), 2.75 (br. s, 2H); m/z 471.1 (M+H)+. | B |
1H NMR (400 MHz, | |||
44 | h3c ν'Ά // FF O H N-^ \\ A n 1/ \__/ - N H3C O H \ F /V-[5-fluoro-6-(1 /7-pyrazol-1 - | DMSO-cfe) δ 11.75 (s, 1H), 7.85 - 7.79 (m, 3H), 7.54 (dd, J=1.5, 8.2 Hz, 1H), 7.48 (d, J=1.2 Hz, 1H), 7.28 (br. d, J=4.9 Hz, 1H), | A |
ylmethyl)-1,2-benzoxazol-3-yl]-2methoxy-5- (methoxymethyl)benzenesulfona mide | 7.15 (d, J=8.6 Hz, 1H), 6.29 (t, J=2.1 Hz, 1H), 5.50 (S, 2H), 4.39 (s, 2H), 3.74 (s, 3H), 3.25 (s, 3H); m/z 447.1 (M+H)+. |
Example 45: Préparation of 2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yi)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme C (Route A).
Toa suspension of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (A2) (2.5 g, 10 mmol) in pyridine (8.0 mL) was added 2-methoxybenzene-1-sulfonyl chloride (3.17 g, 15.4 mmol). The reaction was stirred at 120 °C for 1.5 h. The mixture was cooled to room température and diluted with MeOH. The résultant suspension was filtered. and the filter cake was washed with MeOH (30 mL). The solids were dissolved in DCM (50 mL) and MeOH (30 mL) was added. The DCM was removed under vacuum
- 100 and the precipitate was collected by filtration. The filter cake was dried by lyophilization to provide 2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3yl}benzene-1-sulfonamide (Example 45) (2.5 g, 59% yield) as a white solid. NMR (400 MHz, DMSO-cfe) δ 10.18 (s, 1H), 7.87 (d, J= 2.0 Hz, 1H), 7.80 (dd, J=1.6, 7.9 Hz, 5 1H), 7.66 — 7.59 (m, 1H), 7.49 (d, J=1.5 Hz, 1H), 7.19 (d, J=8.3 Hz, 1H), 7.09 (t, J=7.7
Hz, 1 H), 6.83 (s, 1 H), 6.74 (s, 1 H), 6.30 (t, J=2.0 Hz, 1 H), 5.44 (s, 2H), 3.82 (s, 3H), 3.78 (s, 3H); m/z (ESI+) 415.0 (M+H)+.
Example 45: Alternative préparation of 2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1 10 yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide according to Scheme D.
A 100 mL reactor equipped with an overhead stirrer was charged with 4-methoxy-615 (lH-pyrazol-1-ylmethyl)-1,2-benzoxazol-3-amine (A-2) (10.00 g, 40.94 mmol), 2methoxybenzenesulfonyl chloride (10.15 g, 49.13 mmol), and acetonitrile (100 mL). The resulting suspension was stirred at 25 °C for 55 minutes. Via pipette, dimethylsulfoxide (0.36 mL, 4.09 mmol) was added in one portion. Via syringe, 3,5-lutidine (14.8 mL, 122.82 mmol) was added dropwise over 15 minutes. The resulting light-yellow suspension was stirred at 25 °C for 18 hours to reach >98% conversion as judged by LCMS. The reaction mixture was acidified with 1 M aq. HCl (100 mL), then concentrated to ~80 mL (rotary evaporator, 40 °C, 85 mbar), The slurry was treated with additional 1 M aq. HCl (40 mL) to rinse down the walls of the vessel, then stirred at 20 °C for 2.5 hours. The resulting precipitate was collected by suction filtration. The _ -101filter cake was washed with water (2 x 50 mL), then dried under vacuum at 35 °C for 48 hours, affording crude 2-methoxy-/V-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}benzene-1-sulfonamide (Example 45) (15.2 g, 90% yield, 98% purity by LCMS) as a solid. m/z 415.1 (M+H)+.
To purify the crude product, a suspension of crude 2-methoxy~A/-{4-methoxy-6-[(1/7pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 45) (14.00 g, 33.78 mmol) in dichloromethane (210 mL) was heated in a 40 °C bath until a clear solution was obtained (10 minutes). The mixture was filtered, and the filtrate returned to 10 a clean reaction vessel, using additional dichloromethane (70 mL) to quantitate the transfer. Ethyl acetate (140 mL) was added to the solution over 2 minutes, then the mixture stirred for 2.5 hours. No crystallization was observed, so the solution was concentrated under reduced pressure (200 mbar) to remove dichloromethane (volume was reduced by about 70 mL). More ethyl acetate (140 mL) was added to the residue, 15 and the mixture stirred at room température for 21 hours. The resulting suspension was concentrated under reduced pressure (40 °C, 200 mbar) to about 280 mL, then stirred at room température for 3 hours. The solids were collected by filtration, with additional ethyl acetate (70 mL) used to rinse the reaction vessel and filter cake. The filter cake was dried in a vacuum oven at 35 °C for 23 hours, affording 2-methoxy-N-{4-methoxy20 6-((1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 45) (12.0 g, 85% yield, 97.9% purity by UPLC, no single impurity larger than 0.5%) as a solid. m/z 415.1 (M+H)+.
To purify further, a suspension of 2-methoxy-M-{4-methoxy-6-[(1 /-/-pyrazol-1 -yl)methyl]25 1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 45) (2.0 g, 4.73 mmol) in acetone (80 mL) was heated to reflux (bath température 55 °C) with stirring for 2 hours. While the mixture was still heated, ethyl acetate (30 mL) was added slowly, so that the internai température remained above 45 °C. The resulting slurry was concentrated to about 30 mL under mild vacuum (bath temp 65 °C), then cooled slowly at a rate of 1 30 °C/min to 20 °C (-31 minutes). The resulting precipitate was collected by suction filtration. The filter cake dried under vacuum at 50 °C for 22 hours, yielding 2-methoxyN-{4-methoxy-6’[(1H-pyrazol-l-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 45) (1.825 g, 93% yield, 99.5% purity by UPLC) as a crystalline solid. 1H
- 102 NMR (400 MHz, CHLOROFORM-d) 5 8.14 (dd, J=1.7, 7.8 Hz, 1 H), 8.04 (s, 1 H), 7,59 7.51 (m, 2H), 7.44 (d, J=2.2 Hz, 1H), 7.14-7.06 (m, 1 H), 6.95 (d, J=8.3 Hz, 1H), 6.78 (d, J=0.6 Hz, 1 H), 6.45 (s, 1 H), 6.32 (t, J=2.1 Hz, 1 H), 5.38 (s, 2H), 3.97 (s, 3H), 3.91 (S, 3H).
Example 45b: Préparation of 2-methoxy-A/-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide anhydrous free base (Form 1) according to Scheme C-1 (Route B).
Scheme C-1 :
2-methoxybenzene-1-sulfonyl chloride (7.6 g, 37 mmol) was placed in a 2-neck round bottom flask equipped with an internai thermometer. 4-methoxy-6-[(1H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-amine (A-2) (8.18 g, 33.5 mmol) was added and the contents dissolved in pyridine (55 mL, 0.6 M) with gentle heating. Heating was initiated with an oil bath température of 110° C and internai température of 101 ’ C. After 5 h of heating, the reaction was complété as determined by LCMS analysis. The reaction was cooled to room température and partitioned between DCM (200 mL), 6 N HCl (100 mL) and ice water (100 mL). The product was extracted into DCM (x3) and the combined DCM extract was washed with 1 N HCl (x3) to remove traces of pyridine. The DCM extract was dried over MgSÛ4 and concentrated to a dark oii. The oil was purified via flash chromatography eluting with a gradient of 40 -100% EtOAc in heptane to afford 4.6 g of the product, which was confirmed by NMR. The 4.6 g of the product was recrystallized by first dissolving in CHaCN (60 mL) at reflux until most of the solids had dissolved. This hot solution was filtered using a pre-heated ! hot glass funnel fitted with
- 103 fluted filter paper. This step removes any inorganic or silica gel impurities. The filter paper was washed with small portions of CH3CN adding up to a total wash volume of 10 mL. The filtrate was collected in a 250 mL beaker equipped with a stir bar. MTBE (45 mL) was added to the hot filtrate and stirring was initiated. After 30 seconds of stirring, a white precipitate began to form. Stirring was continued at 400 rpm while a gentle stream of Ng gas was forced across the top of the solution to help speed up the évaporation process. The forced N2 évaporation was continued for 3 h until the total volume was 50 mL. The white solid was filtered washing with MTBE (x2) and heptane (x2). The white powder was placed in a 3-inch diameter crystallizing dish, covered with piece of filter paper and heated in a 70°C vacuum oven for 48 h using a slow flow of N2 in and out of the drying oven to aid the drying process. After drying, 3.9 g of crystalline product was obtained, which was confirmed by NMR. Melting point = 203-204° C. Anal. Calcd for C19H18N4O5S: C, 55.06; H, 4.38; N, 13.52. Found: C, 55.09; H, 4.41 ; N, 13.57.
The crystalline solid prepared above as anhydrous (Form 1) was further characterized by powder X-ray diffraction (PXRD). Powder X-ray diffraction analysis was conducted on a Bruker A25 D8 Advance Powder X-Ray diffractometer fitted with, a theta-2theta goniometer, and a Lynxeye detector with a PSD window size of 3.3°, primary soller slit set to 2.5° and divergence slits were set at 0.6mm constant illumination. The X-ray tube voltage and amperage were set to 40 kV and 40 mA respectively. Data was collected at the Copper wavelength using a step size of 0.02 degrees, a step time of 0.3s from 3.0 to 40.0° 2-theta. The sample was prepared by placing the powder in Si low background cavity holder. The sample powder was pressed using a spatula to ensure that a proper sample height was achieved. Data were collected using Bruker DIFFRAC software and analysis was performed by DIFFRAC EVA software. The PXRD patterns collected were imported into Bruker DIFFRAC EVA software. The peak sélection carried out utilizing the software’s “peak search function” and then was carefully checked and corrected to ensure that ail peak positions had been accurately assigned. Peaks with a relative intensity > 4.0% were chosen. A typical error of ± 0.2° 2-theta in peak positions applies to this data. The minor error associated with this measurement can occur because of a variety of factors including: (a) sample préparation (e.g., sample height), (b) instrument, (c) calibration, (d) operator (including those errors présent when determining the peak locations), and (e) the nature of the material (e.g. preferred orientation and transparency errors).
-104 Therefore, peaks are considérée! to hâve a typical associated error of ± 0.2° 2-thêta. When two peaks, in the Iist, are considered to overlap the less intense peak has been removed from the listing. Peaks existing as shoulders, on a higher intensity adjacent peak, hâve also been removed from the peak iist. While the shoulders may be > 0.2° 25 thêta from the position of the adjacent peak, they are not considered as discernible from the adjacent peak.
To obtain the absolute peak positions, the powder pattern should be aligned against a reference. This couid either be the simulated powder pattern from the crystal structure of the same form solved at room température, or an internai standard e.g.
îo silica or corundum. Simulated powder pattern of 2-methoxyW-{4-methoxy-6-[(1Hpyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-suIfonamide anhydrous (Form 1) was obtained from a single crystal structure. To préparé the single crystal 200 mg of the material of Example 45b was dissolved in CH3CN (3 mL) while heating to reflux. MTBE (2 mL) was added and the mixture was allowed to sit in a test tube open 15 to the air for 48 h, resulting in slow évaporation of the solvents. Large crystals formed, which were filtered and rinsed with MTBE (x2) and heptane (x2) and dried under vacuum. 116 mg (58% recovery) of the material of Example 45b was obtained as a crystalline, white solid as confirmed by 1H NMR. The crystals, visualized by polarized light microscopy, showed large particle size and were triclinic in shape. A simulated 20 powder pattern from the single crystal structure was obtained via a calculation using
Mercury 4.1.0 which is part of the CCDC Software Suite.
The PXRD pattern of 2-methoxy-A/-{4-methoxy-6-[(1/7-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1-sulfonamide Form 1 anhydrous (Example 45a), is shown in FIG. 1. A PXRD peak Iist and relative intensity data for 2-methoxyW-{4-methoxy-625 [(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide anhydrous Form (Example 45a) (2-Theta ’) is provided in Table 12 below. Characteristic PXRD peak positions are indicated by an asterisk.
Table 12: PXRD peak Iist for Example 45 Form 1 Anhydrous Free Base.
Angle °2-theta | % Relative Intensity |
6.7 | 47.7 |
11.1 | 38.5 |
11.4* | 70.9 |
11.9 | 31.3 |
- 105 -
13.4* | 100.0 |
14.1* | 12.3 |
15.7 | 4.9 |
17.5* | 12.6 |
18.1* | 51.5 |
20.0 | 51.5 |
20.5 | 23.1 |
20.9 | 17.3 |
21.1 | 13.6 |
21.4 | 14.9 |
21.9 | 62.6 |
22.3 | 15.7 |
22.8 | 6.3 |
23.7 | 41.4 |
23.9 | 53.3 |
24.5 | 69.9 |
25.3 | 6.5 |
26.1 | 19.2 |
26.5 | 12.0 |
27.6 | 4.2 |
28.0 | 5.2 |
28.3 | 5.9 |
28.6 | 31.9 |
29.1 | 11.4 |
One embodiment of the présent invention relates to a crystalline form of 2methoxy-A/-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1sulfonamide anhydrous free base, having a powder X-ray diffraction pattern comprising 5 peaks at 2Θ values of: 13.4 and 18.1 °2θ ± 0.2 °2θ.
One embodiment of the présent invention relates to a crystalline form of 2methoxy-/V-{4-methoxy-6-[(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 sulfonamide anhydrous free base, having a powder X-ray diffraction pattern comprising peaks at 2Θ values of: 13.4 and 18.1 °2Θ ± 0.2 °2θ, and further comprising at least one peak selected from the 2Θ values of: 11.4, 14.1, and 17.5 °20 ± 0.2 °2θ.
One embodiment of the présent invention relates to a crystalline form of 2methoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-l,2-benzoxazol-3-yl}benzene-1sulfonamide anhydrous free base, having a powder X-ray diffraction pattern comprising peaks at 2Θ values of: 13.4 and 18.1 °20 ± 0.2 °2θ, and further comprising peaks at the
2Θ values of: 11.4, 14.1, and 17.5 °2θ ± 0.2 °2Θ.
-106One embodiment of the présent invention relates to a crystalline form of 2methoxy-N-{4-methoxy-6-[(lH-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-lsulfonamide anhydrous free base, having a powder X-ray diffraction pattern comprising peaks at 2Θ values of: 11.4, 13.4, 14.1, 17.5 and 18.1 °2θ ± 0.2 °2θ.
The examples in the table below were synthesized according to the methods used for the synthesis of 5-ethyi-2-methoxy-/V-{4-methoxy-6-[(1H-pyrazol-1-yl) methyl]-1,2benzoxazol-3-yl}benzene-1~sulfonamide (Example 01), 2,6-dimethoxy-A/-{4-methoxy-6[(3-methyl-1 /7-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 02), and 2,6-dimethoxy-A/-{4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 03) and the general sulfonamide formation method C in high-throughput library format. The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to reaîize.
Table 13:
Example Number | Structure/IUPAC Name | Analytical data | Sulfonamide Formation Method |
46 | vX J W 0 / T o=s-NH / ch3 o F F F /V-{4-methoxy-6-[(1 H-pyrazol-l yl)methyl]-1,2-benzoxazol-3-yl}4-(trifluoromethyl)benzene-1 sulfonamide | m/z (ESI+) 453 (M+H)+. | C |
- 107 -
47 | CCTO ο Λ O=SN^ H 3C'°s/ ^Η3 q h3c 2-methoxy-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-4methylbenzene-1 -sulfonamide | m/z (ESI+) 429 (M+H)T | C |
48 | \JU O ο /^T 0-SNH 0^ / CH3 ch3 N-{4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}3,5-dimethylbenzene-1 sulfonamide | m/z (ESI+) 413 (M+H)+. | C |
49 | 0 Νρθ w o=^nh J ΠβΟ / CH3 ζχ F 5-fluoro-A/-{4-methoxy-6-[(l Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-2- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)+. | C |
- 108 -
50 | Ο / | H3C o=S'nh 0 CH3 o h3c 2-ethoxy-N-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-4methylbenzene-1 -sulfonamide | m/z (ESI+) 443 (M+H)\ | C |
51 | vlJ w o p 'y H3c O=S-NH Cl CH3 O 2-ethoxy-/V-{4-methoxy-6-[(1 Hpyrazol-1 -y l)methy l]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 429 (M+H)\ | C |
52 | VXJ w _ ο r-f F\j o=SNH 0^ CH3 O N-{4-methoxy-6-[(1 H-pyrazol-l yl)methyl]-1,2-benzoxazol-3-yl}2-(trifluoromethyl)benzene-1 sulfonamide | m/z (ESI+) 453 (M+H)\ | C |
53 | vO w 0 /' t O=s-Nh Q / CH13 Q F^F | m/z (ESI+) 453 (M+H)\ | c |
- 109-
AA{4-methoxy-6-[(1 H-pyrazol-l yl)methyl]-1,2-benzoxazol-3-yl}3-(ÎrifluoromeÎhyl)benzene-1 sulfonamide | |||
54 | vX J O O P ΐ o=s-nh i \ J 'CH3 2,3-difluoro-A/-{4-methoxy-6[(1/7-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 421 (M+H)+. | C |
55 | VXJ AJ 0 / '' H3C /?O=Snh Ck oA; ch3 VfCH3 methyl 2-({4-methoxy-6-[(1/-/pyrazol-1 -yl)methyl]-1,2- benzoxazol-3-yl}sulfamoyl)-3m ethyl benzoate | m/z (ESI+) 457 (M+H)+. | C |
56 | 0 NpLJ w o=s-nh 0 “30 y CH3 3-fluoro-N-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-2- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)+. | c |
-110-
57 | VJ w ο / : 0-S-NH J / ch3 f-4J F 3,5-difluoiO-N-{4-methoxy-6[(1H-pyrazol-1-yl) methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 421 (M+H)+, | C |
58 | VJ J w ο O=S-NH O„ F\J CH3 ζχ ch3 2-fluoro-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-5- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)\ | C |
59 | vX J w o p 0=S-NH 7 CH3 H3C\ / > 3-methoxy-A/-{4-methoxy-6-[(1 Hpyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 415 (M+H)+. | c |
- 111 -
60 | -COCO O=S'NH fi Xh3 O 4-(cyclopropyloxy)-A/-{4methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 441 (M+H)+. | C |
\\ JL J O | |||
o=s-nh fi^ / ch3 | |||
CJj | m/z (ESI+) | ||
61 | C | ||
450 (M+H)+, | |||
h3c | |||
N-{4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}4-methylquinoline-8-sulfonamide | |||
τι ΎΧ ° \ 'L II 1 Z \ O o°aJ ΞΕ \ CJ ) .— Z | |||
62 | m/z (ESI+) | p | |
h3c | 435 (M+H)+. | ||
2,6-difluoro-/V-{4-methoxy-6[(1 /-/-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-4- methylbenzene-1 -sulfonamide |
- 112 -
63 | 'WA vXJ Ο ο Γ O=S-^H i / CH3 OrCi F 2-ch I o ro-3 -f lu o ro-/V-{4- meth oxy6-[(1H-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 437 (M+H)+. | C |
64 | vl J w ο / 0=SNH o / 'ch3 3A5-trifluorO-A/-{4-methoxy-6[(1 H-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 439 (M+H)+. | C |
65 | A ο Γ O=S'NH q FV\ CH3 O h3c 2-fluoro-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl) methyl]-1,2benzoxazol-3-yl}-4- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)+. | c |
- 113 -
66 | vXJ ο 0 / । 0=SNH ο / ch3 Ο ° ΝΗ h3c 4-({4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}sulfamoyl)-A/mefhylbenzamide | m/z (ESI+) 442 (M+H)+. | C |
67 | VA J w O Γ γ H3c O=3'nh Ck οΆΑ CH3 o 2-(methoxymethyl)-A/-{4methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 429 (M+H)+, | C |
68 | vJO W 0 / γ^ O^-NH ch3 O Cl F 4-chloro-2,5-difluoro-A/-{4methoxy-6-[(1/7-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 455 (M+H)+. | c |
- 114 -
69 | vlJ w o O=SNH q ”/ CH3 O A° h3c 4-ethoxy-/V-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 429 (M+H)+. | C |
70 | °YVnA o nUJ w o4-nh J K / CH3 h3cAJ 2-fluoro-W-{4-meîhoxy-6-[(1 Hpyrazol-1 -y l)methy l]-1,2benzoxazol-3-yl}-3- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)\ | C |
71 | vXj 0 Γ ' O=S'NH 0^ H3c'°\ J CH3 p Cl 4-ch le ro-2-methoxy-A/-{4methoxy-6-[(1 /-/-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 449 (M+H)+. | c |
72 | I O U 0 \ V h Z A- 0 op~Q T \ ω ) f— Z | m/z (ESI+) 413 (M-t-H)+. | c |
- 115 -
A/-{4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}3,4-dimethylbenzene-1 sulfonamide | |||
73 | vl J o /- T h3cH'NH %Η3 A/-{4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}7-methylquinoline-8-sulfonamide | m/z (ESI+) 450 (M+H)+. | C |
74 | h3cv / O=SNH o, ch3 HjcAJ methyl 2-({4-methoxy-6-[(1/7- pyrazol-1 -yl)methyl]-1,2- benzoxazol-3-yl}sulfamoyl)-6- methylbenzoate | m/z (ESI+) 457 (M+H)+. | C |
75 | VAJ W ° / | 0=^NH Q / CH3 h3C V/ F 3-fluoro-N'{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-5- methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)+. | C |
-116-
76 | nvXJ w o / ” V o=s-NH cl G / CH 3 h3cvJ 2-cyano-N-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2- be nzoxazoi -3 -y l}-3 - methylbenzene-1 -sulfonamide | m/z (ESI+) 424 (M+H)+. | C |
77 | o / 0=SNH CH3 F 4-(difluoromethyl)-A/-{4-methoxy6-((1 H-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 435 (M+H)L | C |
78 | vlJ u ο ) r O-g-NH Q / CH3 h3câj F r ch3 4-fluoro-AL{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-3,5- dimethylbenzene-1 -sulfonamide | m/z (ESI+) 431 (M+H)+. | C |
79 | J w o / T O-g-NH o / ch3 f-^Ça h3c 3-fluoro-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2- be nzoxazo l-3-y l}-4methylbenzene-1 -sulfonamide | m/z (ESI+) 417 (M+H)+. | C |
80 | %] j w 0 fY O=S'NH 0^ / CH3 h3c. /A) ° AA fy-CHa 3,5-dimethoxy-A/-{4-methoxy-6[(1 /7-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 445 (M+H)+. | C |
81 | n x J j uj ο Y'NH ° Η3Ο^Αθ 2-ethyl-A/-{4-methoxy-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}-1,3benzoxazole-5-sulfonamide | m/z (ESI+) 454 (M+H)+. | c |
-118-
82 | vXJ Ο Ο f γ^ O=S'NH q / CH3 η rVcH3 F 4-fluoro-3-methoxy-/V-{4methoxy-6-[(1 /7-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide | m/z (ESI+) 433 (M+H)+. | C |
83 | L? ο / q-c-NH o ΗΟγγ °CH3 O ^O'CH3 2-hydroxy-5-methoxy-/V-{4- methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3yi}benzene-1 -sulfonamide | m/z (ESI+) 431 (M+H)\ | C |
84 | o r O=S-NH q / ch 3 h3c-^\y H3C'° 4-methoxy-/V-{4-methoxy-6-[(1 /7pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}-3- methylbenzene-1 -sulfonamide | m/z (ESI+) 429 (M+H)+. | C |
- 119 -
85 | n h j A O O=g--NH n H3C / %H3 F-j h3C'° 3-fluoro-4-methoxy-M-{4methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}2-methylbenzene-1 -sulfonamide | m/z (ESI+) 447 (M+H)+. | C |
86 | U o r O-S'NH 0. 7/ CH3 O F 2A5-trifluoro-/V-{4-methoxy-6[(1 H-pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | m/z (ESI+) 439 (M+H)+. | C |
Example 87: Préparation of N-(6-{[4-(hydroxymethyl)-1H-pyrazol-1-yl]methyl}-4methoxy-1.2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide according to Scheme E.
- 120Scheme E:
K2CO3
DMF, H2O, 60 °C
h3c ch3
2. TBSCI, TEA, DMAP DCM
34% yield (2 steps)
Step 1
lnt-26
Step 2
TBAF
THF
6% yield
Step 3
NaH
THF
41% yield
Step 1: Synthesis of 6-{[4-({[terf-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrazol-1yl]methyl}-4-methoxy-1,2-benzoxazol-3-amine (E-2).
To a solution of 4-{[4-({[terf-butyl(dimethyl)silyl]oxy}methyl)-1/7-pyrazol·1-yl]methyl}-2fluoro-6-methoxybenzonitrile (E-1 ) (Prepared as in Example 01,500 mg, 1.33 mmol) and /V-hydroxyacetamide (300 mg, 3.99 mmol) in DMF (10.0 mL) and H2O (2.0 mL) was added K2CO3 (1.1 g, 7.99 mmol). The mixture was stirred at 60 °C for 16 h. LCMS analysis showed consumption of the starting material. The reaction mixture was concentrated to remove the DMF and diluted with H2O. The résultant precipitate was collected by filtration. The filter cake was dried under vacuum. LCMS analysis showed a mixture of the desired product and the des-TBS byproduct. The crude solids were combined with a parallel reaction run with 200 mg 4-{[4-({[terîbutyl(dimethyl)silyl]oxy}methyl)-1/-/-pyrazol-1-yl]methyl}-2-fluoro-6-methoxybenzonitrile. The combined solids were taken up in DCM (10.0 mL). TBSCI (178 mg, 1.18 mmol), TEA (149 mg, 1.48 mmol), and DMAP (6.0 mg, 0.49 mol) were added. The reaction was stirred at room température for 16 h. The mixture was diluted with DCM (100 mL) and washed successively with H2O (50 mL), saturated NaHCOa (50 mL), and brine (50 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (20 g SiO2, 60-70% EtOAc/petroleum ether) to provide 6-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrazol-1-yl]methyl}-4-methoxy20447
- 121 1,2-benzoxazol-3-amine (E-2) (280 mg, 34% yield over 2 steps) as a white solid. m/z (ESI+) 388.9 (M+H)\
Step 2: Synthesis of N-(6-{[4-({[iert-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrazol-1yl]methyl}-4-methoxy-1,2-benzoxazol-3-yl)-2,6-ciimethoxybenzene-1-sulfonamide (E-3) according to sulfonamide formation Method B.
To a suspension of NaH (60% dispersion in minerai oil, 40.1 mg, 1.00 mmol) in THF (2.0 mL) was added a solution of 6-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1Hpyrazol-1-yl]methyl}-4-methoxy-1,2-benzoxazol-3-amine (E-2) (130 mg, 0.335 mmol) in THF (2.0 mL). The reaction was stirred at room température for 15 min and then a solution of 2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-26) (95.0 mg, 0.402 mmol) in THF (2.0 mL) was added. The reaction mixture was stirred at room température for 17 h. The suspension was filtered and concentrated to dryness. The residue was purified by flash chromatography (12 g S1O2, 1:1 EtOAc/petroleum ether) to provide N-(6-{[4({[iert-butyl(dimethyl)silyl]oxy}methyl)-1 H-pyrazol-1 -yl]methyl}-4-methoxy-1,2benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide (E3) (80 mg, 41% yield) as a pale-yellow gum. m/z (ESI+) 589.1 (M+H)+
Step 3: Synthesis of N-(6-{[4-(hydroxymethyl)-1H-pyrazol-1-yl]methyl}-4-methoxy1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1 -sulfonamide (Example 87).
To a solution of N-(6-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1 H-pyrazol-1-yl]methyl}4-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1 -sulfonamide (E-3) (80.0 mg, 0.16 mmol) in THF (2.0 mL) was added TBAF (76.3 mg, 0.32 mmol). The reaction solution was stirred for 1 h. LCMS analysis showed consumption of the starting material with formation ofthe desired product mass. The reaction was concentrated to dryness. The residue was taken up in EtOAc (15 mL) and washed with H2O (10 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by préparative HPLC with a YMC-Actus Triart C-18 coiumn (30x150 mm, 5 pm particle size), which was eluted with 5-25% MeCN/H2O (0.05% NH4OH) with a flow rate of 35 mL/min to provide Λ/-(6-{[4-(hydΓOxymethyl)-1H-pyrazol·1“yl]methyl}-4-methoxy1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide (Example 87) (4.5 mg, 6% yield) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 7.73 (br. s, 1 H), 7.40 (br. s, 2H),
- 122 6.74 (br. s, 4H), 5.35 (br. s, 2H), 4.81 (t, J-5.4 Hz, 1 H), 4.34 (d, J=5.4 Hz, 2H), 3.97 3.59 (m, 9H); m/z (ESI+) 475.0 (M+H)L
The examples in the table below were synthesized according to the methods used for the synthesîs of /V-(6-{[4-(hydroxymethyl)-1 /-/-pyrazol-1 -yl]methyl}-4-methoxy-1,2benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide (Example 87). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize. If necessary, séparation of regioisomeric mixtures was carried out under standard methods known in the art, such as S FC or HPLC, and was conducted at any suitable step in the synthetic sequence.
Table 14:
Example Number | Structure/IUPAC Name | Analytical Data | Sulfonamide Formation Method |
88 | ^OH N ' / o / o=s-NH H3C-°v/ CH 3 / r°^ ch3 N-(6-([5-(hydroxymethyl)-1Hpyrazol-1 -yl]methyl}-4methoxy-1,2-benzoxazol-3-yl)2,6-dimethoxybenzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 9.60 (br. s, 1H), 7.79 (d, J=2.2 Hz, 1 H), 7.48 (br. t, J=8.3 Hz, 1H), 6.84 (d, J=0.9 Hz, 1H), 6.78 (S, 2H), 6.76 (S, 1H), 6.23 (d, J=2.2 Hz, 1H), 5.37 (S, 2H), 4.97 (t, J=5.7 Hz, 1 H), 4.38 (d,J=5.9 Hz, 2H), 3.88 (S, 3H), 3.76 (s, 6H); m/z (ESI+) 474.7 (M+H)+ | B |
- 123 -
O ^/ OH | Ή NMR (400 MHz, CD3OD) δ 7.52 (d,J=1.5 | ||
O=s-NH q H3COy/ CH3 ΓΥΑ CH3 | Hz, 1H), 7.47 (t, 7=8.5 Hz, 1 H), 6.74 (d, 7=8.5 | ||
89 | M- (6-{[3 - (hyd roxy m ethyl)-1/7pyrazol-1 -yl]methyl}-4methoxy-1,2-benzoxazol-3-yl)2,6-dimethoxybenzene-1 sulfonamide | Hz, 2H), 6.69 (s, 2H), 6.36 (s, 1H), 5.53 (s, 2H), 4.61 (s, 2H), 3.99 (S, 3H), 3.84 (S, 6H); m/z (ESI+) 474.7 (M+H)+ | B |
Example 90: Préparation of 2,6-dimethoxy-N-{4-methoxy-6-[(1H-pyrazol-1yl)(2H2)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme F.
Scheme F:
D D
Cs2CO3
CD3OD, 40 °C 49% yield
Step 1
1,1,3,3-tetramethylguanidine MeCN, D2O, 60 “C
37% yield
Step 2 H3C<p C\ .0
H JL lnt-26 ^^och3 pyridine, 95 °C
82% yield
D D
Step 3
- 124 Step 1 : Synthesis of 2-fluoro-6-methoxy-4-[(1H-pyrazol-1yl)(2H2)methyl]benzonitrile (F-1).
To a solution of 2-fluoro-6-methoxy-4-[(1/-/-pyrazol-1-yl)methyl]benzonitriie (164 mg, 0.703 mmol) (A-1) in CD3OD (4.0 mL) was added CS2CO3 (229 mg, 0.703 mmol). The mixture was stirred at 40 °C for 2 h. The reaction was cooled to room température and concentrated to dryness. The residue was purified by flash chromatography (24 g S1O2, 0-40% EtOAc/DCM) to provide 2-fluoro-6-methoxy-4-[(1/-/-pyrazoMyl)(2H2)methyl]benzonitrile (F-1) (81.0 mg, 49% yield) as a white solid. 1H NMR (400 MHz, CDCIa) δ 7.61 (d, J=) .71 Hz, 1 H), 7.47 (d, J=2.32 Hz, 1 H), 6.52 - 6.57 (m, 2H), 6.37 (t, J=2.08 Hz, 1H), 3.88-3.91 (m, 3H); m/z (ESI+) 234.2 (M+H)+.
Step 2: Synthesis of 4-methoxy-6-[(1H-pyrazol-1-yl)(2H2)methyl]-1,2-benzoxazol-3amine (F-2).
To a suspension of 2-fluoro-6-methoxy-4-[(1H-pyrazol-1-yl)(2H2)methyl]benzonitrile (F1) (81.0 mg, 0.35 mmol) and N-hydroxyacetamide (78.2 mg, 1.04 mmol) in MeCN (2.7 mL) and D2O (0.3 mL) was added 1,1,3,3-tetramethylguanidine (240 mg, 2.08 mmol). The mixture was stirred at 60 °C for 7 h and 65 °C for an additional 2 h. The réaction was cooled to room température and concentrated to dryness. The residue was purified by flash chromatography (24 g S1O2, 60-100% EtOAc/DCM) to provide 4-methoxy-6[(1H-pyrazol-1-yl)(2H2)methyl]-1,2-benzoxazol-3-amine (F-2) (32 mg, 37% yield) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 7.85 - 7.89 (m, 1 H), 7.49 (d, J=1.83 Hz, 1H), 6.70 (d, J=0.86 Hz, 1H), 6.63 (d, J=0.73 Hz, 1H), 6.30 (t, J=2.08 Hz, 1H), 5.93 (s, 2H), 3.83 - 3.87 (m, 3H); m/z (ESÎ+) 247.2 (M+H)L
Step 3: Synthesis of 2,6-dimethoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yi)(2H2)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 90) according to Sulfonamide Formation Method A.
A mixture of 4-methoxy-6-[(1H-pyrazol-1-yl)(2H2)methyl]-1,2-benzoxazol-3-amine (F-2) (25.0 mg, 0.10 mmol) and 2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-26) (36.0 mg, 0.152 mmol) in pyridine was stirred at 95 °C for 2 h. The resulting gum was diluted with DCM and treated with AcOH (46 pL, 0.812 mmol). The mixture was purified directly by flash chromatography (24 g S1O2, 70-100% EtOAc/heptane) to provide 2,6-dimethoxy20447
-125/V-{4-methoxy-6-[(1H-pyrazol-1-yl)(2H2)methyl]-1,2-benzoxazol-3-yl}benzene-1sulfonamide (Example 90) (37.0 mg, 82% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) ô 9.60 (s, 1 H), 7.88 (d, J=2.08 Hz, 1 H), 7.43 - 7.54 (m, 2H), 6.84 (s, 1 H), 6.73 - 6.80 (m, 3H), 6.30 (t, J=2.08 Hz, 1 H), 3.87 (s, 3H), 3.76 (s, 6H); m/z (ESI +) 5 448.1 (M+H)+.
The example in the table below was synthesized according to the methods used for the synthesis 2,6-dimethoxy-A/-{4-methoxy-6-[(1H-pyrazol-1 -yl)(2H2)methyl]-1,2-benzoxazol3-yl}benzene-1-sulfonamide (Example 90). The following examples were synthesized 10 with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Table 15:
Example Number | Structure/IUPAC Name | Analytical Data | Sulfonamide Formation Method |
91 | D D Oig-NH 0 n WV d VJ CHa 2,6 -d im ethoxy-V{4[(2H3)methyloxy]-6-[(1Hpyrazol-1 -yl)(2H2)methyl]1,2-benzoxazol-3yl}benzene-1 -sulfonamide | dH NMR (400 MHz, DMSOde) δ 9.59 (s, 1 H), 7.87 (d, J=1.83 Hz, 1H), 7.43-7.54 (m, 2H), 6.84 (s, 1H), 6.736.80 (m, 3H), 6.30 (t, J=2.08 Hz, 1H), 3.76 (s, 6H); m/z (ESI+) 450.1 (M+H)+. | A |
Example 92: Préparation of N-{5-bromo-6-[(1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide according to Scheme G.
- 126 -
Scheme G:
Cs2CO3
Int-07
MeCN
70% yield
Step 1
G-1
1,1,3,3-tetramethylgLianidine MeCN, H2O, 75°C
81% yield
©A h3cox ;s.cl
lnt-26 pyridine, 95 °C
84% yield
Step 2
Step 3
Step 1: Synthesis of 5-bromo-2-fluoro-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (G1)
To a solution of 5-bromo-4-(bromomethyl)-2-fluorobenzonitrile (lnt-07) (280 mg, 0.956 mmoL) in MeCN (6.4 mL) was added 1H-pyrazole (71.6 mg, 1.05 mmol) and CS2CO3 (0.374 mg, 1.15 mmol). The mixture was stirred at room température for 6 h. The mixture was diluted with EtOAc and filtered. The filtrate was concentrated to dryness. The residue was purified by flash chromatography (40 g S1O2,10-100%
EtOAc/heptane) to provide 5-bromo-2-fluoro-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (ΟΙ) (188 mg, 70% yield) as a clear oil, which solidified to a pale-yellow solid upon standing. Ή NMR (400 MHz, CDCh) δ 7.83 (d, J=5.7 Hz, 1 H), 7.65 (d, J=1.7 Hz, 1 H),
7.53 (d, J-2.2 Hz, 1 H), 6.52 (d, J=9.3 Hz, 1 H), 6.40 (t, J=2.1 Hz, 1 H), 5.43 (s, 2H); m/z (ESI+) 280.0, 282.0 (M+H)+.
- 127Step 2: Synthesis of 5-bromo-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (G-2)
To a solution of 5-bromo-2-fluoro-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (G-1) (185 mg, 0.66 mmol) and (V-hydroxyacetamide (149 mg, 1.98 mmol) in MeCN (3.5 mL) and H2O (0.35 mL) was added 1,1,3,3-tetramethylguantdine (45,9 mg, 0.399 mmol). The mixture was stirred at 75 °C for 4 h. The réaction was concentrated to dryness. The residue was purified by flash chromatography (40 g S1O2, 30-90% EtOAc/heptane) to provide 5bromo-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (G-2) (157 mg, 81% yieid) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 8.18 (s, 1H), 7.87 (d, J=2.2 Hz, 1H), 7.55 (d, J=1.3 Hz, 1H), 6.80 (s, 1H), 6.50 (s, 2H), 6.34 (t, J=2.1 Hz, 1H), 5.51 (s, 2H); m/z (ESI+) 293.0, 295.0 (M+H)+.
Step 3: Synthesis of N-{5-bromo-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}2,6-dimethoxybenzene-1-sulfonamide (Example 92)
A solution of 5-bromo-6-[(1H-pyrazol-l-yl)methyl]-1,2-benzoxazol-3-amine (G-2) (155 mg, 0.529 mmol) and 2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-26) (188 mg, 0.793 mmol) -in pyridine (0.31 mL) was heated to 95 °C, at which point the reaction became homogeneous. The reaction was stirred at 95 °C for 2 h and then concentrated to dryness. The residue was taken up in a minimal amount of DCM and treated with AcOH (0.10 mL, 1.75 mmol). The mixture was loaded directly onto S1O2 and purified by flash chromatography (40 g S1O2, 35-100% MeOAc/heptane) to provide /V-{5-bromo-6-[(1/-/pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1 -sulfonamide (Example 92) (221 mg, 84% yieid) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 11.55 (S, 1 H), 8.39 (s, 1 H), 7.87 (d, J=2.1 Hz, 1 H), 7.54 (d, J=1.3 Hz, 1 H), 7.47 (t, J=8.4 Hz, 1 H), 6.88 (s, 1 H), 6.74 (d, J=8.4 Hz, 2H), 6.34 (t, J=2.1 Hz, 1 H), 5.52 (s, 2H), 3.75 (S, 6H); m/z (ESI+) 493.0, 495.0 (M+H)+.
The examples in the table below were synthesized according to the methods used for the synthesis of N-{5-bromo-6-[(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}-2,6dimethoxybenzene-1-sulfonamide (Example 92). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize. If necessary, séparation of regioisomeric
- 128 mixtures was carried out under standard methods known in the art, such as SFC or HPLC, and was conducted at any suitable step in the synthetic sequence.
Table 16:
Example number | Structure/IUPAC Name | Analytical data | Sulfonamide formation method |
93 | o y^^^F 0=^-NH H3c Ά ryo ch3 Λ/-{5-ί I uo ro-6-(( 1 /7-pyrazol- 1 -yl)methyl]-1,2- benzoxazol-3-yl}-2,6dimethoxybenzene-1 sulfonamide | Ή NMR (400 MHz, DMSO-de) δ 11.50 (s, 1 H), 7.83-7.90 (m, 2H), 7,437.52 (m, 2H), 7.25 (br. d, J=4.52 Hz, 1H), 6.73 (d, J=8.56 Hz, 2H), 6.30 (t, J=2.08 Hz, 1H), 5.50 (s, 2H), 3.73 (s, 6H); m/z (ESI+) 433.1 (M+H)\ | A |
94 | VXJ M 0 / O=YNH A/-{4-fluoro-6-[(1 H-pyrazol- 1-yl)methyl]-1,2benzoxazol-3-yl}-2,6dimethoxybenzene-1 sulfonamide | 1H NMR (400 MHz, DMSO-de) δ 10.83 (s, 1H), 7.89 (d, J=2.1 Hz, 1H), 7.55-7.46 (m, 2H), 7.27 (S, 1H), 6.98 (br. d, J-10.1 Hz, 1H), 6.77 (d, J=8.4 Hz, 2H), 6.31 (t, J=2.0 Hz, 1H), 5.50 (s, 2H), 3.74 (s, 6H); m/z (ESI+) 433.1 (M+H)+. | A |
Example 95: Préparation of N-{4-ethyl-6-[(1H-pyrazol-1 -yl)methyl]-1,2-benzoxazol3-yl}-2,6-dimethoxybenzene-1 -sulfonamide according to Scheme H.
- 129 Scheme H:
Cs2CO3
2-Me-THF
66% yield
Step 1 kf3b ch3
P(t-Bu)3 Pd G3 K3CO3 PhMe, H2O, 100 °C
66% yield
Step 2
O
HO. A N Me H
1,1,3,3-tetramethytguanidine
MeCN, H2O, 75°C
31% yield
Step 3 lnt-26
Step 1 : Synthesis of 2-bromo-6-fluoro-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (H1) s A suspension of 2-bromo-4-(bromomethyl)-6-fluorobenzonitrile (lnt-08) (459 mg, 1.57 mmol), 1H-pyrazole (159 mg, 2.34 mmol), and CS2CO3 (767 mg) in 2-Me-THF (3.1 mL) was stirred at room température for 5.5 h. LCMS analysis showed consumption of the starting material. The mixture was partitioned between H2O (5 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (20 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography (40 g SiO2, 0-100% EtOAc/heptane) to provide 2-bromo-6-fluoro-4-[(1/7-pyrazol-1-yl)methyl]benzonitrile (H-1) (295 mg, 66% yield) as a yellow oil. 1H NMR (400 MHz, CDCh) δ 7.62 (d, J=1.7 Hz, 1 H), 7.47 (d,
-130J-2.3 Hz, 1 H), 7.28 (s, 1 H), 6.92 (d, J=8.9 Hz, 1 H), 6.38 (t, J=2.1 Hz, 1 H), 5.36 (s, 2H); m/z (ESI+) 280.0, 282.0 (M+H)+.
Step 2: Synthesis of 2-ethyl-6-fluoro-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (H-2) A microwave vial charged with 2-bromo-6-fluoro-4-[(1/-/-pyrazol-1-yl)methyl]benzonitrile (H-1 ) (79.3 mg, 0.283 mmol), potassium ethyltrifluoroborate (60.0 mg, 0.441 mmol), K2CO3 (108 mg, 0.778 mmol), and methanesulfonato(tri-t-butylphosphino)(2amino-1,1 biphenyl-2-yl)palladium(ll) (P(t-Bu)3 Pd (7.9 mg, 0.014 mmol) was sealed, evacuated, and backfilled with Ns. PhMe (0.60 mL) and de-ionized H2O (0.30 mL) were added and the mixture was stirred at 100 °C for 5 h. LCMS analysis showed formation of the desired product mass. The mixture was partitioned between saturated aqueous NH4CI (10 mL) and EtOAc (15 mL). The aqueous layer was extracted with EtOAc (15 mL). The combined organics were washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography (12 g S1O2, 0-100% EtOAc/heptane) to provide 2-ethyl-6-fluoro-4-[(1/-/-pyrazol-1-yl)methyl]benzonitrile (H-2) (43.1 mg, 66% yield) as an off-white solid. 1H NMR (400 MHz, CDCIa) δ 7.60 (d, J=1.6 Hz, 1H), 7.46 (d, J=2.2 Hz, 1H), 6.92 (s, 1H), 6.76 (d, J=9.2 Hz, 1H), 6.36 (t, J=2.1 Hz, 1 H), 5.36 (s, 2H), 2.85 (q, J=7.6 Hz, 2H), 1.28 (t, J=7.6 Hz, 3H); m/z (APCI+) 230.1 (M+H)T
Step 3: Synthesis of 4-ethyl-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (H-3)
To solution of 2-ethyl-6-fluoro-4-[(1/-/-pyrazol-1-yl)methyl]benzonitrile (H-2) (40.6 mg, 0.177 mmol) and N-hydroxyacetamide (43.9 mg, 0.585 mg) in MeCN (1.0 mL) and HsO (0.1 mL) was added 1,1,3,3-tetramethylguanidine (120 mg, 1.0 mmol). The mixture was stirred at 75 °C for 24 h. The mixture was concentrated to dryness and purified by flash chromatography (12 g S1O2, 0-100% EtOAc/heptane) to provide 4-ethyl-6-[(1H-pyrazol1-yl)methyl]-1,2-benzoxazol-3-amine (H-3) (13.2 mg, 31% yield). ‘‘H NMR (400 MHz, CDCÎ3) δ 7.60 (d, J=1.6 Hz, 1 H), 7.45 (d, J=2.0 Hz, 1 H), 7.04 (s, 1 H), 6.87 (s, 1 H), 6.34 (t, J=2.0 Hz, 1 H), 5.44 (s, 2H), 4.35 (br. s, 2H), 2.93 (q, J=7.6 Hz, 2H), 1.34 (t, J-7.6 Hz, 3H); m/z (APCI+) 243.1 (M+H)+.
- 131 Step 4: Synthesis of M-{4-ethyl-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl} 2,6-dimethoxybenzene-1-sulfonamide (Example 95)
Asuspension of 4-ethyl-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (H-3) (13.2 mg, 0.055 mmol) and 2.6-dimethoxybenzene-1-sulfonyl chloride (lnt-26) (21.3 mg,
0.090 mmol) in pyridine (0.15 mL) was stirred at 95 °C for 3 h. LCMS analysis showed consumption of the starting material. The reaction was concentrated to dryness and purified by flash chromatography (4 g S1O2, 0-100% EtOAc/heptane) to provide Λ/-{4ethyl-6-[(1 /-/-pyrazol-1 -yljmethyl]-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1 sulfonamide (Example 95) (12.0 mg, 50% yield) as a white solid. 1H NMR (400 MHz,
DMSO-76) Ô10.14 (s, 1H), 7.87 (d, 7=2.2 Hz, 1H), 7.57-7.50 (m, 1H), 7.49 (d, 7=1.5 Hz, 1H), 7.20 (br. s, 1H), 7.06 (br. s, 1 H), 6.79 (br. d, 7=7.8 Hz, 2H),6.29 (t, 7=2.1 Hz, 1H), 5.46 (S, 2H), 3.77 (br. s, 6H), 3.07 (q, 7=7.5 Hz, 2H), 1.21 (t, 7=7.5 Hz, 3H); m/z (APCI+) 443.1 (M+H)+.
The example in the table below was synthesized according to the methods used for the synthesis A/-{4-ethyl-6-[(1/7-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}-2,6dimethoxybenzene-1 -sulfonamide (Example 95). The following example was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Table 17:
Example number | Structure/IUPAC Name | Analytical data | Sulfonamide formation method |
96 | vXJ w 0 Γ 04-nh l CH3 A/-{4-cyclopropyl-6-[(1 Hpyrazol-1 -yl)methyl]-1,2be nzoxazo I -3 -y l}-2,6- | 1H NMR (400 MHz, DMSOd6) δ 10.15 (s, 1H), 7.85 (d, 7=2.1 Hz, 1H), 7.52 (br. t, 7=8.6 Hz, 1H), 7.48 (d, 7=1.5 Hz, 1H), 7.11 (s, 1 H), 6.79 (d, 7=8.4 Hz, 2H), 6.73 (s, 1H), 6.29 (t, 7=2.0 Hz, 1H), 5.42 (S, 2H), 3.76 (s, 6H), 2.81 -2.69 (m, 1H), | A |
- 132-
dîmethoxybenzene-1 sulfonamide | 1.06-0.98 (m, 2H), 0.78- 0.70 (m, 2H); m/z (APCI+) 455.1 (M+H)L |
Example 97: Préparation of 5-cyclopropyl-2-methoxy-N-{6-[(1 H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme J.
Scheme J:
PPh3, DIAD
2-Me-THF, 0°C
22% yield
Step 1
Pd(OAc)2, X-Phos K2CO3 CPME, H2O, 100 °C
bf3k
TFA
DCM
67% yield
Step 3
53% yield
Step 2
Step 1 : Synthesis of 5-bromo-N-[(3,5-dimethoxyphenyl)methyl]-2-methoxy-N-{4methoxy-6-[(1 H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (J-2) io To a solution of 5-bromo-2-methoxy-/V-{4-methoxy-6-[(1 H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}benzene-1 -sulfonamide (J-1) (Prepared as in Example 01, 700 mg, 1.42 mmol), PPha (930 mg, 3.55 mmol), and (3,5-dimethoxyphenyl)methanol (358 mg,
-1332.13 mmol) m 2-Me-THF (30 mL) at 0 °C was added DIAD (574 mg, 2.84 mmol) dropwise. The solution was stirred for 16 h to provide a pale-yellow suspension. The suspension was filtered, and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (40 g S1O2, 1:2 petroleum ether/EtOAc) to provide 5bromo-Λ/-[(3l5-dimethoxyphenyl)methyl]-2-meΐhoxy“/V-{4-methoxy-6-[(1H-pyrazol·1yl)methyi]-1,2-beπzoxazol·3-yl}benzene-1-sulfonamide (J-2) (200 mg, 22% yield) as a white solid.
Step 2: Synthesis of 5-cyciopropyl-/V-[(3,5-dîmethoxyphenyl)methyl]-2-methoxyN-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1sulfonamide (J-3)
To a solution of 5-bromo-/V-[(3,5-dÎmethoxyphenyi)methyl]-2-methoxy-A/-{4-methoxy-6[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (J-2) (200 mg, 0.311 mmol) in CPME (10.0 mL) and H2O (1.0 mL) was added potassium cyclopropyltrifluoroborate (138 mg, 0.932 mmol), Pd(OAc)2 (14.0 mg, 0.062 mmol), K2CO3 (172 mg, 1.24 mmol), and X-Phos (44.4 mg, 0.093 mmol). The mixture was evacuated and back-fi1led with N2 (3x) and then stirred at 100 °C under an atmosphère of N2 for 16 h. The reaction was cooled to room température, diluted with EtOAc (20 mL), and filtered. The filtrate was concentrated to dryness. The residue was purified by flash chromatography (20 g SiÛ2, EtOAc) to provide 5-cyclopropyl-A/-[(3,5dimethoxyphenyl)methyl]-2-methoxy-N-{4-methoxy-6-[(1/-/-pyrazol-1-yl)methyl]-1,2benzoxazol-3-yl}benzene-1-sulfonamide (J-3) (100 mg, 53% yield) as a white solid. m/z (ESI+) 605.3 (M+H)+.
Step 3: Synthesis of 5-cyclopropyl-2-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1yl)methyl)-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 97)
To a solution of 5-cyclopropyl-N-[(3,5-dimethoxyphenyl)methyl]-2-methoxy-N-{4methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (J-3) (100 mg, 0.165 mmol) in DCM (2.0 mL) was added TFA (2.0 mL). The mixture was stirred for 1 h and then concentrated to dryness. The residue was purified by flash chromatography (12 g S1O2, 1:10 MeOH/EtOAc). The material was repurified by préparative HPLC with a Phenomenex Gemini-NX column (150x30 mm, 5 pm particle size), which was eluted with 2-42% MeCN/HpO (+0.05% ΝΗλΟΗ) with a flow rate of 30
- 134 mL/min to provide 5-cyclopropyl-2-methoxy-/V-{4-methoxy-6-[(1H-pyra2ol-1-y!)methyl]1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Example 97) (50 mg, 67% yield) as a white solid. 1H NMR (400 MHz, DMSO-rte) δ 10.10 (brs, 1H), 7.88 (d, J=1.9 Hz, 1H), 7.51 (dd, J=1.6, 11.0 Hz, 2H), 7.27 (br. d, J=6.8 Hz, 1 H), 7.05 (br. d, J=8.9 Hz, 1 H), 6.82 (br. s, 1 H), 6.72 (br. s, 1 H), 6.30 (t, J=1.9 Hz, 1 H), 5.44 (s, 2H), 3.83 (s, 2H), 3.90 (br. d, J=8.3 Hz, 1 H), 3.73 (s, 2H), 3.76 - 3.67 (m, 1 H), 2.01 - 1.89 (m, 1 H), 1.04 - 0.78 (m, 2H), 0.70-0.42 (m, 2H). m/z (ESI+) 454.8 (M+H)\
Example 98: Préparation of N-(6-((1H-pyrazol-1-yl)methyl)-4methoxybenzo[d]isoxazol-3-yl)-2,6-dimethoxybenzenesulfonamide [or 2,6dimethoxy-N-{4-methoxy-6-[(1H-pyrazoi-1-yl)methyl]-1,2-benzoxazol-3yl}benzene-1-sulfonamide] according to Scheme K.
Scheme K:
14b
N=\
HN-A
NaH
DMF step 1
O
A .OH
H3C N 3 H
KOt-Bu
DMF step 2
h3c.
lnt-26 CH3
Pyridine step 3
Example 98
- 135Step 1: Alternate synthesis of 4-((1H-pyrazol-1-yl)methyl)-2-fluoro-6methoxybenzonitrile (A-1) from 14b
A solution of 1H-pyrazole (2.0 g, 29.6 mmol) and NaH (60% w/w dispersion in minerai oil, 1.5 g, 37.1 mmol) in DMF (520 mL) was stirred at 0 °C for 1 h. A solution of 4(bromomethyl)-2-fluoro-6-methoxybenzonitrile (14b) (6.0 g, 24.7 mmol) in DMF (80 mL) was then added and the mixture was stirred at RT overnight. The reaction was quenched with water and the mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Pet, Ether/EtOAc = 6/1) to give 4-((1 H-pyrazol-1-yl)methyl)-2-fluoro-6-methoxybenzonitrile (A-1) (2.4 g, 42%) as a yellow solid. m/z 232.0 [M+H]+.
Step 2: Alternate synthesis of 6-((1H-pyrazol-1-yl)methyl)-4methoxybenzo[d]isoxazol-3-amine (A-2) using potassium fert-butoxide
To a solution of acetohydroxamic acid (3.7 g, 49.5 mmol) in anhydrous DMF (150 mL) at RT was added potassium tert-butoxide (5.6 g, 49.5 mmol) and the mixture was stirred at RT for 1 h. 4-((1H-Pyrazol·1-yl)methyl)-2-fluoro-6-methoxybenzonitrile (A-1) (3.8 g, 16.5 mmol) was then added and stirring was continued at 60 °C for 4 h. Water was added and the mixture was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Pet. Ether/EtOAc = 5/1) to give 6((1 H-pyrazol-1 -yl)methyl)-4-methoxybenzo[cf]isoxazol-3-amine (A-2) (2.1 g, 53%) as a yellow solid. m/z 245.0 [M+H]+. 1H NMR (400 MHz, DMSO-cfe) δ 7.87 (dd, J=1.6, 0.4 Hz, 1H), 7.50 (dd, J=1.6, 0,4 Hz, 1H), 6.69 (s, 1H), 6.62 (s, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.93 (S, 2H), 5.41 (s, 2H), 3.86 (s, 3H).
Step 3: Synthesis of N-(6-((1H-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol-3yl)-2,6-dimethoxybenzenesulfonamide (Example 98)
A mixture of 6-((1 H-pyrazol-1 -yl)methyl)-4-methoxybenzo[c(]isoxazol-3-amine (A-2) (50 mg, 0.205 mmol) and 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) (73 mg, 0.308 mmol) in pyridine (1 mL) was heated at 120 °C for 2 h under microwave irradiation (Batch 1).
- 136A mixture of 6-((1 H-pyrazol-1 -yl)methyl)-4-methoxybenzo[tf|isoxazol-3-amine (A-2)(500 mg, 2.1 mmol) and 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) (746 mg, 3.2 mmol) in pyridine (5 mL) was heated at 120 °C for 2 h under microwave irradiation (Batch 2). This reaction was repeated once again on exactly the same scale (Batch 3).
A mixture of 6-((1/7-pyrazol-1-yl)methyl)-4-methoxybenzo[c/]isoxazol-3-amine (A-2)(350 mg, 1.4 mmol) and 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) (509 mg, 2.2 mmol) in pyridine (4 mL) was heated at 120 °C for 2 h under microwave irradiation (Batch 4). The four reaction mixtures were combined, diluted with water, adjusted to pH 5-6 with 2 M aqueous HCl and extracted with EtOAc (300 mL x 3). The combined organic extracts îo were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
The residue was purified by column chromatography (Pet. Ether/EtOAc = 2/1) to give N(6-((1 H-pyrazol-1 -yl)methyl)-4-methoxybenzo[c(]isoxazol-3-yl)-2,6dimethoxybenzenesulfonamide (Example 98) (1.07 g, 43%) as a white solid. m/z 445.0 [M+H]+. 1H NMR (400 MHz, DMSO-de) δ 9.58 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.50 15 7.46 (m, 2H), 6.83 (s, 1 H), 6.76 (m, 3H), 6.30 (s, 1 H), 5.44 (s, 2H), 3.87 (s, 3H), 3.76 (s,
6H).
Example 98: Alternative préparation of 2,6-dimethoxy-N-{4-methoxy-6-[(1Hpyrazol-1-yl)methyl]-1.,2-benzoxazol-3-yl}benzene-1 -sulfonamide according to 20 Scheme L.
Scheme L:
- 137 Step 1 : Alternate synthesis of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-amine (A-2) using 1,1,3,3-tetramethylguanidine.
A suspension of 2-fluoro-6-methoxy-4-(1H-pyrazol-1-ylmethyl)benzonitrile (A-1) (15.43 g, 66.7 mmol), W-hydroxyacetamide (15.0 g, 200 mmol), and 1,1,3,3-TMG (46.1 g, 400 mmol) in acetonitrile (270 mL) and deionized water (30 mL) was heated to 60 °C for 7 hours. The acetonitrile was removed under vacuum, and the residual thick oil was partitioned between ethyl acetate (300 mL) and deionized water (250 mL). The aqueous iayer was extracted with ethyl acetate (2 x 150 mL). Ail the organic layers were combined and washed with satd. aq. NaCI. Some solids began to form in the organic Iayer, so methanol (~10 mL) was added and the suspension heated until homogeneous. After cooling to room température, the organic Iayer was dried over sodium sulfate, filtered, and concentrated. The resulting pale-yellow solid was suspended in ethyl acetate (125 mL) and heated briefly to reflux. The suspension was allowed to cool to room température, the resulting solids were collected by filtration, and the filter cake was rinsed with heptane. The filtrate and heptane rinse were concentrated to dryness, the residual solid suspended in ethyl acetate (15 mL), the suspension briefly heated to reflux, and a second crop of precipitate was collected as before. The combined precipitate crops were dried under vacuum to give 4-methoxy-6[(1 /7-pyrazol-1 -yl)methyl]-1,2-benzoxazol~3-amine (A-2) (11.86 g, 48.6 mmol) as a pale-yellow powder. 1H NMR (400 MHz, DMSO-de) δ 7.87 (d, J=1.8 Hz, 1H), 7.49 (d, J=1.2 Hz, 1 H), 6.69 (s, 1 H), 6.62 (s, 1 H), 6.30 (t, J=2.1 Hz, 1 H), 5.93 (s, 2H), 5.41 (s, 2H), 3.86 (S, 3H). LCMS: [M+H]+ 245.
Step 2: Synthesis of 22,6-dimethoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Example 98)
A mixture of 4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol·3-amine (A-2) (9.5 g, 39 mmol) and 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) (12.1 g, 51.1 mmol) in pyridine (20 mL) was heated to 97 °C internai for 1 hour. After cooling to 50 °C, the solution was poured into a flask containing crushed ice (200 g) and 6N HCl (100 mL). The reaction flask was rinsed with dichloromethane to quantitate the transfer. The resulting aqueous mixture was extracted with dichloromethane (4 x 100 mL). The combined organic extracts were washed with deionized water and satd. aq. NaCI, dried over magnésium sulfate, filtered, and concentrated to a yellow foam. Methyl acetate (50
- 138 mL) was added to the foam and the suspension stirred at room température for 1 hour. Solids were collected by suction filtration and rinsed with heptane. After drying under vacuum, crude 2,6-dimethoxy-N-[4-methoxy-6-(1H-pyrazol-1-ylmethyl)-1,2-benzoxazol3-yl]benzenesulfonamide (Example 98)(16.1 g, 95%) was obtained as an orange-tan 5 solid. Trituration of the crude solid with methyl acetate two more times did not remove the orange color, so the crude product was triturated in warm dichloromethane, allowed to cool to room température, and filtered to give a cream-colored white solid. The dichloromethane mother liquor was further purified by chromatography (330 g silica column, eluting with 60-100% ethyi acetate in heptane) to give a white solid. The solids ίο from both the DCM trituration and the chromatography of the DCM fïltrate were combined, stirred in refluxing methyl acetate, and cooled to room température over 2 hours. The resulting solid was collected by suction filtration and dried in a 100 °C vacuum oven overnight, affording purified 2,6-dimethoxy-N-[4-methoxy-6-(1/-/-pyrazol·1ylmethyl)-1,2-benzoxazol-3-yl]benzenesulfonamide (Example 98) (15.3 g, 89%) as an 15 off-white powder.
Three batches of Example 98 (total 54.3 g), prepared as described above, were combined, suspended in methyl acetate (250 mL), and heated to reflux for 1 hour. After removing from the heating bath, stirring was continued for 4 hours as the mixture cooled to room température. The resulting precipitate was collected by filtration and 20 rinsed with heptane. The solid was dried under vacuum at room température for 2 hours, then dried further in a 130 °C vacuum oven for 16 hours, affording 2,6dimethoxy-Λ/-[4-methoxy-6-(1/-/-pyrazol·1 -yl methyl)-1,2-benzoxazol-3yl]benzenesulfonamide (Example 98) (53.55 g, 99%) as an off-white solid. 1H NMR (400 MHz, DMSO-de) δ 9.60 (s, 1H), 7.88 (d, J=1.7 Hz, 1H), 7.45-7.52 (m, 2H), 6.83 (s, 25 1 H), 6.77 (d, J=8.4 Hz, 3H), 6.30 (t, J=2.1 Hz, 1 H), 5.44 (s, 2H), 3.87 (s, 3H), 3.76 (s,
6H). LCMS: [M+H]+ 445. Anal. Calcd for C20H20N4O6S: C, 54.05; H, 4.54; N, 12.61 ; S, 7.21. Found: C, 53.91; H, 4.58; N, 12.51; S, 7.09.
Example 99: Préparation of Λ/-(6-((1H-pyrazol·1-yl)methyl)-430 methoxybenzo(d]isoxazol-3-yl)-3-methylquînoline-8-sulfonamide according to Method AC.
Example 100: Préparation of 2,6-dimethoxy-N-(4-methoxy-6-((4-methyl-1H-pyrazol1-yl)methyl)benzo[r/]isoxazol-3-yl)benzenesulfonamide according to Method AC.
To a solution ofthe amine (0.2 mmol, 1.0 eq.) in pyridine (2 mL) was added the sulfonyl chloride (1.5 eq.) and the mixture was heated at 120 °C under microwave irradiation for 2 h. The mixture was partitioned between water and EtOAc, the layers were separated, 10 and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep. TLC to give the title compound. Variations to above conditions hâve been noted in Table 18.
Table 18:
Example | Name and Structure | Analytical | Intermediates | Notes |
99 | h3c η | ox,O N-o AA n\A [IJ h AA fA. ch3 /V- (6-( ( 1 H-pyrazol-1 yl)methyl)-4- methoxybenzo[d]isoxazol·3- | 1H NMR (400 MHz, DMSO-de) δ 8.92 (br. s, 1H), 8.33 (d, J=3.2 Hz, 1H), 8.21 (br. s, 1H), 7.99 (br. s, 1H), 7.81 (br. s, 1 H), | 6-((1Hpyrazol-1 yl)methyl)4-methoxybenzo[d]isoxazol-3amîne (J2) | 1.2 eq. sulfonyl chloride used; 5 mL pyridine used. |
- 140 -
yl)-3-methylquinoline-8- | 7,64 (br, s, 1 H), | Adjusted to | ||
sulfonamide | 7.43 (br. s, 1H), | pH 5 with 1 | ||
6.82 - 6.47 (m, | M aq. HCl | |||
2H), 6.24 (s, 1H), | prior to | |||
5.32 (s, 2H), 3.82 (S, 3H), | workup. | |||
2.43 (s, 3H); m/z | Prep, TLC | |||
450.0 [M+H]+. | (Pet. Ether/EtOA C=1/2) | |||
2,6- | ||||
Ή NMR (400 | dimethoxy | |||
MHz, CDCh) δ | benzene- | |||
9.83 (br. s, 1H), | sulfonyl | Reaction | ||
HjC. 9 O O N~O | 8.21 (s, 1H), 7.37-7.35 (m, | chloride (lnt-26) | mixture was | |
[I J N I v \ N CHa 1 0 | 2H), 7.19 (S, 1H), | concentrât | ||
ch3 ch3 | 6,76 (S, 1H), | 4-methoxy- | ed prior to | |
100 | 2,6-dimethoxy-A/-(4- | 6.58 (d, J=8.4 | 6-((4- | workup. |
methoxy-6-((4-methyl-1/7- | Hz, 2H), 6.46 (S, | methyl-1/7- | ||
pyrazol-1- | 1H), 5.29 (s, 2H), | pyrazol-1 - | Prep. TLC | |
yl) methyl) benzo[d]isoxazol- | 3.96 (S, 3H), | yl)methyl)b | (DCM/MeO | |
3-yl)benzenesulfonamide | 3.87 (S, 6H), | enzo[tf|isox | H, 20/1) | |
2.07 (S, 3H); m/z | azol-3- | |||
459.0 [M+H]+ | amine (Int- 25) |
Example 101: Préparation 2,6-dimethoxy-N-(4-methoxy-6-(1-methyl-1H-pyrazol-4yl)benzo[d]isoxazol-3-yl)benzenesulfonamide according to Scheme M.
- 141 -
Scheme Μ:
To a solution of /V-(6-bromo-4-methoxybenzo[d]isoxazol-3-yl)-2,6dimethoxybenzenesulfonamide (lnt-27) (40 mg, 0.09 mmol) in 1,4-dioxane (8 mL) and water (2 mL) was added (1 -methyl-1H-pyrazol-4-yl)boronic acid (80 mg, 0.631 mmol), NazCChOOO mg, 0.948 mmol) and Pd(PPh3)4 (37 mg, 0.032 mmol) and the mixture was heated at reflux under a N2 atmosphère overnight. The mixture was adjusted to pH 4-5 with 1 M aqueous HCl, diluted with EtOAc and washed with water, brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep. TLC (DCM/MeOH = 50/1) to give the title compound (22 mg, 55%) as a white solid. m/z 445.0 [M+H]+. 1H NMR (400 MHz, DMSO-cfe) δ 9.52 (s, 1H), 8.35 (s, 1H), 8.05 (S, 1 H), 7.50 (t, J = 8.5 Hz, 1 H), 7.38 (s, 1 H), 7.05 (s, 1 H), 6.78 (d, J = 8.5 Hz, 2H), 3.98 (S, 3H), 3.87 (s, 3H), 3.78 (s, 6H).
Example 102: Préparation of 2,6-dimethoxy-N-(5-methyl-7-(1-methyl-1H-pyrazol-4yl)benzo[d]isoxazol-3-yl)benzenesulfonamide according to Scheme N.
Scheme N:
- 142
Exampie 102
To a solution of Λ/-(7-bromo-5-methyIbenzo[c/]isoxazol-3-y 1)-2,6dimethoxybenzenesulfonamide (lnt-29)(50 mg, 0.117 mmol) in 1,4-dioxane (8 mL) and water (2 mL) was added (1-methyl-1H-pyrazol-4-yl)boronic acid (22 mg, 0.176 mmol), NaaCOa (50 mg, 0.468 mmol) and Pd(dppf)Cl2 (9 mg, 0.012 mmol) and the mixture was heated at reflux under a N2 atmosphère overnight. The mixture was adjusted to pH 5 with 1 M aqueous HCl, diluted with water and extracted with EtOAc (30 mL x 3). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep. TLC (Pet. Ether/EtOAc = 3/1 ) to give the title compound (24 mg, 48%) as a white solid. m/z 429.0 [M+Hp. 1H NMR (400 MHz, DMSO-cfe) δ 8.24 (s, 1H), 7.99 (s, 1H), 7.55 (s, 1H), 7.497.22 (m, 2H), 6.67 (d, J=8.6 Hz, 2H), 3.88 (s, 3H), 3.69 (s, 6H), 2.39 (s, 3H).38 (s, 1 H), 7.05 (S, 1 H), 6.78 (d, J=8.5 Hz, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 3.78 (s, 6H).
Example 103: Préparation of 3-hydroxy-2,6-dimethoxy-N-{4-methoxy-6-[(1Hpyrazol-1 -yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide according to Scheme O.
OH
Example 104: Préparation of 2-hydroxy-6-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide according to Scheme O.
- 143 -
Example 105: Préparation of N-{6-[(4-hydroxy-1H-pyrazol-1-yl)methyl]-4-methoxy1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide according to Scheme s O.
Scheme 0:
OH
enzymatic oxidation
To a 500 mL Erlenmeyer flask was added HPLC grade H2O (27.2 mL), aqueous potassium phosphate buffer (1.0 M, 4.0 mL, pH 7.5), aqueous MgCh (165 mM, 0.8 mL), dexamethasone-induced male rat liver microsomes (4.0 mL, 20 mg/mL, Xenotech) and a solution of 2,6-dimethoxy-A/-{4-methoxy-6-[(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-3
- 144 yl}benzene-1-sulfonamide (Prepared as in Example 98, 5 mM in MeCN, 0.20 mL, 1.0 pmol). The incubation was commenced with addition of a freshly prepared aqueous solution of NADPH (4.0 mL, 13 mM). The uncapped Erlenmeyer flask was shaken in a water bath maintained at 37 °C for 1.5 h. The incubation mixture was quenched by 5 adding MeCN (40 mL) followed by centrifugation at ~1700 g for 5 min. The supernatant was partially evaporated in a vacuum centrifuge. The remaining solution was treated with MeCN (0.5 mL), neat formic acid (0.5 mL) and de-ionized HsO to a provide final volume of -50 mL. The solution was subjected to centrifugation at -40,000 g for 30 min. The supernatant was adsorbed onto a Zorbax Polaris C18-A HPLC column (250x4.6 mm, 5 pm particle size) using a JASCO PU-1580 HPLC pump at a flow rate of
0.8 mljmin over -60 min. The HPLC column was transferred to a Thermo LTQ Vélos mass spectrometer in line with a Waters Acquity UHPLC instrument comprised of a quaternary pump, autosampler and photodiode array UV/vis detector. A gradient of MeCN/H2O (+0.1% formic acid) was applied to separate products of interest. After passing through the PDA detector, the eluent was split at a ratio of approximately 15:1 with the larger portion going to a fraction collecter and the smaller portion to the mass spectrometer. Fractions were collected every 20 s and those containing peaks of interest were analyzed by UHPLC-UV-HRMS using a Thermo Orbitrap Elite highresolution ion trap mass spectrometer in line with a Thermo Accela LIHPLC and diode array UV/vis detector with a CTC Analytics Leap auto injecter (Thermo-Fisher).
Samples were injected (10 μι) onto a Phenomenex Kinetex C18 UHPLC column (50x2.1 mm, 1.7 μm particle size) maintained at 45 °C, which was eluted with a MeCN/H2O (+0.1% formic acid) gradient with a flow rate of 0.4 mL/min. After UHPLCUV-HRMS analysis, fractions were pooled, and the solvent was removed by vacuum 25 centrifugation. The dried samples were analyzed by NMR spectroscopy and quantified by external calibration against the 1H NMR spectrum of a 5.0 mM benzoic acid standard solution in DMSO-cfe using the ERETIC2 function within Topspin V3.2. A/-{6-[(4-hydroxy1/-Lpyrazol-1-yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1sulfonamide (Example 105) (0.028 pmol, 3% yield) was obtained as the first-eluting peak. 1H NMR (600 MHz, DMSO-ûfe) δ 8.45 (s, 1 H), 7.38 (m, 1 H), 7.32 (s, 1 H), 7.06 (s, 1H), 6.70 (m, 3H), 6.63 (s, 1H), 5.22 (s, 2H), 3.86 (S, 3H), 3.69 (s, 6H). HRMS (ESITOF) calculated for (C2oH2iN407S)[M+H]+ m/z = 461.1125, found 461.1121 (-0.45 ppm). 3-Hydroxy-2,6-dimethoxy-/V-{4-methoxy-6-[(1H-pyrazol-1 -yl)methyl]-1,2-
- 145 benzoxazol-3-yl}benzene-1-sulfonamide (Example 103) (0.072 gmol, 7% yield) was obtained as the second-eluting peak. 1H NMR (600 MHz, DMSO-cte) δ 9,33 (s, 1H), 7.88 (d, 7=2.4 Hz, 1 H), 7.50 (s, 1 H), 7.01 (d, 7=9.0 Hz, 1 H), 6.80 (s, 1 H), 6.76 - 6.68 (m, 2H), 6.31 (t, 7=2.3 Hz, 1 H), 5.44 (s, 2H), 3.87 (s, 3H), 3.76 (s, 3H), 3.65 (s, 3H). HRMS 5 (ESI-TOF) calculated for (C2oH2iN40?S)[M+H]+ m/z = 461.1125, found 461.1123 (-0.25 ppm). 2-Hydroxy-6-methoxy-N-{4-methoxy-6-[(1H-pyrazol-1-yl) methyl]-1,2-benzoxazol3-yl}benzene-1-sulfonamide (Example 104) (0.19 gmol, 19% yield) was obtained as the third eluting peak. 1H NMR (600 MHz, DMSO-76) δ 7.86 (s, 1H), 7.50 (s, 1H), 7.13 (m, 1 H), 6.63 (S, 1 H), 6.53 (m, 2H), 6.40 (d, 7=8.1 Hz, 2H), 6.30 (s, 1 H), 5.41 (s, 2H), 3.83 (s, 3H), 3.72 (s, 3H). HRMS (ESI-TOF) calculated for (C19H19N4O6S) [M+H]+ 431.1020, found 431.1017 (-0.28 ppm).
Example 106: Préparation of N-{6-[hydroxy(pyridin-2-yl)methyl]-4-methoxy-1,2benzoxazol-3-yl}-2,6-dimethoxybenzenesulfonamide according to Scheme P.
Example 107: Préparation of 2,6-dimethoxy-N-[4-methoxy-6-(pyridin-2-ylmethyl)1,2-benzoxazol-3-yl]benzenesulfonamide according to Scheme P.
Scheme P:
- 146 -
Step 1: Synthesis of N-{6-[hydroxy(pyridin-2-yl)methyl]-4-methoxy-1,2benzoxazol-3-yl}-2,6-dimethoxybenzenesulfonamide (Example 106):
A solution of /V-(6-bromo-4-methoxybenzo[c(]isoxazol-3-yl)-2,6- dimethoxybenzenesulfonamide (lnt-27) (628 mg, 1.42 mmol) in anhydrous THF (20 mL) was cooled to -78 °C. n-BuLi (1.20 mL of 2.5 in hexanes, 3.00 mmol) was added dropwise. The resulting slurry was stirred at -78 °C for 1 h. Then, a solution of pyridine2-aldehyde (187 mg, 1.75 mmol) in anhydrous THF (2 mL) was added dropwise. The resulting reaction mixture was stirred at -78 °C for 1 h. Additional pyridine-2-aldehyde (75 mg, 0.71 mmol) in 1 mL anhydrous THF was added.The resulting reaction mixture was warmed to room température and stirred at room température for 18 h. The reaction was quenched with HOAc (0.5 mL). The quenched reaction mixture was partitioned between EtOAc (50 mL) and water (50 mL). The organic phase was separated, washed with brine, dried over sodium sulfate, fîltered and purified via flash chromatography eluting with a gradient of 0 -100% EtOAc in heptane, then 0 - 20% 2PrOH in EtOAc to afford A/-{6-[hydroxy(pyridin-2-yl)methyl]-4-methoxy-1,2-benzoxazol3-yl}-2,6*dimethoxybenzenesulfonamide (Example 106) as a solid (247 mg, 37%). 1H NMR (400 MHz, CDCh) δ 8.61 (d, J=4.9 Hz, 1 H), 8.23 (s, 1 H), 7.82 (t, J=7.7 Hz, 1 H), 7.42 - 7.33 (m, 3H), 7.10 (S, 1H), 6.85 (s, 1H), 6.58 (d, J=8.4 Hz, 2H), 5.99 (s, 1H), 4.01 (S, 3H), 3.88 (S, 6H). m/z 472.2 [M+H].
Step 2: Synthesis of N-(6-(chloro(pyridin-2-yl)methyl)-4methoxybenzo/c/7isoxazol-3-yl)-2,6-dimethoxybenzenesulfonamide (P-1):
To a solution of AL{6-[hydroxy(pyridin-2-yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,625 dimethoxybenzenesulfonamide (Example 106) (113 mg, 0.240 mmol) in anhydrous DCM (5 mL) was added SOCI2 (0.20 mL, 2.7 mmol). The resulting reaction mixture was stirred at room température for 3 h. The solvent was removed, and the resulting residue was partitioned between EtOAc (50 mL) and satd. aqueous NaHCOs (50 mL).
-147The organic phase was separated, dried over sodium sulfate, and concentrated to afford A/-(6-(chloro(pyridin-2-yl)methyl)-4-methoxybenzo/û7isoxazol-3-yl)-2,6dimethoxybenzenesulfonamide (P-1 ) (78 mg, 66% yield) which was used in the next step without further purification. 1H NMR (400 MHz, CDCIa) δ 8.57 (br. d, J=4.2 Hz, 1H), 5 8.25 (S, 1 H), 7.75 (dt, J=1.7, 7.8 Hz, 1 H), 7.57 (d, J=7.Q Hz, 1 H), 7.37 (t, J=8.5 Hz, 1 H),
7.27 - 7.22 (m, 1 H), 7.10 (s, 1 H), 6.82 (s, 1 H), 6.57 (d, J=8.6 Hz, 2H), 6.17 (s, 1 H), 4.00 (s, 3H), 3.87 (s, 6H), missing the sulfonamide NH; m/z 490.1 [M+H]+.
Step 3: Synthesis of 2,6-dimethoxy-N-[4-methoxy-6-(pyridin-2-ylmethyl)-1,210 benzoxazol-3-yl]benzenesulfonamide (Example 107):
To a solution of A/-(6-(chloro(pyridin-2-yl)methyl)-4-methoxybenzo/G7isoxazol-3-y 1)-2,6dimethoxybenzenesulfonamide (P-1) (75 mg, 0.153 mmol) in HOAc (5 mL) was added zinc dust (69 mg, 1.1 mmol) and the solution was heated to 60 °C. After 3 h at 60 °C, the reaction was complété. The reaction was cooled to room température and carefully 15 neutralized with saturated NaHCOa. The organics were extracted with EtOAc (2 x 50 mL) and the combined organic extract was dried over sodium sulfate, concentrated to dryness and purified via flash chromatography eluting with a gradient of 0 -100% EtOAc in heptane followed by 0 - 20% 2-PrOH in EtOAc. Concentration of the pure fractions afforded 2,6-dimethoxy-N-[4-methoxy-6-(pyridin-2-ylmethyl)-1,2-benzoxazol-320 yl]benzenesulfonamide (Example 107) (38 mg, 55% over two steps) as a solid. Ή
NMR (400 MHz, CDCb) δ 8.57 (br. S, 1 H), 8.23 (s, 1 H), 7.65 (t, J=7.6 Hz, 1 H), 7.37 (t, J=8.5 Hz, 1H), 7.19 (br. d, J=6.6 Hz, 2H), 6.89 (s, 1H), 6.64-6.53 (m, 3H), 4.23 (s, 2H), 3.98 (s, 3H), 3.87 (s, 6H). m/z 456.3 [M+H].
Example 108: Préparation of N-{6-[(S*)-hydroxy(1,3-oxazol-2-yl)methyl]-4methoxy-1,2-benzoxazol·3-yl}-2,6-dimethoxybenzenesulfonamïde according to Scheme Q.
- 14810
Example 109: Préparation of N-{6-[(ff*)-hydroxy(1,3-oxazol-2-yl)methyl]-4methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzenesulfonamide according to Scheme Q.
Example 110: Préparation of 2,6-dimethoxy-N-[4-methoxy-6-(1,3-oxazol-2ylmethyl)-1,2-benzoxazol-3-yl]benzenesulfonamide according to Scheme Q.
Scheme Q:
- 149-
Step 1: Synthesis of N-(6-bromo-4-methoxy-1,2-benzoxazol-3-yl)-N-[(2,4dimethoxyphenyl)methyl]-2,6-dimethoxybenzene-1-sulfonamide (Q-1) To a solution of Λ/-(6-bromo-4-methoxybenzo[cΠisoxazol·3-yi)-2,65 dimethoxybenzenesulfonamide (lnt-27) (15 g, 34 mmoi) in THF (300 mL) and 2,4dimethoxybenzyl alcohol (8.54 g, 50,8 mmol), PPha (22.2 g, 84.6 mmol) was added DIAD (13.7 g, 67.7 mmol) dropwise at 0 °C. The reaction solution was warmed to room température and allowed to stir for 16 h. The réaction mixture was diluted with EtOAc (300 mL), washed with water (150 mL), brine, saturated aq. sodium bicarbonate, and ίο brine again. The organic phase was dried over sodium sulfate and filtered. The solvent was removed under reduced pressure to give a mixture that was purified by flash chromatography eluting with 60%-70% EtOAc in petroleum ether to give crude product with some triphenylphosphine oxide remaining. The crude solid was re-crystalized from MeOH to give N-(6-bromo-4-methoxy-1,2-benzoxazol-3-yl)-/V-[(2,4
- 150 dimethoxyphenyl)methyl]-2,6-dimethoxybenzene-1-sulfonamide (Q-1) (8.0 g, 40% yield) as a white solid.
Step 2: Synthesis of rac-N-[(2,4-dimethoxyphenyl)methyl]-W-{6-[hydroxy(1,3oxazol-2-yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1sulfonamide (Q-2)
To a solution of M-(6-bromo-4-methoxy-1,2-benzoxazol-3-yl)-N-[(2,4dimethoxyphenyl)methyl]-2,6-dimethoxybenzene-1-sulfonamide (Q-1) (500 mg 0.843 mmol) in THF (9.5 mL) was added n-BuLi (0.506 mL of a 2.5 M solution in hexanes, 1.26 mmol) dropwise at -78 °C under an argon atmosphère. After 30 min at -78 °C, oxazole-2-carbaldehyde (123 mg 1.26 mmol) was added as a solution in THF (0.5 mL). The reaction was slowly allowed to warm to room température and stirred 16 h. The reaction mixture was poured into saturated aq. NH4CI (20 mL). The aqueous Iayer was extracted with two portions of EtOAc (2 x 20 mL). The combined extract was washed with brine (20 mL), dried over MgSÜ4 and concentrated in vacuo. The residue was purified by flash chromatography eluting with 100% EtOAc to give rac-N-[(2,4dimethoxyphenyl)methyl]-/V-{6-[hydroxy(1,3-oxazol-2-yl)methyl]-4-methoxy-1,2benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide (Q-2) (150 mg, 29% yield) as a yellow gum.
Step 3: Synthesis of N-{6-[(S*)-hydroxy(1,3-oxazol-2-yl)methyll-4-methoxy-1,2benzoxazol-3-yl}-2,6-dimethoxybenzenesulfonamide (Example 108) and N-{6[(R*)-hydroxy(1,3-oxazol-2-yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,6dimethoxybenzenesulfonamide (Example 109)
A solution of rac-A/-[(2,4-dimethoxyphenyl)methyl]-/V-{6-[hydroxy(1,3-oxazol-2yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1 -sulfonamide (Q-2) (150 mg 0.245 mmol) in TFA (5 mL) was stirred at room température for 2 h. A pink solution was observed, and the réaction mixture was concentrated in vacuo. The residue was pre-purified by flash chromatography eluting with EtOAc / MeOH 10:1 to give a racemic mixture of Examples 108 and 109 which was submitted to chiral SFC purification. The compounds were separated from each other using a Chiralpak AS-3 100x4.6mm I.D., 3um column with a mobile phase consisting ofCOs (A) and éthanol with 0.05% DEA (B). Gradient elution from 5% to 40% of B in 4 min and hold 40% B for
- 151 -
2.5 mm, then 5% of B for 1.5 min. After chiral SFC séparation 20 mg of each product was obtained. Peak 1 = Example 108 1H NMR (400MHz, DMSO-de) δ 8.06 (d, J=0.6 Hz, 1H), 7.45 (br. t, J=8.4 Hz, 1H), 7.18 (d, J=0.6 Hz, 1H), 7.15 (s, 1H), 6.86 (s, 1H), 6.74 (d, J=8.4 Hz, 2H), 6.67 (d, J=5.1 Hz, 1 H), 5.93 (d, J=5.3 Hz, 1 H), 3.88 (s, 3H), 3.74 (s, 6H), missing sulfonamide NH peak; m/z 462.0 (M+H)+. Peak 2 = Example 109 Ή NMR (400MHz, DMSO-d6) δ 8.06 (d, J=0.6 Hz, 1 H), 7.50 (t, J=8.5 Hz, 1 H), 7.13 - 7.26 (m, 2H), 6.90 (s, 1 H), 6.78 (d, J=8.4 Hz, 2H), 6.70 (d, J=5.4 Hz, 1 H), 5.95 (d, J=5.3 Hz, 1 H), 3.89 (s, 3H), 3.78 (s, 6H), missing sulfonamide NH peak; m/z 462.0 (M+H)+.
Steps 4 and 5: Synthesis of /V-[(2,4-di methoxy phenyl) met hy!]-2,6-dim et hoxy-/V-{4methoxy-6-[(1,3-oxazol-2-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Q-3)
To a solution of rac-A/-[(2,4-dimethoxyphenyl)methyl]-W-{6-[hydroxy(1,3-oxazol-2yl)methyl]-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1 -sulfonamide (Q-2) (150 mg 0.245 mmol) in DCM (5 mL) was added thionyl chloride (290 mg 2.44 mmol) at room température. The solution was stirred for 1 h while a pale-yellow solution formed. The reaction was complété by T LC and the mixture was quenched with water (20 mL) and extracted with DCM (20 mL). The organic layer was dried over NasSCU, filtered and concentrated to give the secondary chloride (150 mg, yellow oil) which was used in the next step without further purification. To a solution of the secondary chloride (150 mg, 0.238 mmol) in HOAc (5 mL) was added zinc dust (467 mg 7.14 mmol) at room température. The reaction was allowed to stir at room température for 1 h. The reaction was complété by TLC and the mixture was diluted with EtOAc (50 mL) and filtered. The filtrate was adjusted to pH 7- 8 using satd. aq. Na2COa. The organic layer was dried over Na2SÛ4 and concentrated to give a residue which was purified by flash chromatography to afford N-[(2,4-dimethoxyphenyl)methyl]-2,6-dimethoxy-A/-{4methoxy-6-[(1,3-oxazol-2-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Q-3) (80 mg) as yellow oil.
Step 6: Synthesis of 2)6-dimethoxy-A/-[4-methoxy-6-(1,3-oxazol-2-ylmethyl)-1,2benzoxazol-3-yl]benzenesulfonamide (Example 110)
A solution of A/-[(2I4-dimethoxyphenyl)methyl]-2,6-dimethoxy-M-{4-methoxy-6-[(1,3oxazol-2-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1 -sulfonamide (Q-3) (80 mg 0.13
- 152mmol) m TFA (5 mL) was stirred for 1 h at room température. The reaction was concentrated and pre-purified by flash chromatography eluting with EtOAc / MeOH 10:1. The crude product obtained was further purified by prep. HPLC and the pure fractions were frozen and lyophilized to afford 10 mg of product still contaminated by an impurity as determined by 1H NMR. This sample was further purified via prep. TLC to afford 2,6-dimethoxy-A/-[4-methoxy-6-(1,3-oxazol-2-ylmethyl)-1,2-benzoxazol~3yl]benzenesulfonamide (Example 110) (5 mg, 8.4% yield) as a white solid. m/z 446.0 (M+H)+; 1H NMR (400MHz, METHANOL-^) δ 7.87 (s, 1H), 7.43 (t, J=8.5 Hz, 1H), 7.14 (S, 1 H), 6.92 (s, 1 H), 6.72 (d, J=8.5 Hz, 3H), 4.34 - 4.11 (m, 2H), 4.00 (s, 3H), 3.81 (s, 7H).
Example 111: Préparation of 2,6-dimethoxy-W-[4-methoxy-6-(pyrazin-2-ylmethyl)-
1,2- benzoxazol-3-yl]benzenesulfonamide according to Scheme R.
Step 1: Synthesis of 2-f lu or o-4-[hydroxy(py razin-2-yl) methyl ]-6methoxybenzonitrile (R-2).
A 250 mL three-neck round bottom flask was equipped with a thermometer, a stir bar, and a nitrogen inlet. The flask was charged with 4-bromo-2-fluoro-6methoxybenzonitrile (1 b) (4.00 g, 17.4 mmol) and 100 mL anhydrous THF. The flask was capped with a septum stopper, flushed with a nitrogen atmosphère, and cooled down to -20 °C (ice ! MeOH bath). /PrMgCI-LiCI (17.5 mLof 1.3 M, 22.8 mmol) was added dropwise, while maintaining the température below -15 °C. The resulting mixture was stirred at -20 °C for 1 h. Then, pyrazine-2-carboxaldehyde (2.95 g, 1.57 mmol) was
- 153added as a solution in 20 mL anhydrous THF while maintaining the temp below -10 °C. The resulting reaction was stirred at -10 °C for 1 h and then quenched with 4 N HCl (10 mL). The quenched réaction mixture was partitioned between EtOAc (200 mL) and water (200 mL). The organic phase was separated, and the aqueous phase was extracted with EtOAc again (1 x 100 mL). The combined organic phases were dried over Na2SO4, concentrated to dryness and purified via flash chromatography using a gradient of 20 - 100% EtOAc in heptane to afford 2-fluoro-4-[hydroxy(pyrazin-2yl)methyl]-6-methoxybenzonitrile (R-2) (2.6 g, 58% yield) as a gum. m/z 260.0 (M+H)+; 1H NMR (400 MHz, CDCI3) δ 8.67 (d, J=0.7 Hz, 1 H), 8.56 - 8.50 (m, 2H), 6.93 (s, 1 H), 6.87 (d, J=9.2 Hz, 1H), 5.88 (s, 1 H), 4.57 (br. S, 1H), 3.94 (s, 3H).
Steps 2-4: Synthesis of 2-fluoro-6-methoxy-4-[(pyrazin-2-yl)methyl]benzonitrile (R-3).
To a solution of 2-fluoro-4-[hydroxy(pyrazin-2-yl)methyl]-6-methoxybenzonitrile (R-2) (145 mg, 0.559 mmol) and EtaN (0.120 mL, 0.861 mmol) in anhydrous THF (10 mL) at 0 °C was added methanesulfonyl chloride (0.050 mL, 0.64 mmol). The resulting mixture was warmed to room température and stirred for 30 min. The reaction mixture was diluted with DCM (30 mL), washed with water (1 x 30 mL) and satd. aq. NaHCOs (1 x 30 mL). The extract was dried over Na2SO4 and concentrated to dryness. The material was used in the next step without further purification. A mixture of the crude mesylate (173 mg, 0.513 mmol) and LiBr (137 mg, 1.58 mmol) in anhydrous DMF (4 mL) was stirred at room température for 16 h. The reaction mixture was partitioned between EtOAc (50 mL) and water (50 mL). The organic phase was separated, washed with water (1 x 50 mL) and brine (1 x 50 mL), dried over Na2SO4, and concentrated. Purification via flash chromatography was accomplished using a gradient of 0 - 100% EtOAc in heptane to afford 72 mg (44%) of the secondary bromide. The secondary bromide (43 mg, 0.13 mmol) and zinc dust (90 mg, 1.4 mmol) were stirred at 80 °C in HOAc (2 mL) for 8 h. After cooling to room température, the réaction was diluted with EtOAc (50 mL) and carefully washed with satd. aq. NaHCOa (50 mL). The organic layer was then washed with brine (1 x 50mL) and dried over Na2SO4. After concentrating to dryness, the crude product was purified via flash chromatography eluting with a gradient 0 -100% EtOAc in heptane to afford 10 mg (31%) of 2-fluoro-6-methoxy-420447
- 154 [(pyrazin-2-yl)methyl]benzonitrile (R-3) (10 mg, 31% yield). 1H NMR (400 MHz, CDCIa) δ 8.56 (br. s, 3H), 6.74 - 6.69 (m, 2H), 4.18 (s, 2H), 3.94 (s, 3H); m/z 244.0 (M+H)+.
Steps 5-6: Synthesis of 2,6-dimethoxy-W-[4-methoxy-6-(pyrazin-2-ylmethyl)-1,2 5 benzoxazol-3-yl]benzenesulfonamide (Example 111).
To a mixture of 2-fluoro-6-methoxy-4-[(pyrazin-2-yl)methyl]benzonitrile (R-3) (178 mg, 0.732 mmol) and A/-hydroxyacetamide (165 mg, 2.20 mmol) in CH3CN (5 mL) and water (0.5 mL) was added 1,1,3,3-tetramethylguanidine (0.55 mL, 4.4 mmol). The resulting reaction mixture was stirred at 60 °C for 16 h and then cooled to room température. The solvent was removed, and the resulting residue was partitioned between EtOAc and water. The organic phase was separated, and the aqueous phase was extracted a second time with EtOAc (50mL). The combined organic extract was dried over Na2SO4, concentrated to dryness and purified via flash chromatography eluting with a gradient of 40 -100% EtOAc in heptane. This gave 82 mg (44%) of the amine intermediate as an oil. 1H NMR (400 MHz, DMSO-de) δ 8.68 (d, J=1.1 Hz, 1 H), 8.60 - 8.55 (m, 1 H), 8.51 (d, J=2.6 Hz, 1 H), 6.91 (s, 1 H), 6.69 (s, 1 H), 5.87 (br. s, 2H), 4.22 (s, 2H), 3.88 (s, 3H); m/z 257.1 (M+H)+, The amine (73 mg, 0.28 mmol) from the above reaction was treated with 2,6-dimethoxybenzene-1-sulfonyl chloride (lnt-26) (100 mg, 0.43 mmol) and pyridine (2 mL). The reaction mixture was stirred at 110 °C for 3 h.
Then, additional 2,6-dimethoxybenzene-1 -sulfonyl chloride (lnt-26) (50 mg, 0.21 mmol) was added and heating at 110 °C was continued for an additional 1 h. After cooling to room température, the réaction mixture was partitioned between ethyi acetate (20 mL) and 2N HCl (20 mL). The organic phase was separated, dried over NasSCX and purified via flash chromatography eluting with a gradient of 20 - 100% EtOAc in heptane followed by a second gradient of 0 - 20% 2-PrOH in EtOAc to afford 2,6-dimethoxy-A/[4-methoxy-6-(pyrazin-2-ylmethyl)-1,2-benzoxazol-3-yl]benzenesulfonamide (Example 111) (44 mg, 34% yield) as a solid. 1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.68 (d, J=1.0 Hz, 1 H), 8.58 - 8.53 (m, 1 H), 8.50 (d, J=2.4 Hz, 1 H), 7.49 (t, J=8.5 Hz, 1 H), 7.07 (s, 1H), 6.83 (s, 1H), 6.77 (d, J=8.6 Hz, 2H), 4.25 (s, 2H), 3.89 (S, 3H), 3.77 (s,
6H); m/z 456.8 (M+H)+.
The examples in the table below were synthesized according to the methods used for the synthesis 2,6-dîmethoxy-A/-[4-methoxy-6-(pyrazin-2-ylmethyl)-1,2-benzoxazol-320447
- 155 yl]benzenesulfonamide (Example 111). The following examples were synfhesized with non-critical changes or substitutions to the exemplified procedures that one skilled in the art would be able to realize. If necessary, séparation of regioisomeric mixtures was carried out under standard methods known in the art, such as SFC or HPLC, and was 5 conducted at any suitable step in the synthetic sequence.
Table 19:
Example | Name and Structure | Analytical | Notes |
112 | H 3c. 9 ,p N-0 .A // \ Œ η Ά CH3 ch3 oh N-{6-[(S*)-hydroxy(1,2oxazol-3-yl)methyl]-4methoxy-1,2-benzoxazol-3yl}-2,6dimethoxybenzenesulfonam ide, Isomer-A | Ή NMR (400MHz, METHANOL-cfe) δ 8.58 (d, 7=1.4 Hz, 1H), 7.47 (t, 7=8.5 Hz, 1H), 7.19 (s, 1H), 6.88 (s, 1H), 6.74 (d, 7=8.5 Hz, 2H), 6.47 (d, 7=1.6 Hz, 1H), 6.04 (S, 1H), 4.03 (S, 3H), 3.85 (s, 6H); m/z 462.2 [M+H]+. | Single enantiomer, absolute stereochemistry unknown; 1 st peak on Chiralpak AS-3 150x4.6mm LD., 3 pm column. Mobile phase A: CO2 B:iso-propanol (0.05% DEA); Scheme Q |
113 | h3cl ? O 0 n-o ./ri // \ CT «Λα a ch3 i । 3 ch3 oh AL{6-[(R*)-hydroxy(1,2oxazol-3-yl) methyl]-4methoxy-1,2-benzoxazol-3yl}-2,6dimethoxybenzenesulfonam ide, Isomer-B | 1H NMR (400MHz, METHANOL-74) δ 8.58 (d, 7=1.5 Hz, 1H), 7.47 (t, 7=8.5 Hz, 1H), 7.19 (S, 1H), 6.88 (S, 1H), 6.74 (d, 7=8.5 Hz, 2H), 6.47 (d, 7=1.6 Hz, 1H), 6.04 (s, 1H), 4.03 (S, 3H), 3.85 (s, 6H); m/z 462.0 [M+H]+. | Single enantiomer, absolute stereochemistry unknown; 2nd peak on Chiralpak AS-3 150x4.6mm I.D., 3 pm column. Mobile phase A: CO2 B:iso-propanol (0.05% DEA); Scheme Q |
156 -
114 | H3C. 9 0 Ο N-0 A. .S' // \ fl hyS «a , Q CHs CH3 A/-(6-(isoxazol-3-ylmethyl)4-m ethoxy ben zo [d] isoxazo I 3-yl)-2,6- d i m eth oxybe nzen esu If o nam ide | 1H NMR (400MHz, M ETHANOL-cU) δ 8.55 (S, 1H), 8.35 (s, 1H), 7.48 (t, 7=8.6 Hz, 1H), 6.95 (S, 1 H), 6.82 - 6.73 (m, 3H), 4.04 (s, 3H), 3.98 (s, 2H), 3.86 (s, 6H); m/z 446.2 [M+H]+. | Scheme Q |
115 | h3c^ 9 o.. „o n-o Q «Π Π CH3 ch3 oh N-{6-[(S*)- hydroxy(pyrimidin-2yl)methyl]-4-methoxy-1,2be nzoxazo I-3 -y l}-2,6d i m ethoxy be n ze n esu If on am ide | 1H NMR (400MHz, METHANOL-74) δ 8.74 (d, 7=4.8 Hz, 2H), 7.61 (d, 7=8.3 Hz, 1H), 7.46 (t, 7=8.5 Hz, 1H), 7.37 (t, 7=4.9 Hz, 1H), 6.82 (d, 7=8.2 Hz, 1H), 6.72 (d, 7=8.6 Hz, 2H),6.14(s, 1H), 4.61 (br. s, 1H), 4.04 (s, 3H), 3.83 (s, 6H); m/z 472.7 [M+H]+. | Single enantiomer, absolute stereochemistry unknown; 2nd Peak on ChiralCel OD-3 150x4.6mm I.D., 3 pm Mobile phase: A: CO2 B: 2-PrOH (0.1% Ethanolamine) Scheme Q |
116 | H3C_ 9 ZO N-O H J H Υη N' j ? 0'''^^ CH3 ch3 2,6-dimethoxy-/V-[4methoxy-6-(pyrimidin-2ylmethyl)-1,2-benzoxazol-3yl]benzenesulfonamide | 1H NMR (400MHz, DMSO-de) δ 9.38 (br. s, 1 H), 8.75 (d, 7=4.9 Hz, 2H), 7.48 (t, 7=8.4 Hz, 1H), 7.38 (t, 7=5.0 Hz, 1H), 7.03 (s, 1 H), 6.836.73 (m, 3H), 4.33 (s, 2H), 3.88 (S, 3H), | Scheme Q but using cat. Pd[PPh3]4 and EtsZn in DMFforthe dechlorination step. |
- 157-
3.77 (s, 6H); m/z 456.8 [M+Hp | |||
117 | H3C^ 9 % p N-ο A. x·3- \ I h η Y γΛ \-An N J L N H i 0 % M ch3 । , । , J ch3 oh N-{6-[(S*)-hydroxy(1Hpyrazol-3-yl)methyl]-4methoxy-1,2-benzoxazol-3yl}-2,6dimethoxybenzenesulfonam ide, Isomer A | NMR (400MHz, DMSO-Pe) δ 9.54 (s, 1 H), 7.50 (t, J=8.5 Hz, 2H), 7.15 (S, 1H), 6.89 (S, 1H), 6.77 (d, J=8.5 Hz, 2H), 6.12 (S, 1H), 5.83 (S, 1H), 3.89 (S, 3H), 3.77 (S, 6H); m/z 461.0 [M+H]1 | Single enantiomer, absolute stereochemistry unknown; Peak 1 on Chiralpak AY-3 100x4.6mm I.D., 3 pm Mobile phase: A: CO2 B:iso-propanol (0.05% DEA). Scheme Q |
118 | H3C. 9 O O N-0 \ίλ·ο H XJX mh CHa ch3 oh W-{6-[(A*)-hydroxy(1Hpyrazol-3-yl)methyl]-4methoxy-1,2-benzoxazol-3yl}-2,6dimethoxybenzenesulfonam ide, Isomer B | 1H NMR (400MHz, DMSO-cfe) δ 9.54 (s, 1H), 7.35 - 7.59 (m, 2H), 7.15 (s, 1H), 6.89 (S, 1H), 6.77 (d, J=8.5 Hz, 2H),6.12 (br. s, 1H), 5.83 (br. S, 1 H), 3.89 (S, 3H), 3.77 (s, 6H); m/z 461.0 [M+H]+ | Single enantiomer, absolute stereochemistry unknown; Peak 2 on Chiralpak AY-3 100x4.6mm I.D., 3 pm Mobile phase: A: CO2 B:iso-propanol (0.05% DEA). Scheme Q |
119 | h3c 0 f 9 ^ch3 V/\s-nh ° o ° N^Y|j F=N- ' Nx k H L NH 2,6-dimethoxy-A/-[4- methoxy-6-(1 H-pyrazol-3- | NMR (400MHz, METHANOL-^) δ 7.55 (br. S, 1H), 7.49 (br. t, J=8.6 Hz, 1 H), 6.92 (S, 1H), 6.82 6.66 (m, 3H), 6.17 (s, 1H), 4.12 (s, 2H), 4.03 (S, 3H), 3.86 (s, | Scheme Q |
- 158 -
ylmethyl)-1,2-benzoxazol-3yl]benzenesulfonamide | 6H); m/z 445.0 [M+H]+ | ||
120 | Ην ZO N-o OÂXU CH3 A, . 1, , 3 ch3 oh Λ/-{6-[(S*)-hydroxy (1,2oxazol-4-yl) methyl] -4methoxy-1,2-benzoxazol-3yl}-2,6- d i m eth oxy be nze n esu If on am ide, Isomer A | 1H NMR (400MHz, METHANOL-cU) δ 8.55 (S, 1H), 8.37 (s, 1 H), 7.48 (br. t, J=8.4 Hz, 1H), 7.17 (s, 1H), 6.89 (S, 1H), 6.75 (br. d, J=8.5 Hz, 2H), 5.92 (S, 1H), 4.05 (S, 3H), 3.86 (s, 6H); m/z 461.7 [M+H]+ | Single enantiomer, absolute stereochemistry unknown; 1 st Peak on Chiralpak AS-3 150x4.6mm I.D., 3 pm Mobile phase: A: CO2 B: éthanol (0.05% DEA) Scheme Q |
121 | h3c_ ? ,0 N-0 ch3 θ 3 ch3 oh Λ/-(6-(hydroxy (isoxazol-4yl)methyl)-4- m ethoxy be n zo [d] isoxazo I-3A/-{6-[(fî*)-hydroxy(1,2oxazol-4-yl)methyl]-4methoxy-1,2-benzoxazol-3yl}-2,6- dimethoxybenzenesulfonam ide, Isomer B | 1H NMR (400MHz, METHANOL-cU) ô 8.55 (S, 1H), 8.37 (s, 1 H), 7.48 (br. t,j=8.5 Hz, 1H), 7.17 (s, 1H), 6.89 (s, 1H), 6.75 (br. d, J=8.4 Hz, 2H), 5.92 (s, 1H), 4.05 (s, 3H), 3.86 (S, 6H); m/z 461.8 [M+H]+ | Single enantiomer, absolute stereochemistry unknown; 2nd Peak on Chiralpak AS-3 150x4.6mm I.D., 3 pm Mobile phase: A: CO2 B: éthanol (0.05% DEA) Scheme Q |
122 | h3c. 9 ,p N-o ...s. n \ ^9 OAÀ° CH3 ch3 2,6-dimethoxy-A/-[4methoxy-6-(1,2-oxazol-4- | 1H NMR (400MHz, METHANOL-d4) δ 8.55 (S, 1H), 8.35 (s, 1H), 7.48 (t, J=8.6 Hz, 1H), 6.95 (S, 1H), 6.82-6.73 (m, 3H), 4.04 (S, 3H), 3.98 (S, | Scheme Q |
- 159 -
ylmethy 1)-1,2-benzoxazol-3yl]benzenesulfonamide | 2H), 3.86 (S, 6H); m/z 446.2 [M+H]+ | ||
123 | h3c 9 0^,0 N-o A. -Si // \ Q H Y i ï h oAAXn GH3 ch3 oh rac-N-{6-[hydroxy(pyrazin-2yl) methyl] -4-methoxy-1,2benzoxazol-3-yl}-2,6dimethoxybenzenesulfonam ide | Ή NMR (400 MHz, CDCIa) δ 8.62 (br. s, 1H), 8.55 (br. s, 2H), 8.21 (S, 1H), 7.38 (t, <7=8,50 Hz, 1H), 7.10 (S, 1H), 6.72 (S, 1H), 6.59 (d, <7=8.44 Hz, 2H), 5.94 (S, 1H), 4.44 (br. s, 1 H), 4.01 (S, 3H), 3.88 (S, 6H); m/z 473.2 [M+H]+ | Scheme P |
124 | ch3 ? 0. O M-o y AA A n-ch3 i o CH* 6h3 2,6-d i m ethoxy-W-{4methoxy-6-[(1 -methyl-1 Hpyrazol-4-yl)methyl]-1,2benzoxazol-3yl}benzenesulfonamide | 1H NMR (400MHz, METHANOL-94) δ 7.46 (t, J=8.5 Hz, 1H), 7.42 (s, 1H), 7.33 (S, 1H), 6.87 (s, 1H), 6.74 (S, 1H), 6.72 (S, 1H), 6.69 (s, 1H), 4.01 (s, 3H), 3.93-3.90 (m, 2H), 3.84 (s, 6H), 3.83 (s, 3H); m/z 459.1 [M+H] + | Scheme R |
125 | HaA°xA A h A H LA ο7 0Η ch3 ch3 N-{6-[(S*)-hydroxy (1,3oxazol-4-yl) methyl] -4methoxy-1,2-benzoxazol-3yl}-2,6- | 1H NMR (400MHz, METHANOL-94) δ 8.14 (S, 1H), 7.78 (S, 1 H), 7.36 (br. t, J=8.1 Hz, 1H), 7.03 (br. s, 1H), 6.81 (br. s, 1H), 6.68 (br. d, J=8.4 Hz, 2H), 5.80 (S, 1H), | Single enantiomer, absolute stereochemistry unknown. 1st Peak on Chiralpak IG-3 50x4.6mm I.D., 3 pm Mobile phase: A: CO2 B:methanol(0.05% DEA) Isocratic: 40% B. |
-160-
dimethoxybenzenesulfonam ide | 3.94 (s, 3H), 3.72 (br. s, 6H); m/z 461.7 [M+H]+ | Scheme Q | |
126 | H3C'<? 0, ,0 N-°V ¢-% H Ί h OZ OH ch3 ch3 W-{6-[(R*)-hydroxy(1,3oxazol-4-yl)methyl]-4methoxy-1,2-benzoxazol-3yi}-2,6dimethoxybenzenesulfonam ide | 1H NMR (400MHz, METHANOL-cfe) δ 8.14 (S, 1H), 7.82 (s, 1H), 7.48 (t, J=8.5 Hz, 1H), 7.16 (S, 1H), 6.94 (S, 1H), 6.74 (d, J=8.6 Hz, 2H), 5.84 (S, 1 H), 4.04 (s, 3H), 3.85 (s, 6H); m/z 461.7 [M+H]+ | Single enantiomer, absolute stereochemistry unknown. 2nd Peak on Chiralpak IG-3 50x4.6mm I.D., 3 pm Mobile phase: A: CO2 B:methanol(0.05% DEA) Isocratic: 40% B. Scheme Q |
127 | HïC'? o, ,o «Λ Λ ÂVv-» H Ί h O— ch3 ch3 2,6-dimethoxy-N-[4methoxy-6-(1,3-oxazol-4ylmethyl)-1,2-benzoxazol-3yl]benzenesulfonamide | 1H NMR (400MHz, METHANOL-cfe) δ 8.16 (S, 1H), 7.76 (s, 1H), 7.44 (t, J=8.4 Hz, 1H), 6.90 (S, 1H), 6.75-6.72 (m, 2H), 6.71 (s, 1 H), 4.00 (d, J=2.7 Hz, 5H), 3.81 (s, 6H); m/z 445.8 [M+H]+ | Scheme Q |
Example 128: Préparation of N-{5-fluoro-4-methoxy-6-[(1H-pyrazol-1-yl)methyl]1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide according to Scheme S.
- 161 Scheme S:
o
1,1,3,3-tetramethylguanidine
ACN,H2O step 6
S-6
lnt-26
Pyridine step 7
Step 1: Synthesis of methyl 4-(benzylamino)-2,5-difluoro-3-methoxybenzoate (S-1).
A solution of benzylamine (38.0 mL, 347 mmol), methyl 2,4,5-trifluoro-3methoxybenzoate (51.0 g, 232 mmol), and triethylamine (161 mL, 1160 mmol) in DMSO (500 mL) was heated at 100 °C for 18 hours. After cooling to room température, the mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with satd. aq. NaCI, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with 5/1 pet. ether/ethyl acetate) to give methyl 4-(benzylamino)-2,5-difluoro-3-methoxybenzoate (S-1) (41 g, 57% yield) as a light-yellow oil. LCMS m/z 308.1 [M+H]+; 1H NMR (400MHz, CHLOROFORM-d) δ 7.43 - 7.20 (m, 6H), 4.74 (br s, 1 H), 4.63 (br s, 2H), 3.97 - 3.80 (m, 6H).
Step 2: Synthesis of methyl 4-amino-2,5-difluoro-3-methoxybenzoate (S-2).
A solution of methyl 4-(benzylamino)-2,5-difluoro-3-methoxybenzoate (S-1) (41 g, 133 mmol) in methanol (500 mL) was treated with Pd/C (7.0 g) and stirred at 50 °C under hydrogen (45 psi) for 48 hours. The suspension was filtered through a pad of Celite®, and thefiltrate concentrated to give methyl 4-amino-2,5-difluoro-3-methoxybenzoate (S20447
-162 -
2) (28.0 g, 96% yield) as an off-white solid. LCMS m/z 217.9 [M+H]+; 1H NMR (400MHz, DMSO-de) δ 7.27 (dd, J=6.3, 11.6 Hz, 1 H), 6.21 (s, 2H), 3.77 (d, J=1.1 Hz, 6H).
Step 3: Synthesis of methyl 4-cyano-2,5-difluoro-3-methoxybenzoate (S-3) s A suspension of methyl 4-amino-2,5-difluoro-3-methoxybenzoate (S-2) (28.0 g, 129 mmol) and copper(l) cyanide (34.6 g, 387 mmol) in CHsCN (1 L) was warmed to 65 °C. Isoamyl nitrite (22.7 g 193 mmol) was added dropwise and the reaction was stirred at 65 °C for 1 h. Analysis by LCMS showed some of the starting material remained and additional isoamyl nitrite (15.1 g 129 mmol) was added. The reaction was heated at 65 ίο °C for 18 h. After cooling to room température, the reaction was diluted with EtOAc (200 mL) and filtered. The filtrate was concentrated and purified via flash chromatography eluting with a gradient of 0 - 50% EtOAc in heptane to give methyl 4-cyano-2,5-difluoro-3-methoxybenzoate (S-3) (14.0 g, 47% yield) as a yellow solid. 1H NMR (400MHz, CHLOROFORM-d) 5 7.36 (dd, J=4.8, 8.4 Hz, 1H), 4.21 (d,
J=3.1 Hz, 3H), 3.97 (s, 3H).
Step 4: Synthesis of 3,6-difluoro-4-(hydroxymethyl)-2-methoxybenzonitrile (S-4) To a solution of methyl 4-cyano-2,5-difluoro-3-methoxybenzoate (S-3) (14 g 62 mmol) in THF (400 mL) was added LiBH4 (20 g, 92 mmol) slowly at 0 °C. After the addition 20 was complété, the reaction was warmed to room température and then heated to 50 °C for 2 h. After cooling to room température, the reaction mixture was quenched by the slow addition of H2O (100 mL) and the organics were extracted with EtOAc (2 x 300 mL). The combined organic extract was washed with brine and satd. NaHCOa, dried over Na2SO4 and filtered. After removing the solvent, 3,6-difluoro-4-(hydroxymethyl)-225 methoxybenzonitrile (S-4) (10 g, 81%) was obtained as a yellow solid. This material was ta ken on to the next step without further purification. 1H NMR (400MHz, CHLOROFORM-d) 5 7.06 (dd, J=4.8, 8.8 Hz, 1 H), 4.81 (S, 2H), 4.17 (d, J=3.3 Hz, 3H), 2.48 (br s, 1H).
Step 5: Synthesis of 3,6-difluoro-2-methoxy-4-[(1H-pyrazol-1yl)methyl]benzonitrile (S-5)
- 163 To a solution of 3,6-difluoro-4-(hydroxymethyl)-2-methoxybenzonitrile (S-4) (10 g, 50 mmol) and 1-(methanesulfonyl)-1/7-pyrazole (lnt-13) (8.8 g, 60 mmol) in CH3CN (500 mL) was added CS2CO3 (24.5 g, 75.3 mmol) was stirred at 70 °C for 2 h. Analysis by LCMS showed that the starting material was consumed. The reaction was cooled to room température and filtered. After the filtrate was concentrated, the residue was purified by flash chromatography eluting with a gradient of 20 - 50% EtOAc in Petroleum ether to give 3,6-difluoro-2-methoxy-4-[(1 H-pyrazol-1-yl) methyl] benzonitrile (S-5) (8.4 g, 67% yield) as a yellow gum. LCMS m/z 250.0 [M+H]+; 1H NMR (400MHz, DMSO-de) δ 7.89 (d, J=2.2 Hz, 1 H), 7.62 - 7.40 (m, 1 H), 6.76 (dd, J=5.0, 9.1 Hz, 1 H), 6.33 (t, J=2.1 Hz, 1 H), 5.49 (d, J=1.1 Hz, 2H), 4.13 (d, J=3.2 Hz, 3H).
Step 6: Synthesîs of 5-fluoro-4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2benzoxazol-3-amine (S-6)
To a solution of 3,6-difluoro-2-methoxy-4-[(1H-pyrazol-1-yl)methyl]benzonitrile (S-5) (8.4 g, 34 mmol) and N-hydroxyacetamide (7.6 g, 100 mmol) in CH3CN (400 mL) and water (80 mL) was added 1,1,3,3-tetramethylguanidine (23 g, 200 mmol) slowly. The mixture was heated at 60 °C for 16 h. The mixture was cooled and concentrated to remove the CH3CN. A yellow solid precipitated from solution which was washed with water and then a mixture of 10% EtOAc in petroleum ether. The resulting pale-yellow solid was filtered to give 5-fluoro-4-methoxy-6-[(1/-/-pyrazol-1-yl)methyl]-1,2benzoxazol-3-amine (S-6) (6.1 g, 69% yield) as a pale yellow solid. LCMS m/z 262.9 [M+H]+; 1H NMR (400 MHz, CHLOROFORM-d) δ 7.59 (d, J=1.7 Hz, 1H), 7.43 (d, J=2.2 Hz, 1 H), 6.70 (d, J=9.2 Hz, 1 H), 6.50 (s, 1 H), 6.35 (t, J=2,1 Hz, 1 H), 5.31 (s, 2H), 2.23 (tt, J=5.1,8.4 Hz, 1 H), 1.20-1.14 (m, 2H), 0.81 -0.73 (m, 2H).
Step 7: Synthesîs of N-{5-fîuoro-4-methoxy-6-[(1H-pyrazoî-1-yl)methyl]-1,2benzoxazol-3-yl}-2,6-dimethoxybenzene-1 -sulfonamide (Example 128)
To a solution of 5-fluoro-4-methoxy-6-[(1/-/-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-amine (S-6) (6.1 g, 23 mmol) in pyridine (100 mL) was added 2,6-dimethoxybenzenesulfonyl chloride (lnt-26) (6.1 g, 26 mmol) and the resulting mixture was stirred at 70 °C for 18 h. The mixture was concentrated and purified by flash chromatography eluting with 10% MeOH in DCM to give crude Example 128 (8 g) as yellow solid. A suspension of the yellow solid in CH3CN (100 mL) was refluxed for 10 min. Most of the solids remained.
- 164So, additional CHaCN (500 mL) was added in 100 mL incréments until the solid completely dissolved. The solution was allowed to cool to for 5 min and MTBE (400 mL) was added under vigorous stirring. White solids began to form, and the mixture was concentrated to 1/3 volume and the solution was stirred vigorously at 20 °C for 18h. The 5 precipitate was collected by filtration, washed with heptane, and dried under vacuum to give 3.2 g (30%) of Example 128 as a white solid. The filtrate was concentrated to give 4.7 g of crude Example 128 as yellow solid which was further purified as described below. The 4.7 g was re-purified by flash chromatography eluting with a gradient of 0 20% EtOAc in DCM to afford 3 grams of a white solid which was dissolved in CH3CN 10 (10 mL) and MTBE (25 mL). The colorless solution was stirred until it turned cloudy and a white solid precipitated. The white solid was collected by filtration and washed with MTBE (3 x 5 mL). This batch of white solid was combined with the 3.2 g batch and the combined solid was suspended in CH3CN (30 mL) and then heated to dissolve. MTBE (60 mL) was added gradually and a white solid precipitated from solution. The mixture 15 was cooled to room température and concentrated to a total volume of 30 mL. The resulting white solid was collected by filtration and washed with MTBE (3x10 mL), dried in vacuum oven ai 60 °C for 6 h to give A/-{5-fluoro~4-methoxy-6-[(1 H-pyrazol-1 yl)methyl]-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide (Example 128) (5.3 g, 49% yield) as a white solid. Ή NMR (400 MHz, DMSO-cfe) δ 10.13 (br. s, 1H), 20 7.86 (br. s, 1 H), 7.59 - 7.43 (m, 2H), 6.90 (br. d, J=3.3 Hz, 1 H), 6.78 (br. d, J=8.5 Hz,
2H), 6.31 (br. s, 1H), 5.50 (br. s, 2H), 4.04 (br. s, 3H), 3.76 (s, 6H); m/z 463.0 [M+Hp.
The examples in the table below were synthesized according to the methods used for the synthesis of W-{5-fluoro-4-methoxy-6-[(1 H-pyrazol-1 -yl)methyl]-1,2-benzoxazol-325 yl}-2,6-dimethoxybenzene-1-sulfonamide (Example 128), N-{4-ethyl-6-[(1H-pyrazol-1yl)methyl]-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1 -sulfonamide (Example 95), 5ethyl-2-methoxy-A/-{4-methoxy-6-[(1H-pyrazol-1-yl)methyl]-1,2-benzoxazol-3yl}benzene-1 -sulfonamide (Example 01), 2,6-dimethoxy-N-{4-methoxy-6-[(3-methyl-1/7pyrazol-1-yl)mθthyi]-1,2-benzoxazol·3-yl}benzθne-1-sulfonamide (Example 02), and 30 2,6-dimethoxy-A/-{4-methoxy-6-[(5-methyl-1H-pyrazol-1-yl)methyipi ,2-benzoxazol-3yl}benzene-1 -sulfonamide (Example 03), and the general sulfonamide formation methods A-D. The following examples were synthesized with non-critical changes or
- 165 -
substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Table 20:
Example number | Structure/lUPAC Name | Anaiytical data | Sulfonamide formation method |
129 | H Ο 'θ N N i / O / 0 f T F /^Vs-Nn 0^ v# 0 CH3 A/-{5-fluoro-4-methoxy-6-[(1 Hpyrazol-1 -yl) methyl]-1,2benzoxazol-3-yl}-2methoxybenzene-1 -sulfonamide | NMR (400MHz, DMSO-Cfe) δ 10.63 (br s, 1H), 7.86 (d, 7=2.3 Hz, 1H), 7.79 (dd, 7=1.8, 7.8 Hz, 1H), 7.62 (brt, 7=7.3 Hz, 1H), 7.50 (d, 7=1,3 Hz, 1H), 7.21 (d, 7=8.3 Hz, 1H), 7.08 (t, 7=7.7 Hz, 1H), 6.91 (d, 7=4.3 Hz, 1 H), 6.31 (t, 7=2.1 Hz, 1H), 5.50 (S, 2H), 4.03 (d, 7=3.0 Hz, 3H), 3.80 (S, 3H); | D |
130 | vi J o o y- o=S'NH l H3C'°x/ △ o A/-{4-cyclopropyl-6-[(1H-pyrazol1 -yl)methyl]-1,2-benzoxazol-3yl}-2-methoxybenzene-1 sulfonamide | 1H NMR (400MHz, DMSO-de) δ 10.62 (br S, 1 H), 7.86 (d, 7=2.0 Hz, 1H), 7.74 (dd, 7=1.6, 7.9 Hz, 1H), 7.63 (brs, 1H), 7.49 (d, 7=1.3 Hz, 1H), 7.23 (brd, 7=8.5 Hz, 1H), 7.14 - 7.03 (m, 2H), 6.72 (brs, 1H), 6.29 (t, 7=2.1 Hz, 1H), 5.42 (s, | D |
- 166 -
2H), 3.78 (s, 3H), 2.76 (brs, 1H), 1.10-0.95 (m,2H), 0.80-0.66 (m, 2H); m/z 425.1 (M+H)+ | |||
131 | A P N-ο JH AJ H IM At ch3 3,4-dimethyl-N-{5-methyl-6-[(1/7pyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | 1H NMR (400MHz, DMSO-de) δ 7.72 (d, J=2.2 Hz, 1H), 7.57 (s, 1H), 7.53 (brd, J=7.8 Hz, 1H), 7.49 (d, J=1.5 Hz, 1H), 7.44 (s, 1H), 7.14 (brd, J=7.8 Hz, 1H), 6.72 (S, 1H), 6.29 (t, J=2.0 Hz, 1 H), 5.41 (S, 2H), 2.31 (S, 3H), 2.21 (S, 3H), 2.20 (S, 3H); m/z 397.0 (M+H)+ | A |
132 | H3C. I N-o AAo ch3 2-methoxy-/V-{5-methyl-6-[(1 Hpyrazol-1 -yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide | 1H NMR (400MHz, DMSO-d6) δ 11.58 (br S, 1H), 7.84 (dd, J=1.3, 7.8 Hz, 1H), 7.78 (d, J=2.2 Hz, 2H), 7.59 (br t, J=7.9 Hz, 1H), 7.51 (d, J=1.5 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.08 (t, J=7.6 Hz, 1H), 6.87 (S, 1 H), 6.31 (t, J=2.0 Hz, 1H), 5.47 (S, 2H), 3.76 (S, 3H), 2.36 (S, 3H); m/z 399.0 (M+H)+ | A |
- 167 133
2- meth oxy-A/-{4-m eth oxy-6- [ (2H1,2,3-triazol-2-yl)methyl]-1,2benzoxazol-3-yl}benzene-1 sulfonamide 1H NMR (400MHz, DMSO-cfe) δ 10.22 (br s, 1H), 7.86 (S, 2H), 7.80 (dd, J=1.5, 8.0 Hz, 1H), 7.61 (br s, 1H), 7.18 (brd, J=8.5 Hz, 1H), 7.08 (brt, J=7.5 Hz, 1H), 6.90 (s, 1H), 6.74 (s, 1H), 5.77 (S, 2H), 3.82 (S, 3H), 3.77 (s, 3H); m/z 416.1 (M+H)+
Biological Assav Section 1
KAT Assay Protocol:
A. Compound préparation
1. Préparé 10 mM stock solutions in 100 % DMSO from solid material
2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fold in 100% DMSO for 11 -point dose response
B. Reagent préparation
1. Préparé 1x assay buffer containing 10 mM Tris HCL pH 8.0, 2.5 mM NaCI, 0.5mM EDTA, 0.005% BSG and 0.02% Tween-20
2. Dilute Histone peptide (CPC Scientific) and AcCoA (Sigma) together in assay buffer to 2x.
3. Dilute KAT enzyme in assay buffer to 2x.
C. Enzyme reaction
1. Final reaction conditions for each KAT assay in a 20ul assay reaction volume:
i. KAT5 25 nM, 1 uM AcCoA, 2 uM H4 1-21 peptide, 30-minute reaction
- 168 - ii. KAT6A 15 nM, 1 uM AcCoA, 2 uM H3 1-21 peptide, 45-minute reaction iii. KAT6B 25 nM, 1 uM AcCoA, 2 uM H3 1 -21 peptide, 60-minute reaction iv. KAT7 12.5 nM, 1 uM AcCoA, 2 uM H3 1-21 peptide, 45-minute reaction
v. KAT8 15 nM, 1 uM AcCoA, 2 uM H3 1-21 peptide, 45-minute reaction
2. Add 0.5 ul of diluted compound to the assay plate (384-well V-bottom polypropylene plates) or 0.5 ul of DMSO for control wells.
3. Add 10 ul of 2x Histone peptide/ 2x AcCoA mix to the assay plate.
4. Add 10 ul of 2x enzyme to the assay plate.
5. Stop the reaction after the indicated time with the addition of 2 ul of 5% formic acid
6. Each reaction was analyzed using self-assembled monolayer desorption/ionization time-of-ftight mass spectrometry (Mrksich, Milan (2008) Mass Spectrometry of Self-Assembled Monolayers: A New Tool for Molecular Surface Science ACS Nano 2008 2 (1), 7-18; SAMDI Tech, Inc. (Chicago, IL)).
7. Area under the curve (AUC) for both substrate and product peaks was determined for KAT5 at M.W. 2561 [Substrate + H]+ and 2603 [Product + H]+ with a +/-1 Da tolérance, respectively
8. Area under the curve (AUC) for both substrate and product peaks was determined for KAT6A, KAT6B, KAT7 and KAT8 at M.W. 2723 [Substrate + H]+ and 2765 [Product + H]* with a +/-1 Da tolérance, respectively.
9, Percent conversion to product was calculated by: AUCproduct/(AUCsubstrate + AUCProduct).
D. Data analysis
1. ICso values were determined by fitting the % conversion at each inhibitor concentration to the 4-parameter IC50 équation using Pfizer proprietary curve fitting software.
- 169-
2. K, values were determined by lifting the % conversion at each inhibitor concentration to the Morrison équation for tightbinding compétitive inhibitors using Pfizer proprietary curve fitting software.
Materials
KAT enzymes were expressed using a baculovirus expression system and purified at Pfizer, La Jolla, Histone H3 (1-21) peptide (ARTKQTARKSTGGKAPRKQLA, SEQ ID NO:3) and Histone H4 (1-21) peptide (SGRGKGGKGLGKGGAKRHRKV, SEQ ID NO:4) were purchased from CPC Scientific (Sunnyvale, CA). Acetyl coenzyme A was purchased from Sigma-Aldrich (St. Louis, MO). Ail other biochemical reagents were purchased from Sigma-Aldrich or ThermoFisher Scientific (Waltham, MA).
KAT Reactions
KAT assays were performed at room température in assay buffer containing 1 μΜ AcCoA, 2 μΜ histone peptide, 10 mM Tris HCL pH 8.0, 2.5 mM NaCI, 0.5mM EDTA, 0.005% BSG and 0.02% Tween-20. 10 ul of2x Histone peptide/AcCoA mix was added to a 384-well V-bottom polypropylene assay plate containing 0.5 ul of serially diluted test compound in 100% dimethyl sulfoxide (DMSO). To start the reaction, 10 ul of 2x enzyme solution was added to the assay plate. KAT assays were terminated after 3060 minutes with the addition of 2 ul of 5% formic acid. Ail assays used histone H3 (1 21 ) peptide except for the KAT5 assay which used histone H4 (1 -21 ) peptide. The final enzyme concentration for each KAT was as follows: KAT5, 25 nM; KAT6A, 15 nM; KAT6B, 25 nM; KAT7, 12.5 nM; KAT8 15 nM. Each reaction was analyzed using selfassembled monolayer desorption/ionization time-of-flight mass spectrometry (Mrksich, Milan (2008) Mass Spectrometry of Self-Assembled Monolayers: A New Tool for Molecular Surface Science ACS Nano 2008 2 (1), 7-18; SAMDI Tech, Inc. (Chicago, IL)).
- 170 Data Processing and analysis
Area under the curve (AUC) for both substrate and product peaks was determined for KAT5 at M.W. 2561 [Substrate + H]+ and 2603 [Product + H]+ with a +/- 1 Da tolérance, 5 respectively. Area under the curve (AUC) for both substrate and product peaks was determined for KAT6A, KAT6B, KAT7 and KAT8 at M.W. 2723 [Substrate + H]+ and 2765 [Product + H]+ with a +/-1 Da tolérance, respectively. Percent conversion to product was calculated by: AUCproduci/(AUCsubstrate + AUCproduct). IC50 values were determined by fitting the % conversion at each inhibitor concentration to the 410 parameter IC50 équation using Pfizer proprietary curve fitting software. Ki values were determined by fitting the % conversion at each inhibitor concentration to the Morrison équation for tightbinding compétitive inhibitors using Pfizer proprietary curve fitting software.
KAT6a and KAT6b Ki’s are provided in Table 21 and KAT5, KAT7, and KAT8
Ki’s are provided in Table 22 below.
Table 21 :
Example No. | KAT6a Ki at 1 μΜ AcCoA (nM) | KAT6a Ki at 10 μΜ AcCoA (nM) | KAT6b Ki at 1 μΜ AcCoA (nM) | KAT6b Ki at 25 μΜ AcCoA (nM) |
1 | 0.55 | 0.43 | 0.68 | 1.14 |
2 | 46.9 | N/D | 50.4 | N/D |
3 | 3.79 | 1.54 | 8.63 | N/D |
4 | 10.3 | N/D | 60,8 | N/D |
5 | 1.11 | 1.38 | 2.68 | N/D |
6 | 1.50 | 2.32 | 2.50 | N/D |
7 | 21.0 | N/D | 28.3 | N/D |
8 | 1.54 | 3.23 | 5.74 | 6.63 |
9 | 0.74 | 0.83 | 0.42 | 1.55 |
10 | 2.72 | 4.65 | 2.27 | N/D |
11 | 2.86 | 5.57 | 14.6 | N/D |
- 171 -
12 | 1.82 | 1.70 | 1.88 | 2.14 |
13 | 17.7 | N/D | N/D | N/D |
14 | 1.12 | 0.49 | N/D | 1.05 |
15 | 0.65 | 0.35 | N/D | 0.60 |
16 | 1.27 | 0.64 | N/D | 1.73 |
17 | 0.70 | 0.51 | N/D | 1.21 |
18 | 0.83 | 0.38 | N/D | 0.96 |
19 | 2.18 | N/D | N/D | 3.44 |
20 | 0.34 | 0.87 | 1.78 | 4.08 |
21 | 1.23 | N/D | N/D | 1.14 |
22 | 16.5 | N/D | 13.2 | N/D |
23 | 1.22 | 1.24 | 0.87 | 1.34 |
24 | 1.01 | 0.46 | N/D | 1.89 |
25 | 2.74 | 1.83 | N/D | 4.46 |
26 | 8.01 | 3.16 | N/D | 12.7 |
27 | 1.17 | 0.68 | N/D | 2.39 |
28 | 4.40 | N/D | N/D | 5.06 |
29 | 0.53 | N/D | N/D | 1.40 |
30 | 60 | N/D | N/D | N/D |
31 | 0.32 | N/D | N/D | 0.89 |
32 | 1.4 | N/D | N/D | 2.1 |
33 | 3.1 | N/D | N/D | N/D |
34 | 30 | N/D | N/D | 4,2 |
35 | 15 | N/D | N/D | N/D |
36 | 17 | N/D | N/D | N/D |
37 | 17 | N/D | N/D | N/D |
38 | 16 | N/D | N/D | N/D |
39 | 0.74 | N/D | N/D | 0.26 |
40 | 0.47 | N/D | N/D | N/D |
41 | 0.36 | N/D | N/D | 0.36 |
42 | 0.72 | N/D | N/D | 0.48 |
43 | 3.6 | N/D | N/D | N/D |
- 172 -
44 | 12 | N/D | N/D | 43 |
45 | 2,28 | N/D | 2.11 | 1.55 |
46 | 32.9 | 13.1 | N/D | N/D |
47 | 1.14 | 0.49 | N/D | 1.32 |
48 | 14.9 | 6.51 | N/D | N/D |
49 | 9.77 | 4.14 | N/D | N/D |
50 | 0.46 | 0.40 | N/D | 0.98 |
51 | 2.71 | 1.67 | N/D | 4.13 |
52 | 14.6 | 7.32 | N/D | N/D |
53 | 16.1 | 8.78 | N/D | N/D |
54 | 57.0 | 38.0 | N/D | N/D |
55 | 291 | 178 | N/D | N/D |
56 | 14.9 | 7.31 | N/D | N/D |
57 | 16.0 | N/D | N/D | N/D |
58 | 11.1 | 5.23 | N/D | N/D |
59 | 13.0 | 6.25 | N/D | N/D |
60 | 9.81 | 4.64 | N/D | N/D |
61 | 0.95 | 0.92 | N/D | 1.56 |
62 | 9.64 | 3.90 | N/D | N/D |
63 | 15.8 | 10.9 | N/D | N/D |
64 | 25.3 | 11.0 | N/D | N/D |
65 | 6.04 | 4.44 | N/D | 12.1 |
66 | 95.4 | 65.6 | N/D | N/D |
67 | 20.0 | 10.2 | N/D | N/D |
68 | 14.9 | 10.5 | N/D | N/D |
69 | N/D | 9.10 | N/D | N/D |
70 | 2.28 | 3.27 | N/D | 1.90 |
71 | 1.18 | 1.17 | N/D | 2.81 |
72 | 2.86 | 2.36 | N/D | 6,97 |
73 | 2.31 | 1.70 | N/D | 1.36 |
74 | 24.8 | 13.6 | N/D | 0.00 |
75 | 9.13 | 6.42 | N/D | 13,8 |
- 173 -
76 | 7.89 | 3.62 | N/D | 60.1 |
77 | 8.56 | 11.89 | N/D | 29.6 |
78 | 5.64 | 5.73 | N/D | 26.0 |
79 | 5.11 | 4.98 | N/D | 4.27 |
80 | 15.6 | 5.32 | N/D | N/D |
81 | 18.2 | 9.96 | N/D | N/D |
82 | 16.9 | 12.2 | N/D | N/D |
83 | 13.7 | 7.76 | N/D | N/D |
84 | 7.86 | 5.61 | N/D | 12.3 |
85 | 13.3 | 8.77 | N/D | N/D |
86 | 28.9 | 7.11 | N/D | N/D |
87 | 38.6 | N/D | 133 | N/D |
88 | 682 | N/D | N/D | N/D |
89 | 6.50 | N/D | 12.4 | N/D |
90 | 0.46 | 0.80 | 1.63 | N/D |
91 | 0.38 | 0.75 | 1.30 | 1.38 |
92 | 1.07 | 0.45 | N/D | 2.73 |
93 | 0.64 | 1.02 | 1.20 | 2.33 |
94 | 5.15 | N/D | N/D | 2.50 |
95 | 9.88 | N/D | N/D | 8.35 |
96 | 1.58 | N/D | N/D | 3.67 |
97 | 1.10 | N/D | N/D | 2.74 |
98 | 0.35 | 0.66 | 1.23 | 2.82 |
99 | N/D | N/D | N/D | N/D |
100 | 40.3 | N/D | 58.3 | N/D |
101 | N/D | N/D | N/D | N/D |
102 | N/D | N/D | N/D | N/D |
103 | 0.30 | 0.51 | N/D | N/D |
104 | 6.11 | 3.89 | N/D | N/D |
105 | 3.08 | 6.28 | N/D | N/D |
106 | 35 | N/D | N/D | N/D |
107 | 1.7 | 2.6 | N/D | 2.9 |
- 174 -
108 | 72 | N/D | N/D | N/D |
109 | 44 | N/D | N/D | N/D |
110 | 2.5 | 2.1 | N/D | 8.8 |
111 | 13 | N/D | N/D | N/D |
112 | 82 | N/D | N/D | N/D |
113 | 14 | N/D | N/D | N/D |
114 | 1.9 | N/D | N/D | 2.0 |
115 | 1220 | N/D | N/D | N/D |
116 | 3.0 | N/D | N/D | 25 |
117 | 202 | N/D | N/D | N/D |
118 | 357 | N/D | N/D | N/D |
119 | 21 | 13 | N/D | N/D |
120 | 831 | 212 | N/D | N/D |
121 | 1576 | >600 | N/D | N/D |
122 | 164 | 25 | N/D | N/D |
123 | 138 | N/D | N/D | N/D |
124 | 700 | N/D | N/D | N/D |
125 | 230 | N/D | N/D | N/D |
126 | 230 | N/D | N/D | N/D |
127 | 8.6 | N/D | N/D | N/D |
128 | 0.54 | 0.59 | N/D | 1.2 |
129 | 0.33 | N/D | N/D | N/D |
130 | 0.77 | N/D | N/D | N/D |
131 | 28.3 | N/D | N/D | N/D |
132 | 4.1 | N/D | N/D | N/D |
133 | 2.9 | N/D | N/D | N/D |
- 175 Table 22:
Example No. | KAT5 Ki at 1 μΜ AcCoA (μΜ) | KAT7 K at 1 μΜ AcCoA (μΜ) | KATS Ki at 1 μΜ AcCoA (μΜ) |
1 | 0.12 | 0.05 | 0.11 |
2 | 13.0 | 0.70 | 36.7 |
3 | 9.79 | 1.72 | 17.4 |
4 | 5.98 | 0.90 | 20.6 |
5 | 0.53 | 0.08 | 0.66 |
6 | 0.98 | 0.12 | 3.32 |
7 | 4.53 | 0.23 | 4.46 |
8 | 1.71 | 0.06 | 2.87 |
9 | 0.62 | 0.05 | 0.82 |
10 | 60.2 | 9.32 | 19.4 |
11 | 12.5 | 5.96 | 3.26 |
12 | 1.17 | 0.92 | 1.07 |
13 | N/D | 1.04 | N/D |
14 | 0.27 | 0.05 | 0.42 |
15 | 0.07 | 0.03 | 0.17 |
16 | 0.83 | 0.12 | 1.75 |
17 | 0.15 | 0.09 | 0.22 |
18 | 0.13 | 0.12 | 0.10 |
19 | 0.80 | 0.15 | 0.96 |
20 | 0.15 | 0.00 | 0.47 |
21 | 1.03 | 0.12 | 0.83 |
22 | 11.7 | 12.9 | 17.4 |
23 | 2.07 | 0.04 | 1.97 |
24 | 0.19 | 0.02 | 0.16 |
25 | 12.5 | 1.08 | 12.5 |
26 | 125 | 7.79 | 27.1 |
27 | 0.22 | 0.05 | 0.53 |
28 | 3.05 | 0.45 | 3.26 |
-176-
29 | 0.18 | 0.06 | 1.01 |
30 | 60 | 1.1 | >250 |
31 | N/D | 0.056 | N/D |
32 | N/D | 0.060 | N/D |
33 | N/D | 0.31 | N/D |
34 | N/D | 1.2 | N/D |
35 | N/D | 0.42 | N/D |
36 | N/D | 0.98 | N/D |
37 | N/D | 4.6 | N/D |
38 | N/D | 0.53 | N/D |
39 | N/D | 0.008 | N/D |
40 | N/D | 0.38 | N/D |
41 | N/D | 0.23 | N/D |
42 | N/D | 0.16 | N/D |
43 | N/D | 0.57 | N/D |
44 | 2.255 | 0.63 | 9.0 |
45 | 0.32 | 0.09 | 0.90 |
46 | N/D | 1.03 | N/D |
47 | 0.18 | 0.04 | 0.56 |
48 | N/D | 0.41 | N/D |
49 | N/D | 0.37 | N/D |
50 | 0.26 | 0.02 | 0.35 |
51 | 0.77 | 0.09 | 1.11 |
52 | N/D | 0.66 | N/D |
53 | N/D | 0.30 | N/D |
54 | N/D | 1.16 | N/D |
55 | N/D | 15.0 | N/D |
56 | N/D | 0.60 | N/D |
57 | N/D | 0.45 | N/D |
58 | N/D | 0.86 | N/D |
59 | N/D | 0.22 | N/D |
60 | N/D | 0.42 | N/D |
- 177-
61 | 0.20 | 0.04 | 0.54 |
62 | N/D | 0.36 | N/D |
63 | N/D | 0.94 | N/D |
64 | N/D | 0.63 | N/D |
65 | 3.06 | 0.22 | 12.50 |
66 | N/D | 4.05 | N/D |
67 | N/D | 1.76 | N/D |
68 | N/D | 0.25 | N/D |
69 | N/D | 0.37 | N/D |
70 | 0.41 | 0.14 | 3.26 |
71 | 0.32 | 0.03 | 1.44 |
72 | 2.96 | 0.14 | 12.5 |
73 | 0.71 | 0.25 | 3.26 |
74 | N/D | 2.87 | N/D |
75 | 5.70 | 0.32 | 12.50 |
76 | 4.38 | 0.33 | 12.5 |
77 | 8.45 | 0.46 | 12.5 |
78 | 9.92 | 0.54 | 12.5 |
79 | 1.44 | 0.22 | 3.26 |
80 | N/D | 0.36 | N/D |
81 | N/D | 1.62 | N/D |
82 | N/D | 0.64 | N/D |
83 | N/D | 0.78 | N/D |
84 | 4.63 | 0.19 | 12.50 |
85 | N/D | 1.14 | N/D |
86 | N/D | 0.37 | N/D |
87 | 10.8 | 1.84 | 17.9 |
88 | N/D | 10.5 | N/D |
89 | 12.5 | 1.85 | 3.26 |
90 | 0.61 | 0.06 | 0.73 |
91 | 0.57 | 0.06 | 0.66 |
92 | 0.11 | 0.03 | 0.24 |
- 178 -
93 | 0.43 | 0.05 | 0.47 |
94 | 3.64 | 0.63 | 3.26 |
95 | 12.5 | 4.34 | 3.26 |
96 | 11.7 | 0.90 | 12.5 |
97 | 1.03 | 0.12 | 1.51 |
98 | 0.37 | 0.04 | 0.50 |
99 | N/D | N/D | N/D |
100 | 6.22 | 0.61 | 4.95 |
101 | N/D | N/D | N/D |
102 | N/D | N/D | N/D |
103 | NA | 0.15 | N/D |
104 | N/D | 2.06 | N/D |
105 | N/D | 0.23 | N/D |
106 | N/D | 1.9 | N/D |
107 | N/D | 0.37 | N/D |
108 | N/D | 1.3 | N/D |
109 | N/D | 3.1 | N/D |
110 | N/D | 0.23 | N/D |
111 | N/D | 0.39 | N/D |
112 | N/D | 1.5 | N/D |
113 | N/D | 2.8 | N/D |
114 | N/D | 0.22 | N/D |
115 | N/D | >15 | N/D |
116 | 8.7 | 0.095 | 69 |
117 | N/D | 0.20 | N/D |
118 | N/D | 2.3 | N/D |
119 | N/D | 0.65 | N/D |
120 | N/D | 2.4 | N/D |
121 | N/D | >15 | N/D |
122 | N/D | 7.4 | N/D |
123 | N/D | 4.6 | N/D |
124 | N/D | 6.287 | N/D |
- 179 -
125 | N/D | 7.509 | N/D |
126 | N/D | 4.152 | N/D |
127 | N/D | 0.137 | N/D |
128 | N/D | 0.049 | N/D |
129 | N/D | 0.0106 | N/D |
130 | N/D | 0.1000 | N/D |
131 | N/D | 0.662 | N/D |
132 | N/D | 0.124 | N/D |
133 | N/D | 0.0192 | N/D |
Bioloqical Assav Section 2
Protein Préparation
KAT5
Molecular Biology: A codon optimized DNA sequence (for expression in Escherichia coli) encoding amino acid residues Ξ to 461 (Uniprot Q92993-2) of human KAT5 isoform was synthesised by GenScript USA Inc (Piscataway, New Jersey, USA). This was ligated into a modified pET43a E. coli expression vector designed to encode an Nio terminal hexahistidine tag followed by a tobacco etch virus protease (TEV) cleavage site and by the KAT5 sequence. The resulting protein sequence is listed below (SEQ ID NO:5).
MGHHHHHHGTENLYFQGSAEVGEIIEGCRLPVLRRNQDNEDEWPLAEILSVKDISGRK 15 LFYVHYIDFNKRLDEWVTHERLDLKKIQFPKKEAKTPTKNGLPGSRPGSPEREVKRKV
EWSPATPVPSETAPASVFPQNGAARRAVAAQPGRKRKSNCLGTDEDSQDSSDGIPS APRMTGSLVSDRSHDDIVTRMKNIECiELGRHRLKPWYFSPYPQELTTLPVLYLCEFCL KYGRSLKCLQRHLTKCDLRHPPGNEIYRKGTISFFEIDGRKNKSYSQNLCLLAKCFLDH KTLYYDTDPFLFYVMTEYDCKGFHIVGYFSKEKESTEDYNVACILTLPPYQRRGYGKLL 20 IEFSYELSKVEGKTGTPEKPLSDLGLLSYRSYWSQTILEILMGLKSESGERPQITINEISE ITSIKKEDVISTLQYLNLINYYKGQYILTLSED1VDGHERAMLKRLLRIDSKCLHFTPKDW SKRGKWAS*
- 180 Protein Expression: To produce recombinant KAT5 protein, expression plasmid was transformed into E. coli BL21 DE3 strain and grown with shaking at 37°C in 1 L volumes of Terrifie broth (TB) supplemented with 100 pg/mL Ampicillin and 50 μΜ zinc until an OD600 of 0.8 was reached. Cultures were transferred to 18°C and protein expression 5 induced by the addition of Isopropyl β-D-l-thiogalactopyranoside to a final concentration of 0.5 mM and the cultures shaken overnight for further 16 hours.
Following expression, cell cultures were centrifuged at 5000 x g for 20 min and cell pellet stored frozen at -20°C.
Protein Purification: Protein purification was initiated by thawing the cell pellet (25 g wet weight) in Lysis buffer (50 mM Hepes pH 7.4, 500 mM NaCI, 5 mM imidazole, 5% [v/v] glycerol, 0.1% [w/v] CHAPS, 2 mM 2-mercaptoethanol, 3 mM MgCIs, 0.5 mg/mL lysozyme, benzonase endonuclease [EMD Millipore], 1 mM PMSF, complété protease inhibitor tablets EDTA-free [Roche]) using a ratio of 6 mL of buffer per 1 g of cells. Cells 15 were further lysed by sonication using a Misonix Liquid Processor (6 x 30 second puises, amplitude 60 [70 watts]) and then centrifuged at 48,000 x g at 4°C. Supernatant (cell lysate) was mixed with 20 mL of Q-Sepharose FF resin (GE Healthcare) preequiiibrated with Q buffer (20 mM Hepes pH 7.4, 1 M NaCI). The unbound fraction from Q-Sepharose FF was then incubated with 5 mL of cOmplete His-Tag Purification Resin 20 (Roche), pre-equilibrated with IMAC Wash Buffer (20 mM hepes pH 7.4, 500 mM NaCI, 35 mM imidazole). The resin was washed with IMAC Wash Buffer, and bound KAT5 eluted with IMAC Elution buffer (20 mM hepes pH 7.4, 500 mM NaCI, 300 mM imidazole). IMAC-eluted protein was immediately desalted into Storage buffer (50 mM Na citrate pH 6.5, 500 mM NaCI, 5% [v/v] glycerol) using 2 x HiPrep 26/10 desalting columns (GE Healthcare) in sériés. Desalted protein was further purified by passing through a HiLoad 26/60 Superdex 75 column pre-equilibrated in Storage buffer. Finally, KAT5 protein was concentrated to 1.5 mg/mL using Amicon Ultra centrifugal filter unit (Utra-15 MWCO 10 kDa), flash-frozen in liquid nitrogen and stored in -70°C freezer.
KAT6A
Molecular Biology: The DNA sequence encoding amino acid residues 507 to 778 (Uniprot Q92794-1) of human KAT6A was amplified by PCR and was ligated into a modified pET E. coli expression vector designed to encode a NusA solubility tag
- 181 followed by a hexahistidine tag and a tobacco etch virus protease (TEV) cleavage site and by the KAT6A sequence. The resulting protein sequence is listed below (SEQ ID NO:6).
MNKEILAWEAVSNEKALPREKIFEALESALATATKKKYEQEIDVRVQIDRKSGDFDTFR RWLWDEVTQPTKEITLEAARYEDESLNLGDYVEDQIESVTFDRITTQTAKQVIVQKVR EAERAMVVDQFREHEGEIITGWKKVNRDNISLDLGNNAEAVILREDMLPRENFRPGD RVRGVLYSVRPEARGAQLFVTRSKPEMLIELFRIEVPEIGEEVIEIKAAARDPGSRAKIA VKTNDKRIDPVGACVGMRGARVQAVSTELGGERIDIVLWDDNPAQFVINAMAPADVA SIWDEDKHTMDIAVEAGNLAQAIGRNGQNVRLASQLSGWELNVMTVDDLQAKHQAE AHAAIDTFTKYLDIDEDFATVLVEEGFSTLEELAYVPMKELLEIEGLDEPTVEALRERAK NALATIAQAQEESLGDNKPADDLLNLEGVDRDLAFKLAARGVCTLEDLAEQGIDDLADI EGLTDEKAGALIMAARNICWFGDEATSGSGHHHHHHSAGENLYFQGAMGRCPSVIEF GKYEIHTWYSSPYPQEYSRLPKLYLCEFCLKYMKSRTILQQHMKKCGWFHPPVNEIYR KNNISVFEVDGNVSTIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTQNDVKGCHLVGY FSKEKHCQQKYNVSCIMILPQYQRKGYGRFLIDFSYLLSKREGQAGSPEKPLSDLGRL SYMAYWKSVILECLYHQNDKQISIKKLSKLTGICPQDITSTLHHLRMLDFRSDQFVIIRRE KLIQDHMAKLQLNLRPVDVDPECLRWTP
Protein Expression: To produce recombinant KAT6A protein, expression plasmid was transformed into E. coli BL21 DE3 strain and grown with shaking at 37°C in 1 L volumes of Terrifie broth (TB) supplemented with 100 pg/mL Ampicillin until an OD600 of 0.8 was reached. Cultures were transferred to 18°C and protein expression induced by the addition of Isopropyl β-D-l-thiogalactopyranoside to a final concentration of 0.5 mM and the cultures shaken overnight for further 16 hours. Following expression, cell cultures were centrifuged at 5000 x g for 20 min and cell pellet stored frozen at -20°C.
Protein Purification: Protein purification was initiated by thawing the cell pellet (40 g wet weight) in Lysis buffer (25 mM Tris-HCI pH 7.8, 500 mM NaCI, 5 mM DTT, 0.01% [v/v] Triton-X 100, 5% [v/v] glycerol, 2 mM MgCI2, 10 mM Imidazole, 0.5 mg/mL lysozyme, benzonase endonuclease [EMD Millipore], 1 mM PMSF, complété protease inhibitor tablets EDTA-free [Roche]) using a ratio of 5 mL of buffer per 1 g of cells. Cells were further lysed by 3 passes (at 15000 psi) through an ice cooled Avestin C5 cell
- 182 crusher and then centrifuged at 48,000 x g at 4°C. Supematant (cell lysate) was filtered through a 5 pm filter and applied onto 5 mL HiTrap IMAC Sepharose FF column (GE Healthcare) pre-equilibrated with IMAC wash buffer (25 mM Tris-HCI pH 7.8, 500 mM NaCI, 5 mM DTT, 0.01% [v/v] Triton-X 100, 5% [v/v] glycerol, 20 mM Imidazole) using a 5 Profinia Affinity chromatography purification system (Bio-Rad). The IMAC column was then washed with IMAC Wash buffer and bound KAT6A protein eluted with IMAC
Elution buffer (25 mM Tris-HCI pH 7.8, 500 mM NaCI, 5% [v/v] glycerol, 5 mM DTT, 250 mM Imidazole). IMAC-eluted protein was further purified by passing through a HiLoad 26/60 Superdex 200 column pre-equilibrated in Storage buffer (25 mM Tris-HCI pH 7.8, iû 500 mM NaCI, 5 mM DTT, 5% [v/v] glycerol). Finally, KAT6A protein was concentrated to < 1 mg/mL using Amicon Ultra centrifugal filter unit (Utra-15 MWCO 10 kDa), flashfrozen in liquid nitrogen and stored in -70°C freezer.
KAT7
Molecular Biology: A codon optimized DNA sequence encoding amino acid residues 325 to 611 (Uniprot 095251 -1) of human KAT7 was synthesised by GenScript USA Inc (Piscataway, New Jersey, USA). This was ligated into a modified pET43a E. colt expression vector designed to encode an N-terminal hexahistidine tag followed by a tobacco etch virus protease (TEV) cleavage site and by the KAT7 sequence. The resulting protein sequence is listed below (SEQ ID NO:7).
MGHHHHHHGTENLYFQGSRLQGQITEGSNMIKTIAFGRYELDTWYHSPYPEEYARLG RLYMCEFCLKYMKSQTILRRHMAKCVWKHPPGDEIYRKGSISVFEVDGKKNKIYCQNL CLLAKLFLDHKTLYYDVEPFLFYVMTEADNTGCHLIGYFSKEKNSFLNYNVSCILTMPQ 25 YMRQGYGKMLIDFSYLLSKVEEKVGSPERPLSDLGLISYRSYWKEVLLRYLHNFQGKE
ISIKEISQETAVNPVDIVSTLQALQMLKYWKGKHLVLKRQDLIDEWIAKEAKRSNSNKTM DPSCLKWTPPKGTAS
Protein Expression: To produce recombinant KAT7 protein, expression plasmid was 30 transformed into E. coli BL21 DE3 RIL strain and grown with shaking at 37°C in 1 L volumes of Terrifie broth (TB) supplemented with 100 pg/mL Ampicillin and 50 pM zinc until an OD600 of 0.8 was reached. Cultures were transferred to 18°C and protein expression induced by the addition of Isopropyl β-D-l-thiogalactopyranoside to a final
- 183 concentration of 0,5 mM and the cultures shaken overnight for further 16 hours. Following expression, cell cultures were centrifuged at 5000 x g for 20 min and cell pellet stored frozen at -20°C.
s Protein Purification: Protein purification was initiated by thawing the cell pellet (10 g wet weight) in Lysis buffer (50 mM Hepes pH 7.5, 300 mM NaCI, 5 mM DTT, 5 mM Imidazole, 0.05% [v/v] Brij 35, 10% [v/v] glycerol, 3 mM MgCIs, 0.5 mg/mL lysozyme, benzonase endonuclease [EMD Millipore], 1 mM PMSF, complété protease inhibitor tablets EDTA-free [Roche]) using a ratio of 10 mL of buffer per 1 g of cells. Cells were ίο further lysed by sonication using a Misonix Liquid Processor (6 x 30 second puises, amplitude 60 [70 watts]) and then centrifuged at 48,000 x g at 4°C. Supematant (cell lysate) was incubated with 1 mLofcOmplete His-Tag Purification Resin (Roche), preequilibrated with IMAC Wash Buffer 1 (25 mM Hepes pH 7.5, 800 mM NaCI, 5 mM imidazole, 10% [v/v] glycerol, 5 mM DTT, 0.01% [v/v] Brij 35, 50 mM arginine, 50 mM glutamic acid). The resin was sequentially washed with IMAC Wash buffer 1 and (MAC Wash buffer 2 (25 mM hepes pH 7.5, 300 mM NaCI, 20 mM imidazole, 10% [v/v] glycerol, 5 mM DTT, 0.01% [v/v] Brij 35, 50 mM arginine, 50 mM glutamic acid). Bound KAT7 protein was eluted with IMAC Elution buffer (25 mM hepes pH 7.5, 200 mM NaCI, 500 mM imidazole, 10% [v/v] glycerol, 5 mM DTT 0.01% [v/v] Brij 35, 50 mM arginine,
50 mM glutamic acid). The eluting protein was collected directly into 4 volumes of
Desalt Buffer (50 mM Na citrate pH 6.5, 200 mM NaCI, 0.01% [v/v] Brij 35, 10% [v/v] glycerol, 5 mM DTT) to bring the final imidazole concentration to 100 mM. IMAC-eluted protein was immediately desalted into Desalt buffer using 2 x HiPrep 26/10 desalting columns (GE Healthcare) in sériés. Desalted protein was further purified by passing through a HiLoad 26/60 Su perd ex 75 column pre-equilibrated in Storage Buffer (50 mM Na citrate pH 6.5, 200 mM NaCI, 10% [v/v] glycerol, 5 mM DTT). Finally, KAT7 protein was concentrated to 3.5 mg/mL using Amicon Ultra centrifugal filter unit (Utra-15 MWCO 10 kDa), flash-frozen in liquid nitrogen and stored in -70°C freezer.
30 Acetyltransferase Biochemical Assay
To détermine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 pL in 384-well low volume assay plates. The reactions were performed in assay buffer (100 mM Tris-HCI, pH 7.8, 15 mM
-184NaCI, 1 mM EDTA, 0.01% Tween-20, 1 mM Dithiothreitol, and 0.01% m/v chicken egg white albumin).
Reactions were set up with 1pM Acetyl coenzyme A, 100 nM of full-length recombinant histone labelled by limited biotinylation (KAT6A, KAT7: H3.1, KAT5), 5 10/5/ 8/40/ 20 nM of KAT5/KAT6A/KAT7 enzyme respectively, and an acetyl-lysine spécifie antibody (H3.1 : Cell Signaling Technology, H4: Abcam). 11 -point dilution sériés of the test compounds were prepared in DMSO; a volume of 100 nLwas transferred using a pin tool into assay plates containing substrates, before adding enzyme to start the reaction. Positive (no compound, DMSO only) and négative 10 (AcCoA omitted) control reactions were included on the same plates and received the same amount of DMSO as the compound treated wells. After adding ail reagents, the plates were sealed with adhesive seals and incubated for 90 min at room température. An additional 4 pL of assay buffer containing AlphaScreen® Protein A acceptor beads and Streptavidin donor beads (PerkinElmer, Waltham, 15 MA) to a final concentration of 8 pg/mL was thenadded. After incubation for 2 hours the plates were read using an EnVision 2103 multi label plate reader (PerkinElmer) in HTS AlphaScreen® mode. IC50 values were obtained from the raw readings by calculating percent inhibition (%l) for each reaction relative to Controls on the same plate (%I=(I-CN)/(CP-CN) where CN/ CP are the averages of the négative/ positive 20 reactions, respectively), then fitting the %l data vs. compound concentration [I] to %I=(A+((B-A)/(1+((C/[I])AD)))) where A is the lower asymptote, B is the upper asymptote, C is the IC50 value, and D is the slope.
The results are shown in the Table 23 below:
Table 23:
Example | TIP60-KAT5 IC50 (μΜ) | MOZ-KAT6A IC50 (μΜ) | HBO1-KAT7 IC50 (μΜ) |
98 | = 0.256 | = 0.0059 | = 0.035 |
99 | = 0.98 | = 0.013 | = 0.12 |
100 | = 11.17 | = 0.03 | = 0.34 |
101 | = 11.23 | = 1.26 | = 1.55 |
- 185102
125.00
48.75
1.40
Historié H3 Lysine 23 Acétylation Biomarker Assay
Compounds were tested for their ability to inhibit acétylation of the histone H3K23 marker in the following assay:
The cell line U2OS was seeded at a densiîy of 9,000 cells per well in 96 well optical quality tissue culture plates in RPMI medium and 10% foetal bovine sérum, and allowed to adhéré for 24 hours under standard culture conditions (37 degree Celsius, 5% CO2). At the end of this period the medium was aspirated. Compound dilutions prepared in 10 DMSO were added to medium, with négative control wells reserved for treatment with
DMSO only and 100% inhibition positive Controls receiving a potent inhibitor compound (e.g. cas 2055397-28-7, benzoic acid, 3-fluoro-5-(2-pyridinyl)-, 2-[(2fluorophenyl)sulfonyl]hydrazide) (Baell, J., Nguyen, H.N., Leaver, D.J., Cleary, B.L., Lagiakos, H.R., Sheikh, B.N., Thomas. T.J., Aryl sulfonohydrazides,
WO2016198507A1,2016) at 10 pM concentration and 200 pL transferred to the cells.
After incubation for 24 hours, the cells were fixed with 3.7% formaldéhyde in PBS for 20 minutes at room température, washed (5x5 minutes) with phosphate buffer saline containing 0.1%Tween 20 and blocked with Odyssey blocking buffer (Ll-COR, Lincoln, NE) containing 0.1%TritonX100. Anti-H3K23ac spécifie antibody (Abcam ab177275) in 20 Odyssey blocking buffer containing 0.1 %Tween 20 was added and incubated for 16 hours at 4 degree Celsius. After washing (as above), a secondary antibody labelled with Alexa647 dye (LifeTechnologies) and Hoechst 33342 (1 pg/mL, SigmaAldrich) were added for 1 hour incubation. Plates were washed as previously and read on a
PerkinElmer Phénix high content imaging platform. Using a Columbus image analysis 25 pipeline, individual nuclei were located by Hoechst 33342 stain and the acétylation level was calculated from the Alexa647-related intensity in the same area. The resulting mean intensity per cell was directiy converted to percent inhibition relative to Controls on the same plate and the data fitted against a four-parameter logistic model to détermine the 50% inhibitory concentration (IC50).
The results are shown in Table 24 below:
- 186 Table 24:
Example | Histone H3 Lysine 23 Biomarker IC50 (μΜ) |
98 | = 0.0006 |
99 | N/D |
100 | = 0.046 |
101 | N/D |
102 | N/D |
Histone H3 Lysine 14 Acétylation Biomarker Assay
Compounds were tested for their ability to inhibit acétylation of the histone H3 Lysine 14 10 marker in the following assay:
The cell line U2OS was seeded at a density of 3,000 cells per well in 384-well optical quality tissue culture plates in RPMI medium supplemented with 10% foetal bovine sérum and 10 mM Hepes. The cells were allowed to adhéré for 24 hours under standard culture conditions (37 degree Celsius, 5% CO2). Atthe end of this period the 15 cells were washed with sérum free medium. Compound dilutions prepared in DMSO were added to the sérum free medium, with négative control wells reserved for treatment with DMSO only and 100% inhibition positive Controls receiving a potent inhibitor compound (e.g. (Z)-4-fluoro-A/-((3-hydroxyphenyl)sulfonyl)-5-methyl-[1 ,Γbiphenyl]-3-carbohydrazonic acid) at 10 μΜ concentration. After incubation for 24 20 hours, the cells were fixed with 4% formaldéhyde in PBS for 15 minutes at room température, washed with phosphate buffer saline and blocked with blocking buffer containing 0.2% TritonXIOO and 2% BSA. Anti-H3K14ac spécifie antibody (Cell Signalling Technologies) in blocking buffer was added and incubated overnight at 4 degree Celsius. After washing, a secondary antibody labelled with AlexaFluor 488 dye 25 (ThermoFisher) and Hoechst 33342 (1 pg/mL, Life Technologies) were added for 2
- 187 hours incubation at room température. Plates were washed and read on a PerkinElmer Opéra HCS high content imaging platform. Using a Columbus image analysis pipeline, individual nuclei were located by Hoechst 33342 stain and the acétylation level was calculated from the AlexaFluor 488-related intensity in the same area. The resulting mean intensity per cell was converted to percent inhibition relative to Controls on the same plate and the data fitted against a four-parameter logistic model to détermine the 50% inhibitory concentration (IC50).
The results are shown in Table 25 below:
Table 25:
Example | Histone H3 Lysine 14 Biomarker IC50 (μΜ) |
98 | N/D |
99 | = 1.55 |
100 | -1 .36 |
101 | N/D |
102 | = 28.33 |
H2A.Z Lysine 7 Acétylation Biomarker Assay
Compounds were tested for their ability to inhibit the histone H2A.Z Lysine 7 acétylation 15 marker in the following assay:
The cell line U2OS was seeded at a density of 3,000 cells per well in 384-well optical quality tissue culture plates in RPMI medium supplemented with 10% foetal bovine sérum and 10 mM Hepes. The cells were allowed to adhéré for 24 hours under standard culture conditions (37 degree Celsius, 5% CO2). At the end of this period the 20 cells were washed with sérum free medium. Compound dilutions prepared in DMSO were added to the sérum free medium, with négative control wells reserved for treatment with DMSO only and 100% inhibition positive Controls receiving a potent inhibitor compound enantiomer 1 of 7-iodo-/V-(2-(oxazol-2-yl)-2-phenylethyl)-2/7benzo[e][1,2,4]thiadiazine-3-carboxamide 1,1 -dioxide, which is compound 146 of co25 pending application GB1713962.7, filed on 31 August 2018, at 30 μΜ concentration.
After incubation for 24 hours, the cells were fixed with 4% formaldéhyde in PBS for 15
- 188- minutes at room température, washed with phosphate buffer saline and blocked with blocking buffer containing 0.2% TritonXIOO and 2% BSA. Anti-H2A.ZK7ac spécifie antibody (Abcam) in blocking buffer was added and incubated overnight at 4 degree Celsius. After washing, a secondary antibody labelled with AlexaFluor 488 dye (ThermoFisher) and Hoechst 33342 (1 pg/mL, Life Technologies) were added for 2 hours incubation at room température. Plates were washed and read on a PerkinElmer Opéra HCS high content imaging platform. Using a Columbus image analysis pipeline, individuel nuclei were located by Hoechst 33342 stain and the acétylation level was calculated from the AlexaFluor 488-related intensity in the same area. The resulting mean intensity per cell was converted to percent inhibition relative to Controls on the same plate and the data fitted against a four-parameter logistic model to détermine the 50% inhibitory concentration (IC50).
The results are shown in Table 26 below:
Table 26:
Example | H2A.Z Lysine 7 Biomarker IC50 (μΜ) |
98 | N/D |
99 | = 11.40 |
100 | = 14.98 |
101 | N/D |
102 | > 40.00 |
References
Aggarwal and Calvi, Nature, 2004, 430, 372-376 doi:l0.1038/nature02694
Avvakumov et al., Oncogene, 2007, 26, 5395-5407 doi:10.1038/sj.onc. 1210608
Berge et al„ J. Pharm. Sci., 1977, 66, 1-19 doi:10.1002/jps.2600660104
Borrow et al., Nat. Genet., 1996, 14, 33-41 doi:10.1038/ng0996-33
Dekker et al., Drug, Discov. Today, 2014, 19, 654-660 doi:10.1016/j.drudis.2013.11.012
Doyon étal., Mol. Cell., 2006,21, 51-64 doi :10.1016/j.molcel.2005.12.007
Dhuban étal., Sci. Immunol., 2017, 2, 9297 doi:10.1126/sciimmunol.aai9297
Duong et al„ Cancer Res., 2013, 73, 5556-5568 doi:10.1158/0008-5472.CAN-13-0013
-189Ghizzoni et al., Eur. J. Med. Chem., 2012, 47, 337-344 doi: 10.1016/j.ejmech.2011.11.001
Gil et al., J. Proteomics, 2017, 150, 297-309 doî : 10.1016/j.jprot.2016.10.003
Gobert, M. et al., Cancer Research, 2009, 69, 2000-2009 doi:10.1158/0008-5472.CAN5 08-2360
Holbert et al., J. Biol. Chem., 2007, 282, 36603-36613 doi:10.1074/jbc.M705812200 lizuka étal., Mol. Cell. Biol., 2006,26, 1098-1108 doi :10.1128/MCB.26.3.10981108.2006 lizuka et al., Cancer Soi., 2013, 104, 1647-1655 doi:10.1111/cas.12303 îo Jeong, étal., Blood Res 2016 51 (3), 152-154 doi:10.5045/br.2016.51.3.152
Joshi, et al., Immunity 2015, 43, 579-590 doi:10.1016/j.immuni.2015.08.006
Li, B. étal., PNAS, 2007, 104,4571-4576 doi:10.1073/pnas.0700298104
Melero, et al. Nature Reviews Cancer, 2015, 15, 457-472 doi:10.1038/nrc3973
Merson et al., J. Neurosci., 2006, 26, 11359-11370 doi :10.1523/JNEUROSCI.224715 06.2006
Miller, A.M. et al. J. Immunol., 2006, 177, 7398-7405 doi:10.4049/jimmunol.177.10.7398
Persa, E. et al. Cancer Letters, 2015 368(2), 252-261 doi:10.1016/j.canlet.2O15.03.003 Sheikh et al., Stood, 2015, 125(12), 1910-21 doi:10.1182/blood-2014-08-594655
Shi et al, Nature Biotech, 2015, 33, 661 -667 doi: 10.1038/nbt.3235 Su étal., Int. J. Mol. Sel., 2016, 17, 1-18 doi:10.3390/ijms17101594 Stern et al., Crit. Rev. Oncol. Hematol., 2005,54, 11-29 doi:10.1016/j.critrevonc.2004.10.011 Thomas et al., Development, 2000, 127, 2537-2548 PMID:10821753
Tao, H. et al., Lung Cancer, 2012, 75, 95-101 doi:10.1016/j.lungcan.2011.06.002 Turner-lvey et al., Neoplasia, 2014, 16(8): 644-655 doi:10.1016/j.neo.2014.07.007 Valerio et al., Cancer Research, 2017, 77(7), 1753-62 doi:10.1158/0008-5472.CAN16-2374
Vizmanos et al., Genes Chromosomes Cancer, 2003, 36(4), 402-405 doi:10.1002/gcc.10174
Voss et al., BioEssays, 2009,31(10), 1050-1061 doi:10.1002/bies.200900051 Wang, L., étal. EBioMedicine, 2016, 13, 99-112 doi:10.1016/j.ebiom.2016.10.018 Wang, X. et al., Oncogene, 2017, 36, 3048-3058 doi:10.1038/onc.2016.458
- 190Xiao, Y. étal., Cellreports, 2014, 7, 1471-1480 doi :10.1016/j.celrep.2014.04.021
Yan, M. étal., Breast Cancer Research, 2011, 13, R47 doi:10.1186/bcr2869 Zack et al., Nature Genetics 2013 45, 1134-1140 doi: 10.1038/ng.2760 Zhang et al., Mini. Rev. Med. Chem., 2017, 17, 1-8 doi :10.2174/1389557516666160923125031
Claims (35)
1. A compound of formula (I)
or a pharmaceutically acceptable sait thereof, wherein
R1 is hydrogen or 5-6 membered heteroaryl optionally substituted by methyl;
R2 is hydrogen or-(CHRs)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH, provided that one of R1 and R2 is hydrogen, further provided that R1 and R2 are not both hydrogen;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or -OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -Ocyclopropyl;
Ring A is Ce-Cw aryl or 9-10 membered heteroaryl;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -0CHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or-C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy;
R7 is hydrogen, bromo, chloro, fluoro, or methoxy;
R0 is hydrogen or -OH; and n is 0 or 1.
- 192 -
2. The compound or sait of claim 1, wherein R1 is 5-6 membered heteroaryl and R2 is hydrogen.
3. The compound or sait of claim 1, wherein R1 is hydrogen and R2 is 5-6 membered heteroaryl.
4. The compound or sait of claim 1, having formula (II)
wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, -OCHF2, or-OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -Ocyclopropyl;
Ring A is Ce-Cio aryl or 9-10 membered heteroaryl;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or -C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
5. The compound or sait of any one of claims 1-4, wherein Ring A is phenyl, quinolinyl, benzoxazolyl, indanyl, or tetrahydronaphthyl.
6. The compound or sait of claim 5, wherein Ring A is phenyl.
7. The compound or sait of claim 1 or claim 4, having formula (III)
-193-
wherein
R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
R3 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, -CHF2, -CF3, C1-C4 alkoxy, 5 -OCHF2, or-OCF3;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or-Ocyclopropyl;
R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or-C(O)N(H)CH3;
8. The compound or sait of any one of daims 1,4 or 7, having formula (IV)
wherein
9. The compound or sait of any one of daims 1 -8, wherein R5 is methoxy, R6 is methoxy, and R7 is hydrogen.
10. The compound or sait of any one of daims 1-8, wherein R5 is methoxy, R6 is hydrogen, and R7 is hydrogen.
10 R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
11. The compound or sait of any one of daims 1,4, or 7, having formula (VI) wherein
R2a is absent, halogen, C1-C3 alkyl, -CHsOH, or -OH;
R3 is hydrogen, halogen, or C1-C3 alkyl;
R4 is hydrogen, halogen, C1-C3 alkyl, cyclopropyl, C1-C4 alkoxy, or -Ocyclopropyl, provided that at least one of R3 and R4 is hydrogen;
R5 is hydrogen, methyl, -CH2-OCH3, -CFs, C1-C3 alkoxy, or-C(O)OCH3; and
R6 is hydrogen, fluoro, methyl, -OH, or methoxy.
12. The compound or sait of any one of daims 1-11, wherein R2a is absent, fluoro, methyl, -CH2OH or -OH.
13. The compound or sait of any one of daims 1-11, wherein R2a is absent.
14. The compound or sait of any one of daims 1 -7 or 11 -13, wherein R3 is hydrogen, halogen, or C1-C3 alkyl.
15. The compound or sait of any one of daims 1 -7 or 11 -13, wherein R3 is hydrogen, fluoro, bromo, or methyl.
- 195 -
15 R2a is absent, halogen, C1-C3 alkyl, -CH2OH, or -OH;
- 194 R5 is hydrogen, fluoro, cyano, C1-C3 alkyl, -CHF2, -CF3, cyclopropyl, C1-C3 alkoxy, -OCHF2, -OCF3, -O-cyclopropyl, -CH2-O-CH3, -C(O)OCH3, or -C(O)N(H)CH3;
R6 is hydrogen, fluoro, methyl, -OH, or methoxy; and
R7 is hydrogen, bromo, chloro, fluoro, or methoxy.
16. The compound or sait of any one of claims 1 -7 or 11 -13, wherein R4 is hydrogen, fluoro, methyl, ethyl, cyclopropyl, -O-cyclopropyl, or C1-C4 alkoxy,
17. The compound or sait of any one of claims 1 -7 or 11 -13, wherein R4 is hydrogen.
5
18. The compound or sait of any one of claims 1 -7 or 11 -13, wherein R4 is
C1-C3 alkoxy.
19. The compound or sait of any one of claims 1 -7 or 11 -13, wherein R4 is methoxy.
20 or a pharmaceutically acceptable sait thereof.
20. The compound or sait of any one of claims 1 -7 or 11 -13, wherein at least 10 one of R3 and R4 is hydrogen.
21. The compound or sait of any one of claims 11-20, wherein R5 is methoxy and R6 is methoxy.
22. The compound or sait of any one of claims 11 -20, wherein R5 is methoxy and R6 is hydrogen.
15
23. The compound of claim 1, which is
or a pharmaceutically acceptable sait thereof.
24. The compound of claim 1, which is
25. The compound of claim 1, which is
- 196 or a pharmaceutically acceptable sait thereof.
26, A pharmaceutical composition comprising a compound of any one of the preceding daims, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or diluent.
27. A compound of any one of daims 1 -25, or a pharmaceutically acceptable sait thereof, for use in a method of treating cancer.
28. Use of a compound of any one of daims 1 -25, or a pharmaceutically acceptable sait thereof, in the manufacture of a pharmaceutical composition for treating cancer in a patient.
29. The compound or pharmaceutically acceptable sait thereof for use of daim 27 or the use of daim 28, wherein the cancer is breast cancer.
30. The compound or pharmaceutically acceptable sait thereof for use of daim 27 or the use of daim 28, wherein the cancer is ER positive breast cancer.
31. A combination of a compound of any one of daims 1 -25, or a pharmaceutically acceptable sait thereof, with an anti-tumor agent or with radiation therapy, for the treatment of cancer.
32. A combination of a compound of any one of daims 1 -25, or a pharmaceutically acceptable sait thereof, with an anti-tumor agent, for the treatment of cancer.
33. The combination of daim 30 or 31, wherein the cancer is breast cancer.
34. The combination of daim 32, wherein the breast cancer is ER positive breast cancer.
35. A crystalline form of 2-methoxy-/V-{4-methoxy-6-[(1 /-/-pyrazol-1 -yl)methyl]1,2-benzoxazol-3-yl}benzene-1 -sulfonamide anhydrous free base, having a powder Xray diffraction pattern comprising peaks at 2Θ values of: 13.4 and 18.1 °2θ ± 0.2 °2θ.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/863,199 | 2019-06-18 | ||
US62/953,223 | 2019-12-24 | ||
US63/025,278 | 2020-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA20447A true OA20447A (en) | 2022-08-08 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4299135A2 (en) | Benzisoxazole sulfonamide derivatives | |
US9980952B2 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
AU2015315174B2 (en) | Smyd inhibitors | |
CA2796967C (en) | Heterocyclic derivatives as alk inhibitors | |
AU2012284540B2 (en) | TRPV4 antagonists | |
AU2009260810B2 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds | |
EA028626B1 (en) | Tnf-alpha modulating benzimidazoles | |
JP2008508229A (en) | Heterocyclic substituted cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors | |
CN114144230B (en) | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | |
BR112021003447A2 (en) | innovative quinoline-derived inhibitor | |
WO2011019060A1 (en) | Hedgehog signal inhibitor | |
WO2015163472A1 (en) | Heteroaryl compound substituted by triazolyl | |
OA20447A (en) | Benzisoxazole sulfonamide derivatives | |
RU2813356C2 (en) | Derivatives of benzisoxazolesulfonamide |